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Aromatase, a member of the cytochrome P450 superfamily, catalyses the conversion 
of androgens to estrogens; specifically, testosterone to estradiol and androstenedione 
to estrone.  Aromatase is widely expressed across a range of tissues and deleterious 
metabolic effects are observed in both murine aromatase knock-out models and in 
rare human cases of aromatase deficiency.  The effects of pharmacological inhibition 
of aromatase, as employed in the treatment of breast cancer, are not well 
characterised.  This thesis addresses the hypothesis that aromatase inhibition, and 
consequent changes in sex steroid hormone action (higher androgen:estrogen ratio), 
results in disadvantageous changes in body composition and reduced insulin 
sensitivity.   
 
In a cohort study of 197 community-dwelling men, lower testosterone and SHBG 
concentrations were observed in those fulfilling criteria for metabolic syndrome, 
although no relationship with estrogens was observed.  The strongest determinant of 
circulating estrogens was substrate androgen concentration.   
 
A case-control study of aromatase inhibitor treated breast cancer patients and age-
matched controls (n=40) demonstrated decreased insulin sensitivity and increased 
body fat in those treated with aromatase inhibitors; serum leptin concentration and 
leptin mRNA transcript levels (in subcutaneous adipose tissue) were elevated in this 
group.   
 
! ii 
In healthy male volunteers (n=17), 6 weeks of aromatase inhibition (1 mg anastrozole 
daily) resulted in reduced glucose disposal during a hyperinsulinaemic euglycaemic 
clamp study, with d2-glucose and d5-glycerol tracers.  No effects upon hepatic insulin 
sensitivity, lipolysis or body composition were noted, although serum leptin 
concentration was reduced following aromatase inhibitor administration. 
 
In conclusion, aromatase inhibition is associated with increased insulin resistance and, 
in women, increased body fat.  This may be relevant for patients receiving aromatase 
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Sex steroid hormones are thus named because of their well-established role in sexual 
development and fertility.  Beyond their role in reproduction, considerable evidence 
supports effects upon body composition and, more recently, upon fuel metabolism 
and cardiometabolic risk (Mauvais-Jarvis et al. 2013). Phylogenetic analysis suggests 
the single ancestral receptor (ANcSR1), from which other steroid receptors evolved, 
was estrogen responsive and, in predating sexual reproduction, was likely to have had 
a role in regulating cellular metabolism (Eick & Thornton 2011).   Compared to age-
matched men, premenopausal women have greater insulin sensitivity when adjusted 
for lean mass (Park et al. 2003).  Furthermore, evidence from multiple animal models 
supports a critical metabolic role for sex steroid hormones, including the protection 
from insulin resistance afforded to estradiol replete rodents (Stubbins et al. 2012).  
Conversely, menopause and ovariectomy result in adverse effects upon metabolic 
health.  In men, subnormal testosterone levels are associated with increased visceral 
adiposity (Nielsen et al. 2007) as well as an increased risk of developing type 2 
diabetes mellitus (T2DM) (Ding et al. 2006).  
 
Whilst the testes and ovaries are the major source of androgens and estrogens, 
respectively, the adrenal glands are also responsible for androgen generation and 
adipose tissue is increasingly recognised as a significant source of sex steroid 
hormone production.  Indeed, in men and postmenopausal women, estrogens are 
primarily generated in adipose tissue from the conversion of androgens, by the 
enzyme aromatase (Simpson et al. 1999) (figure 1.1). In this context, plasma 
estrogens, whilst perhaps reflecting adipose tissue generation (Belanger et al. 2006), 
do not primarily operate as hormones in the classical sense (i.e. by exerting their 
! 3 
effect at a site distant from their generation) (Simpson et al. 2005).  The importance 
of this local adipose hormone generation, which also involves glucocorticoid and 
androgen metabolism, places limits upon the usefulness of studying plasma hormone 
levels and, equally, in relying upon systemic administration of sex hormones to assess 
their adipose effects.  Indeed, the steroid content of adipose tissue has been estimated 
to be between 40 to 400 fold greater than that of plasma (Belanger et al. 2002). The 
term ‘intracrinology’ has been coined to encompass this important process of local 
hormone generation and action.  Pharmacological inhibition of aromatase is known to 
markedly suppress circulating estrogens and, in men and post-menopausal women, 
this is presumably a consequence of action in the adipose compartment. 
 
A significant body of observational and mechanistic evidence supports a role for sex 
steroid hormones in relation to body composition, insulin sensitivity, diabetes risk and 
mortality.  This thesis will examine the influence of sex hormones upon insulin 
sensitivity, adipose tissue and body composition, principally through assessment of 




Figure 1.1 Steroid hormone biosynthetic pathway (adapted from Payne & 
Hales et al. 2004)
! 5 
1.1 Sex steroids and body composition 
 
1.1.1 Visceral and subcutaneous adipose tissue 
!
The increasing incidence of type-two diabetes, and its attendant cardiovascular 
complications, is largely a result of rising levels of obesity. Risk of cardio-metabolic 
disease varies widely within the obese population, particularly as a function of body 
fat distribution.  Adipose tissue distribution is conventionally described as either 
android (central, abdominal, male pattern) or gynoid (peripheral, gluteo-femoral, 
female pattern).  Android obesity is a much stronger risk factor for the development 
of diabetes and cardiovascular disease than is gynoid obesity.  Following menopause 
women typically shift from a gynoid to android body habitus (Kuk et al. 2005), with a 
coincident convergence in cardiovascular and diabetes risk with reference to their 
male peers (Lemieux et al. 1994). It is this interesting observation from nature which 
initially stimulated interest in the contribution of sex steroid hormones (particularly 
estrogens, which decline precipitously after menopause) to control of body fat 
distribution.  Subsequently, humans with vanishingly rare genetic mutations 
controlling sex steroid hormone generation or action and elegant transgenic animal 
models have lent further support to the centrality of estrogens and androgens in the 
control of adipose distribution. 
 
A substantial body of evidence has accumulated in support of the proposition that 
central fat distribution, and in particular visceral fat, plays a role in the development 
of cardio-metabolic disease (Wajchenberg 2000).  The INTERHEART study 
demonstrated, in a cohort of 27,098 men and women, that Waist-hip ratio (WHR) (a 
proxy for central adiposity) was a more accurate predictor of incident myocardial 
! 6 
infarction than body mass index (BMI) (a proxy for generalised obesity) (Yusuf et al. 
2005).  A number of studies have sought to determine the differential effects of 
visceral and subcutaneous adipose tissue upon insulin sensitivity, all reaching broadly 
similar conclusions.  Utilising computed tomography to quantify subcutaneous and 
visceral fat depots permitted the observation that 54% of the variance in insulin 
sensitivity, in men and women, can be accounted for by intra-abdominal fat volume 
(Cnop et al. 2002), congruent with earlier observations limited to post-menopausal 
women (Brochu et al. 2000).  Further support for this hypothesis is offered by the 
observation that insulin sensitive obese post-menopausal women have 49% less 
visceral adipose mass than their insulin resistant peers (Brochu et al. 2001).  In 
addition to the deleterious effects of visceral fat, some evidence exists to support a 
metabolically protective role for lower limb fat depots (Van Pelt et al. 2005). 
 
Visceral adipose tissue typically accounts for between 5 and 20% of total adipose 
mass, yet appears to contribute disproportionately to the adverse outcomes associated 
with obesity.  The visceral depot differs from subcutaneous fat not only in its unique 
anatomical relationship with the liver but also with respect to its transcriptomic and 
biochemical activity.  The ‘portal paradigm’ seeks to explain the association of 
visceral fat with adverse metabolic outcomes by suggesting increased non-esterified 
fatty acid (NEFA) flux and inflammatory cytokines from visceral adipose tissue result 
in hepatic insulin resistance.  Visceral adipose tissue contains a larger proportion of 
macrophages than subcutaneous fat, which may be associated with the production of 
atherogenic cytokines (Weisberg et al. 2003).  Visceral adiposity is also associated 
with higher levels of plasminogen activator inhibitor-1 (PAI-1) and low-grade 
inflammation (Van Gaal et al. 2006). It remains a possibility that visceral fat is simply 
! 7 
a marker for generalised ectopic fat deposition; however surgical removal of intra-
abdominal fat appears to mitigate insulin resistance in rodents (Gabriely et al. 2002) 
and humans (Thörne et al. 2002), thus lending support to a pathogenic role.  
Conversely, in mice, transplantation of subcutaneous fat into the visceral 
compartment of a recipient animal, results in improved insulin sensitivity and reduced 
fat mass (Tran et al. 2008). 
 
Visceral adipose tissue is less sensitive to the anti-lipolytic effects of insulin (figure 
1.2). It exhibits higher responsiveness to pro-lipolytic catecholamine β1 and β2-
adrenoreceptor signalling and lower responsiveness to anti-lipolytic α2-adrenoreceptor 
signalling, compared with subcutaneous fat (Lafontan et al. 2003).  Adipocytokine 
production also demonstrates site specificities, with leptin secretion higher in 
subcutaneous adipocytes (van Harmelen et al. 1998) and adiponectin higher in 
visceral adipocytes. 
 
Obesity results in increased basal lipolysis with larger fat cells and increased TNFα 
production (Arner et al. 2005). Whilst catecholamine-induced lipolysis is reduced in 
the subcutaneous depot, the opposite is true in the visceral compartment and this is 
more pronounced in men (Nielsen et al. 2004). 
 
Assessment of transcript expression between visceral and subcutaneous adipocytes 
has shown that, as expected, leptin transcript levels are greater in subcutaneous 
adipocytes (Montague et al. 1998). No significant difference in the transcript levels 
for lipoprotein lipase, hormone sensitive lipase, peroxisome proliferator-activated 
receptor gamma (PPARγ) and tumour necrosis factor alpha (TNFα) were noted 
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between compartments.  Microarray analysis in obese individuals has identified 
additional differentially expressed transcripts, though further work is required to 





Figure 1.2  Regulation of lipolysis in human fat cells (from Arner et al. 2005) 
β1,2,3, beta1,2,3-adrenergic receptors; α2A, α2A-adrenergicreceptor, Gi,s, inhibitory (i) or stimulatory (s) G-proteins; 
AC, adenylate cyclase; cAMP, cyclic AMP; cGMP, cyclic GMP, NPRA, natriuretic peptide receptor A; GC, guanylyl 
cyclase; PKG, cGMP-dependent protein kinase; PKA, protein kinase A; TNFα, tumour necrosis factor alpha; P44/42 
and JNK, MAP kinase pathways; TNFR1, TNFα receptor 1;ATGL, adipose-tissue-specific triglyceride lipase; HSL, 
hormone-sensitive lipase; MGL,monoglyceride lipase; TG, triglycerides; DG, diglyceride; MG, monoglyceride; FA, 
fatty acid; IR, insulin receptor; IRS-1,2, insulin receptor substrates 1 and 2; Pl3K, phosphadilyl inositol 3 kinase; 




1.1.2  Direct effects of sex steroids on adipocyte function 
 
1.1.2.1 Estrogens  
 
Estrogens primarily mediate their effects through two nuclear receptors: estrogen 
receptor alpha (ERα) and estrogen receptor beta (ERβ); both of which exist in 
multiple isoforms (Mauvais-Jarvis et al. 2013).  When bound, these receptors 
dissociate from their chaperone heat-shock protein, dimerize and bind to estrogen 
response elements (ERE) to influence transcription.  Interestingly ERα appears to 
promote transcription, whilst ERβ may impede this process by forming heterodimers 
with ERα (Hall et al. 1999).  In addition to their action as classical nuclear receptors, 
estrogen receptors also localise in caveolae where they can facilitate rapid signalling 
through activation of growth-factor receptors and G proteins, which may be of 
particular relevance in relation to the metabolic effects to estrogens (Hammes et al. 
2007). No consensus exists with respect to the distribution of estrogen receptors in 
adipose tissue; both ERα and ERβ have been detected in mature adipocytes and whilst 
some investigators confirm a similar situation in preadipocytes (Pedersen et al. 2001), 
others have isolated only ERα (Dieudonné et al. 2004).  Similarly conflicting reports 
have identified either ERα (Dieudonné et al. 2004) or, alternatively, ERβ1 (Pedersen 
et al. 2001) as the predominant receptor in adipose tissue. The expression of ERα is 
equal across depots and gender, however it is suggested that ERβ levels may be 
higher in women and in subcutaneous fat (Dieudonné et al. 2004).  In vitro, 
administration of estradiol upregulates subcutaneous ERα and β expression in women, 
but only ERα expression in subcutaneous and visceral adipocytes in men (Pequery et 
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al. 2004).  Menopausal status does not appear to influence the distribution of estrogen 
receptors (Shin et al. 2007).   
 
Recent work has sought to define the effects of estrogens upon adipose transcription 
patterns (summarised in table 1.1).  In ovariectomized mice, estradiol replacement 
down-regulated genes favouring lipid storage, including lipoprotein lipase (LPL), 
acetyl-CoA carboxylase-1 (ACC-1) and fatty acid synthase (FAS).  Reductions in 
ACC-1 and FAS were attributed to down-regulation of liver X receptor α (LXRα) and 
SREBP-1c (D’Eon et al. 2005).  In male mice, estradiol administration resulted in 
down-regulation of genes for monocyte-chemoattractant protein (MCP) and androgen 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Administration of estradiol to rats resulted in a marked reduction in LPL activity 
(Hamosh et al. 1975), which is consistent with the finding in cell culture studies of 
reduced LPL mRNA when incubated with estradiol (Homma et al. 2000); a unique 
estrogen response element on the LPL promoter has been identified which helps 
account for these findings (Homma et al. 2000).  In ovariectomized rats, basal and 
isoproterenol stimulated lipolysis were reduced to 50% and 25%, respectively, in 
parametrial fat pads; these changes were reversed with exogenous estradiol therapy 
(Darimont et al. 1997).  In human female subcutaneous adipocytes, estradiol reduced 
LPL activity whilst increasing hormone sensitive lipase (HSL) activity and glycerol 
release (as a proxy of lipolysis) (Palin et al. 2003). 
 
The demonstration that estradiol directly increases α2A-adrenoreceptors in 
subcutaneous adipocytes (but not in visceral adipocytes) provides an appealing 
mechanistic link between higher estrogen levels and gynoid fat distribution.  
Increased α2A-adrenoreceptor expression results in attenuated epinephrine induced 
lipolysis and favours subcutaneous fat deposition (Pedersen et al. 2004). 
 
Estrogens also play a role in adipose development, having been shown as early as the 
1970s to stimulate preadipocyte proliferation (Roncari et al. 1978).  More recently 
human subcutaneous and visceral preadipocyte proliferation was demonstrated to a 
greater extent in women than men, following in vitro incubation with estradiol 
(Anderson et al. 2001). Whether estrogens are capable of inducing adipocyte 
differentiation remains more controversial (Cooke et al. 2004).  However the increase 
in fat cell number observed in models of estrogen deficiency, particularly in the 
visceral compartment, does suggest a fundamental role for estrogens in this regard. 
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Animal models of estrogen deficiency provide further evidence of the centrality of 
estrogens in adipocyte function.  Ovariectomized mice increase adipose mass and 
adipocyte size in excess of their pair-fed littermates.  Estradiol replacement 
ameliorates this phenotype by reducing lipogenic gene expression, increasing 
lipolysis and up-regulating skeletal muscle genes involved in fatty acid oxidation 
(D’Eon et al., 2005). Male estrogen receptor α knockout (ERαKO) mice display a 
distinct phenotype of insulin resistance with adipocyte hypertrophy and hyperplasia 
(Heine et al. 2000).  In female ERαKO mice, obesity is observed in the context of a 
ten-fold elevation in estradiol levels; which may be relevant as ERβ is unaffected in 
this model. When ovariectomy was performed, a reduction in body weight (6%) was 
accompanied by a 45% reduction in fat pad mass and a 16% reduction in adipocyte 
size; thus suggesting ERβ mediates deleterious effects upon adipose tissue (Naaz et 
al. 2002).   
 
1.1.2.2  Androgens 
 
Androgens exert their biological effects when bound to the androgen receptor (AR) 
which, like the estrogen receptor, is a member of the nuclear hormone receptor 
family. Bound receptors form homodimers which interact with androgen response 
elements to effect transcription.  As is the case with estrogens, alternative non-
genomic signalling pathways are likely to exist and this is an area of active research. 
 
In humans, 60% of circulating testosterone is avidly bound to sex hormone binding-
globulin, approximately 38% is weakly bound to albumin and the remainder 
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circulates in a ‘free’ state.  DHT is the most potent activator of AR and is generated 
from testosterone by 5α-reductase. 
 
Androgen receptors have been identified in adipocytes and preadipocytes from both 
men and women. Androgen receptors are more plentiful in visceral than subcutaneous 
preadipocytes in both sexes.  AR expression decreases during the differentiation 
process and has been shown to increase following dihydrotestosterone (DHT) 
exposure (Dieudonne et al. 1998), although others have demonstrated down-
regulation in similar circumstances (Anderson et al. 2002).  The effects of androgens 
upon adipose tissue mRNA transcript levels are summarised in table 1.1.   
 
Employing a serial analysis of gene expression (SAGE) approach, short term ante-
mortem exposure of male mice retroperitonal adipose tissue to DHT was shown to 
stimulate genes involved in glycolysis, fatty acid synthesis, triacylglycerol 
production, cell proliferation and differentiation (Bolduc et al. 2004).  However, the 
same authors demonstrated quite distinct effects upon longer term exposure to DHT, 
including promotion of lipid utilization, inhibition of lipogenesis, increased adipocyte 
apoptosis, increased adiponectin C1Q, increased estrogen clearance and elevated LPL 
expression (Bolduc et al. 2007).  Recently, ovariectomized cynomolgus monkeys 
were treated with DHT and gene expression assessed, in visceral and subcutaneous 
adipose, by microarray analysis and real-time polymerase chain reaction (PCR).  
Transcription in visceral and subcutaneous depots was strongly correlated (r=0.78, 
p<0.001).  Significant effects were noted in genes responsible for extra-cellular 
matrix, cell adhesion and cytoskeletal structure.  Consistent down-regulation of genes 
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involved in fatty acid, phospholipid and triglyceride metabolism was noted, including 
HSL (Nantermet et al. 2008). 
 
In human female subcutaneous adipocytes, incubation with DHT increased LPL 
expression whilst inhibiting that of HSL (the latter effect apparently independent of 
AR activation) (Anderson et al. 2002).  Testosterone was shown to increase LPL 
activity in young men, but only when co-administered with an aromatase inhibitor 
(suggesting that estradiol, arising from androgen aromatization, negates this process) 
(Zmuda et al. 1993). 
 
In men and women, DHT effects a 50% reduction in epinephrine stimulated lipolysis 
in preadipocytes from the subcutaneous, but not visceral, compartment when studied 
in vitro (Dicker et al. 2004); this is associated with a 50% reduction in HSL 
expression and attenuated expression of β2-adrenoreceptors.  Postmenopausal 
women, treated with a 3-month course of testosterone, down-regulated abdominal 
subcutaneous fat expression of HSL and phosphodiesterase-3B (PDE-3B) in concert 
with demonstrable reductions in lipolysis (Zang et al. 2007).  In vitro testosterone also 
appears to mediate increased insulin resistance in female subcutaneous abdominal 
adipocytes (Corbould 2007). 
 
Insights from genetically modified models highlight the importance of androgen 
signalling with respect to metabolism.  AR null mice develop late onset obesity and 
are less physically dynamic with reduced oxygen consumption.  However, food intake 
is unchanged and insulin resistance is not typical.  AR null mice display down-
regulation of HSL and thermogenic uncoupling protein 1 and up-regulation of PPARγ 
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and adiponectin in adipose tissue (Fan et al. 2005; Sato et al. 2003).  In 
orchidectomized mice, DHT replacement but not estradiol, resulted in obesity, 
reduced energy expenditure, reduced fat oxidation but without effects on food 
consumption or locomotor activity.  DHT replacement was associated with increased 
plasma HDL cholesterol and triglyceride levels (Movérare-Skrtic et al. 2006).  In 
ovariectomized mice, DHT replacement resulted in increased body weight and 
visceral fat mass.  In addition, DHT effected up-regulation of FAS, SREBP-2 and 
LPL and a reduction in AMPK phosphorylation in visceral fat (McInnes et al. 2006).  
This study in particular confers greater import upon altered ratios of AR:ER 
activation as a putative mediator of adverse metabolic sequelae.  
 
Androgens appear to play a negative role in the regulation of adipocyte development.  
DHT has been shown to reduce adipogenesis in pluripotent stem cells and promote 
development along a myogenic line (Singh et al. 2003; Singh et al. 2006).  Site 
specific anti-adipogenic effects were noted in rat preadipocytes exposed to DHT 
(Dieudonne et al. 2000), whilst some in vitro studies in human preadipocytes have 
failed to demonstrate any effect (Dicker et al. 2004; Corbould et al. 2007). 
 
1.1.3 Energy intake and expenditure: sex steroid effects 
 
In addition to direct effects upon adipocyte function, sex steroids are known to 
influence energy intake and expenditure.  Ovariectomy leads to weight gain in 
rodents, which is prevented by estrogen replacement.  Increased food intake is 
ameliorated by estrogen replacement, which increases excitatory POMC inputs to the 
arcuate nucleus in mice, independent of leptin (Gao et al. 2006).  Energy expenditure 
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is reduced by 11% in ERα knockout mice with no significant difference in food intake 
(Heine et al. 2000), with little effect observed in ERβ knockout mice.  Exogenous 
estradiol administration is also associated with increased sensitivity to leptin in male 
and female rats (Clegg et al. 2006).  Estradiol administration may also reduce 
hypothalamic expression of the anabolic peptide NPY, as suggested by variability 
across the estrus cycle in mice (Olofsson et al. 2009).  The role of androgens in 
modulating appetite and energy expenditure is much less well defined and, as is often 
the case, complicated by the confounding effect of changes in estrogen concentration 
when aromatizable androgens are administered.  Gender differences in food intake 
may originate from androgen programming effects on POMC neurons in the arcuate 




1.1.4  Sex steroid effects upon body composition: observational 
evidence 
 
1.1.4.1  Estrogens (women) 
 
The direct effect of menopause upon body composition is controversial and it has 
been suggested that many of the observed changes are primarily a consequence of 
ageing, however the balance of evidence supports a significant effect of menopausal 
status upon WHR and fat mass (Poehlman et al. 2002).  In women, a number of 
observational studies have investigated the relationship between menopausal status 
and adipose metabolism with varying results.  In pre- and postmenopausal women, 
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matched for visceral adipose area, no difference in subcutaneous abdominal and 
femoral adipose LPL activity or epinephrine-induced lipolysis was noted (Mauriege et 
al. 2000).  Similar investigations have elicited significantly lower basal lipolysis in 
gluteal subcutaneous adipose tissue, with elevated LPL activity in abdominal and 
gluteal subcutaneous fat, in postmenopausal women (Ferrera et al. 2002).  Another 
study, comparing pre- and postmenopausal women, suggested larger omental fat cell 
size, higher omental basal lipolysis and higher omental/subcutaneous (om/sc) LPL 
activity in the latter group.  However, with the exception of om/sc LPL activity, 
menopausal status was not independently associated with these variables when 
corrected for visceral adipose tissue area (Tchernof et al. 2004).  Previously in obese 
women, plasma estradiol levels were negatively correlated, and total testosterone 
positively correlated, with total post-heparin LPL activity (Iverius et al. 1988).   
 
1.1.4.2  Androgens (women) 
 
Fewer studies have investigated the association of circulating androgens and obesity 
in women.  In women with oligomenorrhoea or hirsutism, free androgen index (FAI) 
and testosterone levels were noted to be significantly greater in the obese (Taponen et 
al. 2003).  A negative association has been observed between plasma testosterone 
levels and visceral fat in premenopausal obese women (Armellini et al. 1994).   
 
1.1.4.3  Estrogens (men) 
 
In men the influence of estrogens on obesity has not been extensively investigated.  
Plasma estradiol has been positively correlated with subcutaneous fat mass in healthy 
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young men (Nielsen et al. 2007), whilst other studies have failed to confirm this 
(Abate et al. 2002).  Plasma estrone (which was closely correlated with subcutaneous 
adipose tissue levels) has been positively correlated with waist circumference and 
body mass index (BMI) in young men (Belanger et al. 2006).   
 
1.1.4.4  Androgens (men) 
 
A number of observational studies have been designed to investigate the relationship 
between androgens and obesity in men.  Free plasma testosterone was inversely 
related to visceral adipose mass in young men as determined by magnetic resonance 
imaging (MRI) (Nielsen et al. 2007).  This finding has been replicated by other 
investigators (Seidell et al. 1990) but not in a similar study, performed in a slightly 
older cohort, where the only inverse association was with subcutaneous fat (Abate et 
al. 2002).  Tissue levels of DHT and testosterone also correlated negatively with waist 
circumference and BMI in young men (Bélanger et al. 2006).  Waist circumference 
appears to be a stronger predictor of testosterone levels than BMI based on an 
analysis of 1548 men in the Tromsø study (Svartberg et al. 2004). 
 
1.1.5 Effect of sex hormone replacement upon body composition 
 
1.1.5.1  Women 
 
Studies in which exogenous estrogens are administered to females are plentiful as a 
result of ‘hormone replacement therapy’ (HRT).  However HRT studies rarely, if 
ever, provide pure insights into the effect of estrogens on adipose tissue for the 
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following reasons: progestins, with varying degrees of androgenicity, are often 
prescribed concurrently; a variety of different estrogen preparations are available; and 
pharmacological doses are required to overcome first pass hepatic metabolism, with 
largely deleterious effects.  Specifically, exogenous oral estrogens act on the liver to 
modulate lipid metabolism and haemostatic factors. This has prompted the 
development of alternative delivery routes (e.g. percutaneous), which seek to obviate 
these unwanted effects (Turgeon et al. 2006). All these factors contribute towards the 
heterogeneity of ‘HRT’, which precludes any simplistic interpretation of this body of 
evidence.  In addition to the heterogeneity of treatment options, good evidence exists 
to suggest age at treatment (and time from menopause) may be critical in determining 
the anti-atherogenic response (Mikkola et al. 2002); it is feasible that a similar 
temporal relationship may apply to adipose responsiveness.  
 
HRT consisting of estradiol valerate and, perhaps significantly, the antiandrogenic 
progestin cyproterone acetate, resulted in sparing of the shift to androgenic fat 
distribution which was noted in early menopause age matched controls (Gambacciani 
et al. 1997).  Similarly a cross-sectional study involving 2175 women confirmed the 
preservation of premenopausal fat distribution in women treated with a variety of 
HRT preparations, in recent onset menopause (Genazzini et al. 2006).  A prospective 
study of estradiol and norethisterone in 38 postmenopausal women (mean age 53) 
also demonstrated significant reductions in android obesity (Arabi et al. 2003).  
Combined estrogen-progesterone HRT, in early postmenopausal women, prevented 
abdominal fat gain, as assessed by DEXA, in a randomised trial (Haarbo et al. 1991).  
However, after adjusting for confounding variables, no significant difference in either 
BMI or WHR was observed in a cross-sectional study investigating HRT effect in 671 
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women (Kritz-Silverstein et al. 1996).  More detailed analysis of body fat distribution, 
with computed tomography, failed to show any difference in visceral or subcutaneous 
fat area between women on HRT (estrogen alone or estrogen-progesterone) and age 
and BMI matched controls (Ryan et al. 2002).  
To assess the short term effects of estrogens upon fat metabolism, the response of 
whole body and subcutaneous adipose lipolysis to intravenous conjugated estrogens 
was assessed.  Estrogen was noted to decrease subcutaneous fat basal lipolysis but did 
not affect whole body lipolysis or insulin mediated suppression (Van Pelt et al. 2006). 
 
The only study investigating the metabolic effects of estrogen antagonism (partial 
agonism) was performed in breast cancer patients receiving tamoxifen, which was 
shown to promote the accumulation of visceral and hepatic fat (Nguyen et al., 2001).  
 
Investigating the potential metabolic benefits of androgen replacement in 
postmenopausal women is a relatively recent concept, originating from prior 
observations of improved energy levels, sexual function and quality of life. Three 
months of testosterone replacement (or testosterone and estradiol in combination) to 
women with a mean age of 55 years resulted in increased body weight and lean mass 
but not fat mass (Zang et al. 2006).  Postmenopausal women receiving a 9 month 
course of nandrolone (a weakly androgenic anabolic steroid) lost subcutaneous fat 
whilst gaining fat in the visceral compartment (Lovejoy et al. 1996).  DHEA 
supplementation in elderly women over a 2-year period did not alter body 
composition (Nair et al. 2006).   
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Assessing the effects of hormonal treatment in female to male transsexuals affords a 
rare insight into the consequences of androgen therapy in genetic females.  
Testosterone, administered on a fortnightly basis, resulted in reductions in 
subcutaneous fat and a concurrent increase in visceral depots (Elbers et al. 2003).  
This corroborated earlier findings of reduced subcutaneous and increased visceral fat 
occurring alongside increased thigh muscle area, as assessed by MRI (Elbers et al. 
1999a).  In female to male transsexuals, gluteal and abdominal subcutaneous 
adipocytes are rendered smaller by testosterone administration and basal lipolysis is 
increased in the latter depot (although no differences in response to isoproterenol or 
insulin were noted) (Elbers et al. 1999b). 
 
Androgen excess is implicated in the pathogenesis of polycystic ovary syndrome 
(PCOS), which is associated with obesity, insulin resistance and elevated 
cardiovascular risk.  In this context, the androgen receptor antagonist flutamide 
effects reductions in visceral fat (Gambineri et al. 2004; Gambineri et al. 2006).  The 
success of this strategy in PCOS raises the possibility of utility in the postmenopausal 
context, which is also characterized by an elevated androgen to estrogen ratio.  
However 9 months of spironolactone (a mineralocorticoid and androgen receptor 
antagonist) therapy failed to alter body fat distribution (Lovejoy et al. 1996). 
 
1.1.5.2  Men 
 
Where female to male transsexuals offer insights into the effects of testosterone in 
women, male to female transsexuals provide a unique opportunity to investigate the 
effects of estrogen therapy (in combination with androgen antagonism) in men.  In 
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this setting, 20 non-obese men received daily ethinyl estradiol and cyproterone 
acetate, which effected increases in visceral and subcutaneous fat of 18% and 38%, 
respectively.  Beneficial changes in HDL cholesterol, LDL cholesterol and hepatic 
lipase activity were counterbalanced by elevations in blood pressure, triglyceride and 
reductions in LDL particle size (Elbers et al. 2003).  These changes in body 
composition are in accord with earlier observations by the same authors (Elbers et al. 
1999a).  Following a year of oestrogen and anti-androgen therapy, subcutaneous fat 
cell size increased as did basal lipolytic rate (though response to insulin and 
isoproterenol was unchanged) (Elbers et al. 1999b). 
 
Akin to estrogen replacement trials in women, androgen replacement is the most 
investigated hormonal manipulation in men.  Suppressing endogenous hormone 
release with GnRH, in healthy young men, afforded the opportunity to assess the dose 
response effect of testosterone replacement on fat distribution (determined by MRI).  
Subphysiological replacement caused gains in inter-muscular, intra-abdominal and, in 
particular, subcutaneous adipose tissue.  Higher testosterone doses did not influence 
intra-abdominal fat but did reduce subcutaneous and, most markedly, inter-muscular 
fat (Woodhouse et al. 2004). In young men, six weeks of exogenous testosterone 
resulted in reduced LPL activity and an increased lipolytic response to norepinephrine 
in abdominal, but not femoral or gluteal subcutaneous adipose tissue, with an 
accompanying reduction noted in WHR (Rebuffe-Scrive et al. 1991). The effect of 
one year of transdermal testosterone patches upon fat distribution was investigated in 
an older cohort of men (age >55 years) with symptomatic androgen deficiency and 
low-normal testosterone levels.  An average increase in plasma testosterone of 30% 
was achieved, which effected a significant reduction in visceral fat, without changes 
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in subcutaneous or total body fat.  Fat free mass and skeletal muscle mass increased 
with testosterone, whilst lipids, insulin and glucose levels were unaltered (Allan et al. 
2007).  
 
A short-term placebo-controlled trial of Testogel (n=183 active and n=179 placebo) in 
men with late onset hypogonadism (LOH), demonstrated approximately 1kg loss of 
fat mass with accompanying increases in lean mass at 6 months (Behre et al. 2012).  
Intra-muscular testosterone enanthate was associated with improvements in lean body 
mass and reductions in fat mass in older men (mean age 71) after a three year 
treatment period, in a placebo controlled study (Page et al. 2005). 
 
Some of the effects of testosterone administration may be attributed to estradiol, 
produced from testosterone, by the action of aromatase in adipose tissue.  This 
significant confounder can be addressed by the use of non-aromatizable androgens, 
such as DHT and oxandrolone.  Oxandrolone was investigated in healthy elderly men, 
where a 12 week course was shown to reduce visceral and subcutaneous adipose 
tissue and reduce the VAT:SAT ratio; an effect observed up to 12 weeks after 
cessation of treatment (Schroeder et al. 2004). 
 
Not all studies confirm the metabolic advantages of testosterone replacement.  In 27 
elderly men, with low bioavailable testosterone, testosterone replacement had no 
effect upon body composition, albeit increasing the average level of bioavailable 
testosterone by a modest 1.1 nmol/l (Nair et al. 2006).  In hypogonadal men with 
T2DM, 40 weeks of intramuscular testosterone undecaonate resulted in increased lean 
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mass and reductions in fat mass, although this was limited to subcutaneous (but not 
visceral) abdominal adipose tissue volume (Gianatti et al. 2014).  
 
Androgen deprivation therapy (ADT) in prostate cancer provides an opportunistic 
means to assess the effects of testosterone in determining body composition and 
appears to increase fat mass at the expense of lean mass (Smith et al. 2004). A 
prospective observational study in 26 men commenced on ADT demonstrated an 
average 13% increase in subcutaneous adipose area with a 23% increase in visceral 
adipose area (Hamilton et al. 2011).   
 
When considering the consequences of androgen deficiency, it is important to 
recognise that levels of estrogens and androgens are inextricably linked by virtue of 
their common biosynthetic pathways.  Across most relevant target tissues, both 
estrogens and androgens are capable of exerting effects, sometimes complementary, 
sometimes divergent.  An elegant study in healthy volunteers, sought to untangle the 
differential contribution of estrogens and androgens with respect to symptoms and 
end-organ effects by suppressing endogenous sex steroids (with the GnRH analogue 
goserelin) and manipulating testosterone and estradiol levels with variable doses of 
testosterone gel and aromatase inhibition.  Testosterone deficiency resulted in reduced 
lean mass and muscle strength, whereas estradiol deficiency was associated with 
increasing fat mass; both estradiol and testosterone deficiency independently 
contributed towards sexual dysfunction (Finkelstein et al. 2012). Whilst the clinical 
focus is often on recognising and treating androgen deficiency, many of the beneficial 
effects of normalising testosterone may be mediated, at least in part, by consequent 
normalisation of estradiol.  Testosterone is converted to the more potent DHT by 5α-
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reductase (5α-R), which amplifies androgen receptor activation.  Treatment with the 
5α-R inhibitor dutasteride (with concomitant testosterone replacement), did not 
significantly alter fat free mass, muscle strength, sexual function or prostate volume 
in healthy men, suggesting testosterone action is sufficient (Bhasin et al. 2012). 
 
1.1.6  Methods for measuring body composition 
 
A range of modalities are available for the assessment of human body composition, 
ranging from relatively straightforward anthropometric measurements, such as BMI 
and WHR, to complex techniques, such as underwater weighing (often considered the 
gold standard), dual-energy X-ray absorptiometry (DEXA) and isotope tracer 
methods.  Body composition can be reduced to a 2-compartment model (fat mass and 
fat free mass) or a 4-compartment model, where FFM is subdivided into muscle, bone 
and water.  All methods rely on assumptions with respect to the composition of 
compartments, which do not necessarily hold, particularly in certain disease states 
(Duren 2008).   
 
1.1.6.1  Indirect methods 
 
BMI is an easy to obtain clinical parameter with strong associations in relation to both 
morbidity and mortality.  Interpretation must take into account racial differences and 
also recognise the limits in subjects where fat free mass contributes disproportionately 
to weight.  As noted earlier, WHR appears to be a more discriminatory predictor of 
cardiovascular disease than BMI (Yusuf et al. 2005).   
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Measurement of skinfold thickness, by use of callipers across a range of anatomical 
locations, provides a more detailed assessment of subcutaneous fat content.  
Regression equations can be employed to estimate body fat percentage, based on 
skinfold thickness, with reasonable agreement reported with under-water weighing 
(Durnin and Wormersley 1974).  However, this method is highly operator dependent 
and technically difficult in obese individuals, where it is much less well validated 
(Duren 2008). 
 
Bioelectric impedance analysis (BIA) estimates body composition by measuring the 
resistance of the body to a small alternating electrical current.  The impedance index 
(height2/ resistance) is directly proportional to body water and regression equations 
are employed to provide an estimate of body fat percentage.  The applicability of BIA 
results is strongly related to how closely subjects match the reference populations 
used to create the regression equations; consequently, the assumptions underlying this 
technique are not necessarily valid in obese individuals (Gray 1989). 
 
1.1.6.2  Direct methods 
 
Total body water can be measured by isotope dilution, where labelled water (most 
commonly deuterated) is administered and, following equilibration, the proportion of 
labelled to unlabelled water permits calculation of total body water.  This technique is 
rendered expensive by the necessity for mass spectrometric analysis and, like other 
methods, depends on assumptions regarding the water content of fat free mass.  
Isotope dilution is prone to overestimate body fat, perhaps due to an inadequate time 
allowance for equilibration (Fogelholm 1997).  Total body potassium is a less 
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commonly employed method where gamma radiation from the naturally occurring 
potassium isotope 40K is measured.  40K is present at a constant concentration which 
permits estimation of total body potassium and, by extrapolation, fat free mass.  This 
technique relies on assumptions regarding the compartmental distribution of 
potassium and also the potassium content of fat free mass; it has largely been 
supplanted by other methods. 
 
Underwater weighing (hydrodensitometry) is regarded as the gold standard for 
assessment of body composition.  Measures of body weight, body volume and 
residual lung volume are incorporated in to either a two-compartment, or more 
recently multi-compartment models (including measures of bone density and total 
body water), to yield an estimate of body fatness.  Air displacement plethysmography 
(ADP) obtains similar measurements (and results) to underwater weighing, and avoids 
the inconvenience associated with submersion (Fields et al. 2002).  
  
Dual-energy x-ray absorptiometry relies on the differential attenuation of two low-
energy levels passing through the body, to discriminate between tissue types.  It has 
the advantage of providing information across different body sections (limbs and 
trunk) as well as quantification of bone mineral content.  The process take no more 
than 20 minutes and is minimally invasive for subjects.  Modern DEXA algorithms 
accord closely with underwater weighing, leading some to consider DEXA as a 
potential reference standard for measurement of body composition (Pritchard et al. 
1993).   
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Whole body CT scanning can provide information on body fat content, based on the 
characteristic attenuation of adipose tissue.  Image analysis software can produce 
estimates of body fat content.  MRI imaging can provide similar information and 
avoids exposure to ionising radiation.  Single slice CT imaging at the L4/5 level can 
provide specific information regarding the balance of visceral to subcutaneous 
adipose tissue.   
 
1.2 Sex hormones and insulin sensitivity 
 
Rodent models attest to the central role sex steroids play in regulating glucose 
metabolism.  Ovariectomy induces obesity and insulin resistance in high fat diet fed 
mice; an effect which is prevented by physiological estradiol replacement (Stubbins et 
al. 2012).  In male rats, gonadectomy induces an insulin resistant state, with marked 
reduction of skeletal muscle glucose uptake; testosterone replacement prevents 
development of this abnormal metabolic state (Holmäng et al. 1992). 
 
1.2.1 Specific effects on muscle, liver and beta cells 
 
In addition to adipose tissue effects, evidence has accumulated in support of a direct 
influence of sex steroid hormones across a range of insulin sensitive tissues, 
particularly liver and muscle.  Sex steroids may also influence insulin secretion 





1.2.1.1  Muscle 
 
In men, plasma testosterone concentration correlates positively with skeletal muscle 
expression of genes involved in oxidative phosphorylation (Pitteloud et al. 2005). 
GLUT4 expression is reduced in the skeletal muscle of testosterone deficient rats 
(Muthusamy et al. 2009). 
 
Ovariectomy is associated with reduced skeletal muscle glucose uptake in female rats 
and is normalised by high does estradiol replacement. No effect on skeletal GLUT4 
protein level was observed suggesting the mechanism may relate to downstream 
signalling or altered GLUT4 trafficking (Campbell et al. 2002).  Other models 
assessing the effect of estrogen suggest a stimulatory effect of ERα upon GLUT4 
expression in skeletal muscle (Barros et al. 2006), with ERβ stimulation perhaps 
responsible for the opposite effect (Barros et al. 2009).  Not all animal models 
confirm a stimulatory effect on glucose uptake (Rogers et al. 2009).   Whilst 
physiological levels of estradiol appear to promote insulin sensitivity, in rats 
supraphysiological levels exert the opposite effect, through repression of muscle 
GLUT4 (Barros et al. 2008).  Estradiol increases skeletal muscle expression of genes 
involved in fatty acid oxidation in female mice (D’Eon et al. 2005) and also induces 
rapid phosphorylation of AMPK, a critical regulator of mitochondrial biogenesis and 








ERα knockout mice display reduced suppression of hepatic glucose output during 
hyperinsulinaemic euglycaemic clamp studies, consistent with marked hepatic insulin 
resistance (Bryzgalova et al. 2006).  High fat diet fed mice were protected from 
insulin resistance, at least in part through reduced hepatic triglyceride accumulation, 
with accompanying reductions in lipogenic transcript levels (Bryzgalova et al. 2008).   
Orchidectomy is associated with reduced insulin receptor protein levels and increased 
IRS-1 Serine636/639 phosphorylation in rats, an effect which is reversed by both 
testosterone and estradiol (Muthusamy et al. 2011); abnormalities in hepatic glucose 
oxidation were reversed by testosterone (but not estradiol) replacement. 
 
1.2.1.3  Beta cells 
 
Testosterone has been shown to reduce beta cell apoptosis in a streptozotocin-induced 
diabetes in male rats through induction of anti-oxidant enzymes (Palomar-Morales et 
al. 2010).  Pancreatic beta cells in high glucose culture medium are protected from 
apoptosis by testosterone, potentially through increased levels of survival proteins, 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA-2) and Bcl2 (Hanchang et al. 
2013). In humans, T2DM is associated with increased beta cell endoplasmic reticulum 
stress, although whether testosterone sufficiency protects against this requires further 
investigation.  Testosterone is also associated with increased insulin mRNA 
expression and insulin secretion, both in rats and primary culture of islet cells 
(Morimoto et al. 2001). 
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Estradiol is also associated with protective effects upon pancreatic beta cells, through 
interaction with extra-nuclear estrogen receptors, which exert their effect through 
modulation of cytosolic kinases.  In rats, estradiol reduced beta cell dysfunction and 
lipid accumulation (Tiano et al. 2011) and, in mice, protects against apoptosis (Liu et 
al. 2009). 
 
1.2.2  Adipokines 
 
The relationship between adipokines and sex steroid hormones is complicated, and 
largely confounded by associated changes in adiposity, in models of androgen and 
estrogen deficiency.  Short-term testosterone replacement in hypogonadal men was 
associated with reductions in circulating leptin and adiponectin (Kapoor et al. 2007).  
Transdermal estrogen replacement therapy reduced leptin and resistin, and increased 
adiponectin, in post-menopausal women (Chu et al. 2006).  Pro-inflammatory 
cytokine levels rise in women following menopause (Pfeilschifter et al. 2002) and, in 
men, levels are inversely correlated with testosterone concentration (Kelly et al. 
2013). 
 
In adipose specific androgen receptor knock-out mice, elevated levels of retinol 
binding protein 4 (RBP4) have been observed (McInnes et al. 2012).  RBP4 is 
associated with insulin resistance and metabolic syndrome in humans although levels 




1.2.3  Sex steroid effects upon insulin sensitivity: observational 
evidence in humans 
 
1.2.3.1  Women 
 
In a meta-analysis of sex hormones and type 2 diabetes risk, women with T2DM were 
shown to have significantly higher circulating estradiol levels, even after adjustment 
for BMI (Ding et al. 2006).  However, no prospective evidence exists to support a 
causative role for estradiol in the development of diabetes.  The same meta-analysis 
showed testosterone levels were significantly higher in women with T2DM, with a 
trend towards increased T2DM risk in prospective studies, in those with higher 
testosterone levels. 
 
1.2.3.2  Men 
 
T2DM and obesity are associated with an increased risk of testosterone deficiency but 
it is also true that testosterone deficiency likely carries an increased risk of developing 
T2DM and expanding body fat; these two related conditions are likely to have a bi-
directional, mutually reinforcing relationship. Androgen levels consistently show 
negative correlations with insulin resistance, although it is often argued that this 
association is not independent of variability in body fat as is borne out by the majority 
of studies (Tchernof et al. 1995; Tsai et al. 2004; Pittleoud et al. 2005).  Other studies 
failed to demonstrate any link between testosterone and insulin resistance (Nielsen et 
al., 2007).   A population based cohort study of middle-aged Finnish men (n = 651) 
identified baseline metabolic syndrome as a risk factor for incident testosterone 
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deficiency (2.6 fold increased risk which remained significant after correction for 
BMI or baseline testosterone) (Laaksonen et al. 2005). 
 
Longitudinal observations from the Framingham Heart Study failed to detect an 
association between total testosterone and development of metabolic syndrome 
(Bhasin et al. 2011), however, elevated estrone (more so than estradiol) was 
associated with incident type 2 diabetes, even after correction for testosterone and 
other relevant confounders (Jasuja et al. 2013). Men with the lowest quartile of total 
testosterone had a significantly increased risk of incident metabolic syndrome 
(adjusted RR 1.38) in the Study of Health in Pomerania (Haring et al. 2009).  Low 
testosterone may be particularly predictive of metabolic syndrome in non-obese men 
(Kupelian et al. 2006).  Men with free testosterone in the lowest tertile are reported as 
being four times more likely to develop T2DM, independent of adiposity (Selvin et al. 
2007); similar findings were noted in a meta-analysis of sex hormones and diabetes 
risk (Ding et al. 2006). Higher levels of estradiol have been associated with reduced 
cardiovascular risk in men aged over 56 years (Arnlöv et al. 2006) but also with an 
elevated risk of diabetes (Ding et al. 2006). Despite the consistency of association, 
these studies do not confirm causality.  It is conceivable that lower testosterone in 
obese men may simply reflect greater androgen inactivation from an expanded 
adipose pool. 
 
Androgen sensitivity may play a role in glucose homeostasis, as evidenced by the 
influence of CAG repeat length in the androgen receptor (associated with reduced AR 
sensitivity) upon insulin sensitivity (Mohlig et al. 2011). 
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1.2.4  Sex steroids and insulin sensitivity: interventional evidence in 
humans 
 
1.2.4.1  Estrogens (women) 
 
In addition to displaying no difference in basal carbohydrate and fat utilization, HRT 
treated women were significantly more insulin resistant, as determined by 
hyperinsulinemic euglycemic clamp studies (Ryan et al. 2002).  This data conflicts 
with studies reporting reduced incidence of T2DM in HRT treated women (Margolis 
et al. 2004) and a crossover study involving 3 months estradiol treatment in diabetic 
postmenopausal women, which demonstrated improvements in HbA1c, C-peptide, 
fasting glucose and a non-significant trend towards higher glucose disposal rate 
(Andersson et al. 1997).  
 
1.2.4.2  Androgens (women) 
 
3 months of testosterone replacement (or testosterone and estradiol in combination; 
mean age 55) resulted in a 20% reduction in glucose disposal, along with increases in 
body weight and lean mass but not fat mass.  Testosterone was also implicated in a 
reduction in HDL levels (Zang et al. 2006). 
 
DHEA supplementation in elderly women over a 2-year period did not alter insulin 
sensitivity or body composition (Nair et al 2006). 
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In hypopituitary women of reproductive age, with proven androgen deficiency, 
testosterone replacement was shown to have, at worst, a neutral effect upon insulin 
resistance (Miller et al. 2007). 
 
Assessing the effects of hormonal treatment in female to male transsexuals affords a 
rare insight into the consequences of androgen therapy in genetic females.  
Testosterone, administered on a fortnightly basis, resulted in deleterious alterations in 
lipids, including: reduced HDL cholesterol, reduced LDL size, increased triglycerides 
and increased hepatic lipase activity (Elbers et al. 2003). 
 
The androgen receptor antagonist flutamide effects reductions in visceral fat, 
improves insulin sensitivity, reduces LDL cholesterol and elevates HDL (Gambineri 
et al. 2004; Gambineri et al. 2006) in women with PCOS.  However, neither the anti-
androgen spironolactone nor the weakly androgenic anabolic steroid nandrolone, 
altered glucose or insulin concentrations in post-menopausal women following 9 
months of therapy (Lovejoy et al. 1996). 
 
1.2.4.3  Androgens (men) 
 
In young men with idiopathic hypogonadotrophic hypogonadism (mean age 40.8, n = 
12), withdrawal of testosterone replacement resulted in increased insulin resistance 
(as determined by homeostatic model assessment – insulin resistance [HOMA-IR]) 
within two weeks, in the absence of any significant change in body composition, 
suggesting a direct role for sex steroid hormones in regulating insulin sensitivity in 
men (Yialamas et al. 2007). In older men, the non-aromatizable androgen, 
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oxandrolone, resulted in improved insulin sensitivity following 12 weeks of therapy 
(Schroeder et al. 2004).   
 
TIMES2 was a randomised controlled trial involving 220 hypogonadal men with 
T2DM or metabolic syndrome; over a 12-month period, transdermal testosterone gel 
improved insulin sensitivity (16.4% as determined by HOMA-IR) as well as exerting 
beneficial effects upon LDL cholesterol and lipoprotein a (Jones et al. 2011).  The 
protocol was subject to a high drop out rate and confounded by changes in other 
medications, so whilst a trend towards improved HbA1c was observed, this did not 
reach statistical significance.  Similar effects have been observed in other small, 
short-term RCTs.  A single-blinded study of 50mg transdermal testosterone in men 
with newly diagnosed T2DM (n=32) showed a significant improvement in HbA1c 
(mean -0.8%) and insulin sensitivity by HOMA-IR at one year, when compared with 
men receiving supervised diet and exercise advice only (Heufelder et al. 2009). 
Similar improvements were noted in a double-blind crossover study in 24 
hypogonadal men with T2DM. After 3 months of intramuscular testosterone therapy, 
significant improvements in HOMA-IR, HbA1c (-0.37%) and fasting glucose were 
observed (Kapoor et al. 2006).  Clearly larger studies, with longer follow-up, are 
required to confirm whether testosterone replacement should be considered as an 
adjunct to established diabetes therapies.  
 
In contrast to these positive studies, in 27 elderly men, with low bioavailable 
testosterone, testosterone replacement had no effect upon insulin sensitivity (Nair et 
al. 2006).  A study of elderly men with testosterone deficiency, who received 
testosterone patches for two years, failed to show any difference in a comprehensive 
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panel of insulin sensitivity measures, with respect to controls (Basu et al. 2007).  
Similarly, a randomised controlled trial of intramuscular testosterone undecanoate (1g 
12 weekly over 40 weeks, n = 88) failed to demonstrate any improvement in either 
HbA1c or insulin sensitivity, as determined by HOMA-IR, in hypogonadal middle-
aged men with T2DM (Gianatti et al. 2014). 
 
Androgen deprivation therapy increased insulin resistance by 12%, as determined by 
HOMA-IR (Hamilton et al. 2011).  Observational evidence, in older men with 
prostate cancer, shows GnRH agonist therapy to be associated with an increased risk 
of incident diabetes (adjusted HR 1.44) (Keating et al. 2006). 
 
1.2.5  Methods for measuring insulin sensitivity 
 
Insulin effects upon whole body glucose disposal are concentration-dependent and 
saturable, with the concentration required to achieve half-maximal response defining 
‘insulin sensitivity’.  Insulin resistance typically reflects impairment of both glucose 
disposal and suppressibility of hepatic glucose production.  A number of 
methodologies are available to quantify insulin sensitivity, either directly or indirectly 
(Muniyappa et al. 2007). 
 
Hyperinsulinaemic euglycaemic clamp techniques, originally developed by DeFronzo 
and colleagues (DeFronzo et al. 1979), are generally considered the ‘gold standard’ 
method for measuring insulin sensitivity.  Following an overnight fast, subjects 
receive a constant intravenous infusion of insulin, ultimately resulting in an elevated 
steady state insulin concentration.  20% dextrose solution is concurrently infused at a 
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variable rate (informed by measurement of arterialized blood glucose levels) to 
maintain euglycaemia.  When steady state conditions are achieved, and assuming 
hyperinsulinaemia is sufficient to ablate hepatic glucose production, the glucose 
infusion rate (GIR) can be regarded as equal to the glucose disposal rate (M).  M is 
often normalised to fat free mass, as skeletal muscle is the major source of insulin-
mediated glucose uptake. Concomitant infusion of isotopically labelled glucose 
permits calculation of both hepatic glucose production and glucose disposal and 
addresses the potential problem of sub-maximal suppression of hepatic glucose 
production when attempting to assess glucose disposal.  Glucose clamp studies are an 
accurate and direct means of assessing insulin sensitivity, however they are both time 
and labour intensive. 
 
Another direct measure is the insulin suppression test, which utilises somatostatin 
analogues to suppress endogenous insulin secretion with concomitant constant 
infusions of glucose and insulin, to achieve steady state levels.  Insulin suppression 
tests correlate well with clamp studies (r = 0.93) but, although easier to conduct, do 
not provide additional information on hepatic glucose production (Greenfield et al. 
1981). 
 
Indirect methods of assessing insulin sensitivity tend to have the advantage of being 
less resource intensive but are typically less accurate and reproducible than glucose 
clamp studies.  In the fasting condition, glucose and insulin concentrations are in a 
basal steady state where insulin levels are relatively steady and hepatic glucose 
production is constant.  Mathematical transformations, which assume equivalence of 
peripheral and hepatic insulin resistance, have been developed to produce estimates of 
! 45 
insulin sensitivity.  One such example is HOMA-IR (Matthews, 1985), which is 
calculated as follows: 
 
(Fasting glucose (mmol/L) x Fasting insulin (µU/mL)) /22.5  
 
The normalising factor of 22.5 is the product of a fasting insulin of 5 µU/mL and 
fasting glucose of 4.5 mmol/L; thus a ‘normal’ individual would have a HOMA-IR of 
1.    HOMA-IR correlates well with glucose clamp assessment of insulin resistance (r 
= 0.88) but is limited in individuals with advanced beta cell failure.  ‘Quantitive 
insulin sensitivity check index’ (QUICKI) is a variant of HOMA-IR which involves 
logarithmic transformation of fasting glucose and insulin values (Katz et al. 2000). 
 
To overcome the limitations of assessments in the fasting state, Matsuda and 
DeFronzo developed a method which assesses both hepatic insulin sensitivity (fasting 
state) and peripheral insulin sensitivity (following oral glucose tolerance test).  
Subjects fast overnight and, following basal blood samples, are given a 75g oral 
glucose load.  Further sampling takes place at 30 minute intervals for 2 hours.  
‘Insulin Sensitivity Index  - Matsuda’ is calculated thus: 
 
10,000/ ([fasting glucose (mg/dL) x fasting insulin (uU/mL)] x [mean glucose 
during OGTT (mg/dL) x mean insulin during OGTT (uU/mL)]) 
 
ISI-Matsuda correlates well with both glucose clamp studies (r = 0.74) and HOMA-
IR (r = 0.92) (Matsuda, 1999).   
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Frequently Sampled Intravenous Glucose Tolerance Tests, using minimal modelling 
techniques, is another dynamic method for indirectly assessing insulin sensitivity.  It 
has the advantage of being less laborious than glucose clamp studies, can provide a 
range of information on beta cell function and insulin sensitivity and correlates 
reasonably well with clamp studies, although insulin sensitivity tends to be 




Aromatase is the enzyme responsible for conversion of androgens to estrogens (figure 
1.1).  As noted previously, in both men and post-menopausal women, estrogen 
receptor activation is largely mediated by local generation of estradiol (in bone, 
breast, adipose tissue etc.).  In this context, it has been suggested that circulating 
estrogen levels are simply a passive indicator of adipose hormone generation and may 
not operate as hormones in a classical sense (i.e. by exerting an effect at a site distant 
from their generation) (Simpson et al. 2005). Estrogen generation by aromatase is just 
one of many steroid metabolic pathways active in adipose tissue.  In vivo assessment 
of adipose steroid metabolism by measuring arterio-venous difference across 
subcutaneous abdominal fat, demonstrated the release of estradiol and estrone in both 
men and women.  Testosterone was removed, across the gradient, in men but released 






1.3.1  Aromatase and adipose generation of sex steroids 
 
1.3.1.1  Regulation of aromatase 
 
Aromatase is a microsomal member of the cytochrome P450 superfamily of enzymes, 
encoded by the CYP19 gene on chromosome 15q21.2.  In humans, aromatase is 
expressed in ovaries, testes, vascular smooth muscle and adipose tissue (Jones et al. 
2006).  Aromatase is regulated by promoters in a tissue dependent manner (Agarwal 
et al. 1997), with promoter I.4 predominant in adipose tissue where it is activated by 
class I cytokines (including IL-6, IL-11 and oncostatin M) and TNFα and has an 
obligatory requirement for glucocorticoids (Zhao et al. 1995).  Promoter II is 
regulated by cAMP and gonadotrophins and is predominant in the ovaries; although it 
is also active, to a lesser extent, in adipose tissue, where PGE2 is believed to drive 
expression (Simpson et al. 2002). In breast cancer, increased aromatase expression in 
peri-tumoral adipose tissue is marked by a switch from promoter I.4 to promoter II 
(Zhao et al. 1996), raising the intriguing possibility that dysregulated aromatase 
expression may arise in the pro-inflammatory milieu of obese adipose tissue.  
 
Activation of promoter I.4 requires glucocorticoid, which is borne out by in vitro 
evidence of increased aromatase expression in adipose stromal cells exposed to 
cortisol (Simpson et al. 1981).  Inhibition of the cortisol-regenerating 11β-
hydroxysteroid dehydrogenase type 1 (11βHSD1) activity, by carbenoxolone, was 
shown to influence the aromatase activity of breast adipose stromal cells in vitro 
(Yang et al. 1997).  More recent evidence has highlighted depot and gender 
specificities of cortisol response.  In vitro, cortisol markedly increases aromatase 
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expression in subcutaneous preadipocytes in women but not men, whilst in omental 
preadipocytes, cortisol effects a more modest increase in expression in both men and 
women (Mcternan et al. 2002).  Leptin down-regulated 11βHSD1 and aromatase 
expression in female intra-abdominal preadipocytes but had the opposite effect in 
men.  Estradiol stimulated 11βHSD1 in women but decreased aromatase expression; 
in men aromatase was up-regulated with no effect upon 11βHSD1.  Androgens 
increased expression of both aromatase and 11βHSD1 in male intra-abdominal 
preadipocytes (Dieudonne et al. 2006). 
 
Obesity has been associated with greater aromatase activity (Kley et al. 1980), which 
may reflect greater adipose mass rather than any up-regulation at a cellular level 
(Cleland et al. 1985).  However generalised obesity (as determined by BMI), although 
not central obesity (as determined by WHR), was correlated with increased 
subcutaneous adipose expression of aromatase mRNA (Wake et al. 2007).   
 
1.3.1.2  Distribution of aromatase in adipose tissue 
 
 In adipose tissue, aromatase is principally expressed in preadipocytes and factors 
which promote adipocyte differentiation, such as PPARγ agonists, reduce its 
expression (Rubin et al. 2000).  Aromatase is preferentially expressed in buttock and 
thigh subcutaneous adipose tissue rather than in the abdominal region (2 – 3 fold 
difference), with no sexual dimorphism but increasing expression with advancing age 
(Bulun et al. 1994).  To assess the prevalent pattern of steroid metabolism, stromal 
cells isolated from various adipose depots were cultured with tritiated 
androstenedione to assess the percentage conversion to estrone and 5-alpha-reduced 
! 49 
androgens.  Aromatase activity was tenfold greater in the upper thigh and buttock 
compared to subcutaneous abdominal and omental fat.  5α-reductase activity, similar 
across all locations, was tenfold greater than aromatase activity in subcutaneous 
abdominal and omental fat (Killinger et al. 1990). 
 
 1.3.1.3  Other sex hormone metabolism in adipose tissue 
 
In addition to aromatase mediated conversion of androgens to estrogens, a number of 
other enzymes, which metabolise sex steroid hormones, are active in adipose tissue. 
17-beta hydroxysteroid dehydrogenase type 5 (17β-HSD5, also known as AKR1C3) 
catalyses the conversion of androstenedione to testosterone; In vitro assessment of 
female preadipocytes has shown greater  activity in the subcutaneous compartment, as 
opposed to the omental depot, in keeping with androgen generation in the 
subcutaneous fat.  The activity of subcutaneous 17β-HSD5 is strongly correlated with 
BMI and reduced with weight loss (Quinkler et al. 2004).  This study does not accord 
with earlier findings which suggested 3-alpha hydroxysteroid dehydrogenase type 3 
(3α-HSD3, also known as AKR1C2, which catalyses the inactivation of DHT) is more 
plentiful than 17β-HSD5 in both the visceral and subcutaneous compartment in 
women (Blouin et al. 2003).  Both 3α-HSD3 and 17β-HSD5 were more highly 
expressed in the subcutaneous adipose.  In women with elevated levels of visceral 
adipose tissue, higher 3α-HSD3 activity was observed in omental preadipocytes 
(Blouin et al. 2003).   
 
17β-HSD3, which also converts androstenedione to testosterone, was found to be 
expressed in female subcutaneous and abdominal adipocytes at significantly higher 
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levels than aromatase.  This is in keeping with in vitro conversion of androstenedione 
to testosterone occurring at a far greater level than androstenedione to estrone.  Intra-
abdominal adipose 17β-HSD3 to aromatase mRNA ratio was positively correlated 
with BMI and WHR, with the converse being true of the corresponding subcutaneous 
ratio (Corbould et al. 2002).  In men, primary culture studies have demonstrated 
greater DHT inactivation (mediated by 3α/β HSD) in mature adipocytes and 
preferentially in the subcutaneous rather than visceral compartment.  Omental 3α/β 
HSD activity was greater in obese men and positive correlations existed between this 
activity and androgen metabolite levels (androstene-glucuronide and 3α-diol-
glucuronide) in all subjects (Blouin et al. 2006).  In keeping with this, plasma 3α-diol-
glucuronide levels have been positively correlated with visceral adiposity (Tchernof 
et al. 1997) and increase with weight gain (Pritchard et al. 1996). Central obesity, but 
not generalised obesity, is associated with increased expression of 3α-HSD3 and 17β-
HSD5, in men and women (Wake et al. 2007).   
 
More recently, expression of the estrogen inactivating enzyme estrogen 
sulfotransferase (EST) has been identified in human subcutaneous adipose tissue, in 
both men and women (Ahima et al. 2011), where it was correlated with TNF-α 
expression.   A murine model of adipose EST over-expression resulted in reduced 
adipose mass and reduced adipose tissue glucose uptake (Khor et al. 2010).  The 
relative importance of adipose EST, in relation to aromatase and other enzymes, 
remains to be established. 
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 Sex hormone metabolism in adipose tissue is clearly a complex process with several 
intimately related pathways acting simultaneously to determine the local balance of 
androgen and estrogen receptor activation. 
 
1.3.2  Aromatase deficiency 
 
Insights into the systemic effects of aromatase action were initially derived from rare 
examples of human aromatase deficiency and also aromatase knockout mice.   
 
Human aromatase deficiency is extremely rare, with only 7 men and 6 women 
identified as of 2006 (Jones et al.  2006).  Men with aromatase deficiency tend to 
present with central adiposity and body mass index in the overweight range.  The 
characteristic lipid profile is of elevated triglyceride and low HDL, which is generally 
ameliorated by estrogen replacement.  Insulin resistance has been reported in most 
cases, with evidence of improvement with estrogen replacement (Herrmann et al. 
2002; Morishima et al. 1995), although not all affected men demonstrate insulin 
resistance  (Carani et al. 1997).  
 
Aromatase-knockout mice (ArKO) develop exaggerated intra-abdominal adiposity, 
with increased adipocyte volume and decreased lean body mass.  At 1 year, insulin 
and leptin levels were increased, with evidence of reduced glucose oxidation; these 
changes were associated with reduced spontaneous physical activity but not with any 
significant change in dietary intake or resting energy expenditure (Jones et al. 2000).  
More detailed assessment of glucose tolerance, using intraperitoneal glucose tolerance 
testing, confirmed marked insulin resistance in male ArKO mice (Takeda et al. 2003).  
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Estradiol replacement reversed changes in adiposity and adipocyte size with 
concomitant reduction in leptin and LPL gonadal adipose mRNA transcript levels.  As 
no effects upon lipolysis or fatty acid oxidation were observed, it seems likely that 
changes in adipocytes are a consequence of increased uptake of circulating lipid 
(Misso et al. 2003).  Male ArKO mice display marked hepatic steatosis accompanied 
by elevated perilipin 2 and FAS mRNA transcript levels in liver; estradiol 
replacement reverses both the steatosis and reduces perilipin 2 and FAS transcript 
levels (Hewitt et al. 2004).  Taken together, the features of human and murine 
aromatase deficiency support a central role for estrogens in maintaining metabolic 
health, although a contribution from changes in circulating androgens cannot be 
completely excluded. 
 
A number of polymorphisms have been identified in CYP19, which are known to 
influence circulating estradiol levels and, in some cases, bone mineral density.  The 
GG genotype of CYP19 rs2470152 is associated with 13% higher circulating estradiol 
levels, and higher lumbar BMD, than the AA genotype in young men (Eriksson et al. 
2009).  Men with high levels of a TTTA repeat polymorphism in intron 4 of CYP19 
(associated with higher aromatase activity in cultured skin fibroblasts), have higher 
concentrations of estradiol and higher lumbar BMD (Gennari et al. 2004), whilst low 
TTTA repeat quantity is associated with obesity and hyperandrogenaemia in 
premenopausal women (Baghaei et al. 2003). CYP19 rs2446405 AA genotype is 
associated with higher insulin sensitivity when compared with the AT genotype in 
peri-menopausal women.  Similarly, the CYP19 rs2414095 AA genotype confers a 




1.3.3  Effect of aromatase inhibitors on steroid hormone concentration 
 
Three ‘third generation’ aromatase inhibitors are currently in clinical use for the 
treatment of hormone receptor-positive breast cancer in post-menopausal women:  
two non-steroidal derivatives, anastrozole and letrozole, and one steroidal derivative, 
exemestane (figure 1.3).    Aromatase inhibitors are associated with lower cancer 
recurrence rates than the selective estrogen receptor modulator tamoxifen (Dowsett et 
al. 2010) and are therefore considered first-line therapy, where typically a five-year 
course is recommended.  In 2012, 1.14 million community prescriptions were issued 
for third generation aromatase inhibitors in England (Prescribing and Primary Care 
Services, Health and Social Care Information Centre, 2013).  
 
Anastrozole appears to be a selective inhibitor of aromatase, with no effect observed 
upon cortisol (including ACTH-stimulated) and aldosterone concentrations (Buzdar et 
al.  2001).  Letrozole, in contrast, was associated with a 26.7% reduction in 8am 
plasma cortisol (with a similar decline in aldosterone) following 4 months of therapy, 
in women with metastatic breast cancer (Bisagni et al. 1996) and also with significant 
reductions in ACTH-stimulated cortisol, at 3 months, in women with advanced breast 







Figure 1.3  Structure and pharmacokinetics of third generation aromatase 




Assessment of the degree and durability of estradiol suppression with aromatase 
inhibitors is surprisingly limited given their widespread use but is perhaps explained 
by the methodological difficulties in accurately measuring estrogens towards the 
lower end of the physiological range.  Within the first few months of therapy in breast 
cancer, greater than 90% suppression of circulating estradiol is achieved with 
letrozole and anastrozole.  Suppression appears to be less complete in healthy male 
volunteers and also where employed as a potential therapy for male hypogonadism 
(table 1.2), presumably as a consequence of secondary elevation of LH and increased 
substrate androgen levels; negative feedback at the pituitary level is primarily 
mediated by circulating estradiol (Raven et al. 2006).  Where a compensatory LH rise 
was prevented by concurrent goserelin acetate (GnRH agonist) administration, greater 
estradiol suppression (up to 91.6%) was observed in healthy male volunteers 
(Finkelstein et al. 2013).  The method used to measure estradiol may be important, as 
the degree of suppression was 58% with RIA compared to >89% with GC-MS, in one 
study, suggesting RIA may also measure cross-reacting estrogen metabolites (Santen 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.3.4  Metabolic effects of aromatase inhibitors 
 
Despite the biological plausibility of aromatase inhibition leading to increased insulin 
resistance, no formal assessment of the effects of this medication class in post-
menopausal women (the main group exposed to this treatment) has been published to 
date.  A single small study (n=11) longitudinally assessed body composition in post-
menopausal breast cancer patients, treated with 3rd generation aromatase inhibitors, 
showing a small increase in lean mass, with no significant change in body fat over 
two years (Van Londen et al. 2011). 
 
Female rats treated with letrozole develop a phenotype consistent with PCOS, with 
inguinal fat accumulation, enlarged adipocytes and insulin resistance, as determined 
by euglycaemic hyperinsulinaemic clamp (Maliqueo et al. 2013), thus lending support 
to the potential for adverse metabolic consequences.    
 
A number of small studies have sought to assess the metabolic effects of aromatase 
inhibition in men.  In young men, 10 weeks of anastrozole did not influence BMI or 
fat mass (determined by DEXA) nor did it influence carbohydrate or lipid oxidation 
(Mauras et al. 2000).  12 weeks of anastrozole (1mg daily [n=12] or 1mg twice 
weekly [n=11]) in elderly men with ‘mild hypogonadism’ (mean age 67) did not 
result in any significant difference in HOMA-IR or fasting insulin concentration 
(Dougherty et al. 2005).  28 days of letrozole (2.5mg daily) did not result in any 
change in fasting glucose or insulin in older men (mean age 76.1 [n=10]) but was 
associated with reductions of 7% and 37% in fasting glucose and insulin, respectively, 
in younger men (mean age 25.9 [n=10]) (Lapauw et al. 2009); serum leptin was also 
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reduced following aromatase inhibitor therapy in this cohort.  Similarly, 7 days of 
letrozole (2.5mg daily) in younger men (mean age 34) resulted in significantly 
improved insulin sensitivity as determined by hyperinsulinaemic euglycaemic clamp, 
an effect which was negated by concomitant estradiol replacement, although this 
intervention also resulted in testosterone levels lower than baseline (Lapauw et al. 
2010); a mixed-meal test, following clamp studies, also demonstrated increased post-
prandial plasma GIP concentrations and lower triglyceride concentrations.  
 
The current evidence base is limited by the short duration of interventions, small 
study populations, employment of suboptimal methodologies for assessing insulin 
sensitivity and in failing to assess the population most commonly exposed to 
aromatase inhibition (i.e. post-menopausal women).   
 
1.3.5  Aromatase inhibitors as therapy for androgen deficiency 
 
Obesity and type 2 diabetes mellitus are associated with a high prevalence of male 
hypogonadism.  A large community-based cross-sectional study in the United States 
(n = 1849) reported rates of subnormal free testosterone in non-diabetic men of 26% 
(lean), 29% (overweight) and 40% (obese); for men with diabetes the proportions 
were significantly higher across the three weight categories at 44%, 44% and 50%, 
respectively (Dhindsa et al. 2010).  Increased aromatase activity, in an inflamed, 
expanded adipose pool, has been implicated as the potential mechanism for 
hypogonadism in this context (figure 1.3).  Metformin reduces aromatase expression 
in cultured breast adipose cells through an effect on cAMP mediated expression 
(Samarajeewa et al. 2011), raising the possibility that a similar effect may exist in the 
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pro-inflammatory milieu of obese adipose tissue.  Total body aromatase activity is 
known to increase in the context of acute illness, lending support to the concept that a 
pro-inflammatory state is conducive to increased aromatisation of androgens (Spratt 
et al. 2006).  Aromatase inhibition has been investigated as a potential therapy for 
obesity related hypogonadism, with once weekly letrozole (2.5mg) resulting in either 
normal or supra-physiological free testosterone concentrations in 12 severely obese 
men over a 6-month period, without a precipitous decline in estradiol (Loves et al. 
2008).    Aromatase inhibitors effectively increase testosterone levels, even in 
eugonadal men, but the resultant decline in estradiol has the potential to adversely 
affect bone mineral density, as was the case in a study of 34 hypogonadal older men, 










1.4  Summary 
 
A substantial body of evidence exists to support a central role for sex steroid 
hormones in the maintenance of metabolic health and body composition.  
Perturbations in either circulating levels of sex steroid hormones, or sex hormone 
action, are associated with adverse changes in body composition, insulin resistance 
and diabetes mellitus, with some effects likely to be gender specific.  Aromatase is a 
central regulator of circulating androgen and estrogen concentration in men and post-
menopausal women and, perhaps more importantly, of tissue concentrations of these 
hormones.  Disruption of aromatase action, be it through genetic mutation or 
pharmacological inhibition, has metabolic consequences, although as with all 
manipulations of sex steroid hormones, the relative importance of estrogen and 
androgen effects can be difficult to discern.  This is additionally complicated by the 
relative balance of androgen receptor, estrogen receptor alpha and estrogen receptor 
beta activation in any given tissue.   
 
Aromatase inhibitors are a commonly prescribed drug class, making a thorough 
assessment of their metabolic sequelae desirable.  This thesis addresses the influence 
of sex steroid hormones upon metabolic health, in both men and women, primarily by 






1.5  Global hypothesis and aims 
 
This thesis sought to examine the effect of sex steroid hormones upon metabolic 
health and, in particular, the effects of pharmacological aromatase inhibition. 
 
I hypothesised that: 
1. Lower levels of circulating estrogens are associated with poorer metabolic 
health in both men and women. 
2. Aromatase inhibition is associated with deleterious effects upon body 
composition. 
3. Aromatase inhibition is associated with increased insulin resistance. 
4. Aromatase inhibition results in alterations in circulating adipokines and 





Materials and methods  
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2.1 Patient Recruitment 
 
2.1.1 Ethical approvals 
 
Ethical approval for human studies was obtained from the Lothian Research Ethics 
Committee.  The following approvals relate to this thesis: 
 
1. Metabolic effects of aromatase inhibition (07/S1101/32), Chief Investigator:  
Dr Fraser Gibb 
2. Assessing the effects of aromatase inhibition on body fat distribution and 
insulin sensitivity in post-menopausal breast cancer patients (08/S1101/54), 
Chief Investigator: Dr Fraser Gibb 
 
 
2.1.2 Recruitment process 
 
Metabolic effects of aromatase inhibition in men 
 
Healthy male volunteers were recruited through advertisements, placed in local 
newspapers, and through posters displayed across NHS Lothian and University of 
Edinburgh sites.   
 
Assessing the effects of aromatase inhibition on body fat distribution and insulin 
sensitivity in post-menopausal breast cancer patients 
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Breast cancer patients on aromatase inhibitor therapy were identified by weekly 
review of case notes at the Breast Cancer Clinic, Western General Hospital, 
Edinburgh.  Age-matched volunteers were recruited from the South East Scotland 
Breast Cancer Screening Programme through posters displayed in the Breast 
Screening Centre, Ardmillan House, Edinburgh.   
 
2.2 Tissue Collection 
 
2.2.1. Blood sampling 
 
Whole blood was collected following cannulation of a peripheral vein and stored on 
ice prior to processing, which occurred within 30 minutes of sample collection.  
Sarstedt Monovette® blood collection tubes were used.  Plasma or serum samples 
were prepared by centrifugation (12,000 rpm, 10 minutes, 4°C) and stored at -80°C 
until analysis. 
 
Blood collected for serum was collected in containers containing a separation 
polyacrylic ester gel.  Glucose samples were collected into tubes containing fluoride 
(1mg/mL blood) and EDTA. 
 
 
2.2.2 Subcutaneous adipose tissue biopsy 
 
Subcutaneous adipose tissue biopsies were performed in the ‘Assessing the effects of 
aromatase inhibition on body fat distribution and insulin sensitivity in post-
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menopausal breast cancer patients’ (Chapter 4) and ‘Metabolic effects of aromatase 
inhibition in men’ (Chapter 5) studies.  Subjects were placed in a recumbent position; 
the abdomen was exposed and, an area approximately 10 cm lateral to the umbilicus 
was cleaned with sterile solution (chlorhexidine). Lidocaine 2%  (Hameln 
Pharmaceuticals, Gloucester, UK) was infiltrated intradermally with a 25G needle and 
into the subcutaneous compartment with a 21G needle (total volume approximately 
5mL).  Following an interval of 2 minutes (to allow the anaesthetic to take effect), a 
12G needle was inserted laterally into the subcutaneous adipose compartment and 
adipose tissue aspirated into a sterile 50mL syringe, under suction.  DEPC water was 
then drawn into the syringe and the contents expelled over a sterile stainless steel 
mesh.  Visible blood clots were removed with sterile tweezers and the remaining 
tissue was promptly transferred into a sterile 2 mL eppendorf which was immediately 
placed on dry ice.  Up to three aspirations were performed in order to obtain sufficient 

















Sarstedt Ltd., Leicester, UK  
 
2.3.2 RNA extraction & cDNA synthesis 
 
" RNeasy Lipid 
minikit 
Qiagen, Crawley, UK Cat. No. 74804 
" QIAzol Lysis 
Reagent 




Sigma, Dorset, UK C7559-5VL 
" Ethanol  Sigma, Dorset, UK E7023-4X4L 
 
2.3.3 Real time quantitative RT-PCR mRNA transcript assays and 
solutions 
 
Primers and probes listed in section 2.4 (table 2.2) 
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" PCR grade water Roche Diagnostics, Mannheim, 
Germany 
Cat. No. 04 707 494 
001 
" LightCycler® 480 
Probe Master 
Roche Diagnostics, Mannheim, 
Germany 
Cat. No. 04 707 494 
001 
" Universal Probe 
Library Probes 
Roche Diagnostics, Mannheim, 
Germany 
 




" Estrone ELISA DRG Diagnostics, Germany EIA-4147 
" Estradiol sensitive 
ELISA 
DRG Diagnostics, Germany EIA-4399 
" Testosterone ELISA DRG Diagnostics, Germany EIA-1559 
" Androstenedione 
ELISA 
DRG Diagnostics, Germany EIA-3265 
" SHBG Immulite 
2000 ELISA 
Siemens Healthcare, Llanberis, 
UK 
 
" Insulin ELISA DRG Diagnostics, Germany EIA-2337 









2.3.5 Tracer and hyperinsulinaemic euglycaemic clamp  
 
" Accu-Chek Blood 
Glucose Monitor 
Roche Diagnostics Ltd., 
Burgess Hill, UK 
 
" 6,6-d2-glucose Cambridge Isotopes, CK Gas 




Cambridge Isotopes, CK Gas 
Products, Hampshire, UK 
DLM-1229-SP-10 
" Actrapid® Insulin Novo Nordisk, Crawley, UK  
" Glucose 20% Baxter, Berkshire, UK  
 
2.3.6 Gas Chromatography – Mass Spectrometry  
 
" HPLC grade water Fisher Scientific, 
Loughborough, UK 
 
" HPLC grade 
acetonitrile 
VWR, Lutterworth, UK  
" Heptane Rathburn, Walkerburn, UK  
" Pyridine Sigma-Aldrich, Dorset, UK  
" Acetic anhydride Sigma-Aldrich, Dorset, UK  
" Glucose Sigma-Aldrich, Dorset, UK  
" Glycerol Sigma-Aldrich, Dorset, UK  
" Methane, research 
grade 
BOC, Edinburgh, UK  
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2.3.7 Liquid Chromatography Tandem Mass Spectrometry  
 
HPLC grade water Fisher Scientific, 
Loughborough, UK 
 
HPLC grade methanol Fisher Scientific, 
Loughborough, UK 
 
HPLC grade acetone Fisher Scientific, 
Loughborough, UK 
 
HPLC grade acetonitrile Fisher Scientific, 
Loughborough, UK 
 
HPLC grade hexane Fisher Scientific, 
Loughborough, UK 
 
Estrone Sigma-Aldrich, Dorset, UK  
Estradiol Sigma-Aldrich, Dorset, UK  
Testosterone Sigma-Aldrich, St Louis, USA  
Androstenedione Sigma-Aldrich, Dorset, UK  
Formic acid ≥98% Sigma-Aldrich, Dorset, UK  
Triethylamine ≥99.5% Sigma-Aldrich, Dorset, UK  
FMP-TS Sigma-Aldrich, Dorset, UK  
3,4-[13C]2-estrone Cambridge Isotope Laboratories, 
Andover, USA 
 
3,4-[13C]2-estradiol Cambridge Isotope Laboratories, 
Andover, USA 
 
2,3,4-[13C3]- Sigma-Aldrich, Dorset, UK  
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androstenedione 
2,3,4-[13C3]-testosterone Sigma-Aldrich, Dorset, UK  
 




All kits for RNA extraction and reverse transcription were from Qiagen, West Sussex, 
UK. 
 
2.4.2 Buffers and Solutions 
 
2.4.2.1 DEPC water 
10 drops of diethylpyrocarbonate (DEPC) were added to 1 litre of distilled water.  
This was mixed and allowed to stand at room temperature for 24 hours prior to 
autoclaving.  Subsequent storage was at room temperature. 
 
2.4.2.2 10x TBE 
Tris base (0.89M), boric acid (0.89M) and EDTA (0.5M, 40 mL) were dissolved in 
distilled water (800 mL).  pH was adjusted to 8.0 by the addition of NaOH (1M) and 






2.4.2.3 0.5x TBE 
 




2.4.3 RNA Extraction from subcutaneous adipose tissue 
 
Approximately 100 mg of adipose tissue was homogenized in Qiazol Lysis Reagent 
(1 mL, Qiagen), using a tissue lyser (Tissue Lyser, Qiagen, UK) and incubated for 5 
minutes at room temperature.  Chloroform (200 µL) was added, mixed and incubated 
at room temperature for 3 minutes, before centrifugation (12,000 g; 15 minutes; 4°C).  
The supernatant (600 µL) was removed and replaced by an equal volume of ethanol 
(70%, v/v), which was mixed by pipetting.  The solution was transferred to a RNeasy 
spin column and the eluate discarded after centrifugation (10,000 g; 30 seconds; RT).  
The column was washed with 700 µL Buffer RW1 and centrifuged (10,000 g; 30 
seconds; RT) with the eluate discarded.  This was followed by a further washing step 
with 500 µL Buffer RPE with centrifugation (10,000 g; 30 seconds; RT) and disposal 
of the eluate.  500 µL RPE buffer was added and the column centrifuged (10,000 g; 2 
minutes; RT).  Subsequently the RNeasy spin column was placed in a fresh 2 mL 
collecting tube and any residual RPE buffer removed by centrifugation (16,000 g; 1 
minute; RT).  The RNeasy spin column was then placed in a fresh Eppendorf (1.5 
mL), 40 µL RNase-free water added and incubated at room temperature for 10 
minutes.  RNA was eluted by centrifugation (10,000 g; 1 minute; RT) and the eluate 
added back to the column for a further 10 minute incubation at room temperature, to 
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increase the potential yield of RNA.  Finally, RNA was re-eluted by centrifugation 
(10,000 g; 1 minute; RT) and stored at -80°C.   
 
2.4.4 RNA Quantification 
 
RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher, West 
Sussex, UK).  Absorbance at 260 nm wavelength (A260) was used to determine 
concentration.  Purity was assessed by the ratio of RNA to DNA (A260/A280); this 
was regarded as acceptable if between 1.9 and 2.1, effectively excluding significant 
contamination with protein or solvent.   
 
2.4.5 cDNA synthesis 
 
Total RNA (0.2 - 0.5 µg) was reverse transcribed using the QuantiTect Reverse 
Transcription kit (Qiagen).  RNA (12 µL) was added to gDNA wipeout buffer (2 µL) 
and incubated (42°C, 2 minutes) to remove any genomic DNA contaminants.   
Quantiscript RT buffer, RT primer mix and Quantiscript Reverse Transcriptase were 
added to each sample (Table 2.1).  A negative control without reverse transcriptase 
was prepared to detect any contamination with genomic DNA (‘RT negative’ in table 
2.1).   A further negative control with water and no RNA was used to detect any RNA 
contamination in the reagents (‘Water control’ in table 2.1).  Samples were incubated 
(42 °C, 15 minutes; then 95 °C, 3 minutes) in a PCR thermal cycler, before cooling to 




 1x reaction volume RT negative Water control 
500ng RNA Make up to 12 µL 
with RNase-free 
water 






2 µL 2 µL 2 µL 
Quantiscript RT 
buffer 
4 µL 4 µL 4 µL 




1µL - 1 µL 
RNase-free water - 1 µL 12 µL 
Total volume 20 µL 20 µL 20 µL 
 




2.4.6 Real-time Polymerase Chain Reaction (RT-PCR) 
 
mRNA quantification was performed using real-time PCR on a LightCycler® 480 
(Roche Diagnostics Ltd., Burgess Hill, UK) using LightCycler® 480 software version 
1.5.   Intron-spanning primers (Invitrogen Ltd., Paisley, UK) were designed using the 
Roche Universal Probe Library Assay Design Center.  Primers and probes for genes 
of interest (and the selected housekeeping gene, cyclophylin A) are summarised in 
table 2.2.  Aliquots from all samples being analysed were pooled and a standard curve 
created by serial dilution with PCR grade water at the following concentrations: 1:4, 
1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512.  An 8 µL Mastermix was prepared which 
constituted: Probe master (5 µL), PCR grade water (2.7 µL), forward primer (0.1 µL), 
reverse primer (0.1 µL) and probe (0.1 µL); this was added to each well. Water and -
RT negative controls (as described in section 2.4.5) were analysed on each plate.  
Diluted cDNA (2 µL) samples were added to each well, plates were sealed with an 
optical adhesive cover and then centrifuged (4214 g, 2 minutes, RT) before being run 
on the PCR system.  A single gene was quantified for all samples on one plate.  All 
samples and standards were analysed in triplicate. 
 
Samples were denatured by heating (95 °C, 5 minutes), followed by 50 cycles of PCR 
amplification:  denaturation (95 °C, 10 seconds), annealing (60 °C, 30 seconds) and 
elongation (72 °C, 1 second).  Finally, samples were cooled to 40 °C for 30 seconds.  
Amplification curves were plotted with cycle number on the x-axis and fluorescence 
intensity on the y-axis.  Excitation was at 483 nm and detection at 533 nm.  
Triplicates were considered acceptable if standard deviation of the crossing point was 
<0.4 cycles.  The standard curve generated from pooled, diluted samples was fitted 
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with a straight line and considered acceptable if reaction efficiency was between 1.7 
and 2.2.   
 
mRNA was quantified and normalised against the expression of the housekeeping 
gene, cyclophilin A.  This housekeeping gene has been successfully employed by 
other investigators under similar experimental conditions (Wake et al. 2007) and was 
present in similar abundance to the genes of interest. There have been reports of 
cyclophilin A upregulation in murine vascular smooth muscle exposed to 
inflammatory stimuli (Nigro et al. 2011) and also of a stimulatory effect of 
hyperglycaemia in in vitro experiments, albeit in monocytes (Ramachandran et al. 
2012).  There is no direct evidence to suggest any effect of sex steroid hormones upon 
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2.5 Enzyme-linked Immunosorbent Assay (ELISA) 
 
2.5.1 Principles of ELISA 
 
Commercially available ELISA kits were used in accordance with manufacturers’ 
instructions.  Microtitre wells are coated with antibody directed to an antigenic site on 
the analyte of interest.  Endogenous analyte competes with analyte-horseradish 
peroxidase conjugate for binding to the antibodies during an incubation phase.  
Subsequently, sample is removed and the plate washed with a supplied wash buffer 
(commonly phosphate buffered saline with Tween detergent).  A detection solution is 
added which releases a coloured dye in the presence of peroxidase activity (e.g. 
3,3’,5,5’-tetramethylbenzidine which is converted to blue-coloured 3,3’,5,5’-
tetramethylbenzidine diimine).  Colour change is inversely proportional to the 
concentration of analyte in the sample.  The reaction is terminated by the addition of 
sulphuric acid, which leads to a yellow colour change.  Light absorption at 450 nm is 
measured by spectrophotometry.   
 
2.5.2 Individual Assays 
 
All assay ranges, limits of detection and coefficents of variation (CV) are reported as 






2.5.2.1 Androstenedione ELISA 
 
Androstenedione was measured using solid phase ELISAs (DRG, Marburg, 
Germany).  The assay range was 0 – 10 ng/mL; limit of detection was 0.019 ng/mL; 
mean intra-assay CV was 9.1%, mean inter-assay CV was 9.6%.   
 
2.5.2.2 Testosterone ELISA 
 
Testosterone was measured using solid phase ELISAs (DRG, Marburg, Germany).  
The assay range was 0 – 16 ng/mL; limit of detection was 0.083 ng/mL; mean intra-
assay CV was 4.16%, mean inter-assay CV was 9.94%.   
 
2.5.2.3 Estradiol  ELISA 
 
Estradiol was measured using high-sensitivity solid phase ELISAs (DRG, Marburg, 
Germany).  The assay range was 0 – 200 pg/mL; limit of detection was < 1.399 
pg/mL; mean intra-assay CV was 7.87%, mean inter-assay CV was 8.78%.   
 
2.5.2.4 Estrone ELISA 
 
Estrone was measured using solid phase ELISAs (DRG, Marburg, Germany).  The 
assay range was 2.21 – 1000 pg/mL; limit of detection was 2.21 pg/mL; mean intra-




2.5.2.5 Sex hormone-binding globulin (SHBG) 
 
SHBG was measured using a solid phase, two site chemiluminescent immunometric 
assay (Immulite 2000, Siemens Healthcare, Llanberis, UK).  The assay range was 
0.02 – 180 nmol/L; limit of detection was 0.02 nmol/L; mean intra-assay CV was 




Insulin was measured using a chemiluminescent microparticle immunoassay 
(Architect, Abbott Laboratories, Wiesbaden, Germany) in the study described in 
chapter 4.  The assay range was 1.0 µU/mL to 300 µU/mL; limit of detection was 1.0 
µU/mL; mean intra-assay CV was 3.6%; mean inter-assay CV was 4.7%. 
 
In the study described in chapter 5, insulin was measured by an ultrasensitive insulin 
ELISA kit (DRG, Marburg, Edinburgh).  The limit of detection was 0.07 mU/L; mean 
intra-assay CV was 5.3%; mean inter-assay CV was 2.7%.    
 
2.6 Measurement of adipokines by multiplex immunoassay 
 
2.6.1 Principles of multiplex immunoassay 
 
Adipokines were measured by Milliplex™ (Merck Millipore, Watford, UK), an 
immunoassay which utilises fluorescent-coded magnetic beads to simultaneously 
measure multiple analytes.  Capture antibody coated beads are incubated with sample, 
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washed and a biotinylated detection antibody added.  After a further washing step, 
beads are incubated with a reporter streptavidin-phycoerythrin (SA-PE) conjugate.  
Finally the beads are passed through an array reader which measures the fluorescence 
of bound SA-PE.  Two ‘panels’ were used: one to measure leptin, MCP-1 and IL-8 
and the other measuring adiponectin and resistin.   
 
2.6.2  Instrumentation 
 
Multiplex assays were performed on a MagPix® system with xPONENT® software, 
version 4.1 (Luminex, Austin, USA).  The instrument comprises two lasers; one to 
excite internal fluorescent dyes, to identify the analyte of interest, and the other to 
excite the fluorescent reporter molecule.  The latter signal was used for quantification 
of the analyte of interest.  Calibration of the instrument was performed prior to each 
use. 
 
2.6.3 Leptin, MCP-1 and IL-8 
 
Samples were analysed in accordance with the manufacturer’s protocol.  Supplied 
standards covered a concentration range of 38 – 600000 pg/mL for leptin, 1.3 – 20000 
pg/L for MCP-1 and 0.64 – 1000 pg/mL for IL-8.  Limits of detection, intra-assay CV 
and inter-assay CV (as provided in the manufacturer’s literature) were: leptin 19 
pg/mL, 5%, 13%; MCP-1 1.2 pg/mL, 2%, 11%; IL-8 0.3 pg/mL, 3%, 14%.  
 
Assay buffer (200 µL) was added to each well.  The plate was sealed and incubated 
for ten minutes (RT) on a plate shaker, after which assay buffer was removed.  25 µL 
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of standards or controls were added to the appropriate wells in duplicate. Assay buffer 
(25 µL) was added to background and sample wells.  Serum matrix (lyophilised 
serum matrix reconstituted in 1 mL deionsed water, 25 µL) was added to background, 
standard and control wells.  Samples (25 µL) were added to sample wells in duplicate.  
Antibody immobilised beads suspension was sonicated (30 seconds) and vortexed (1 
minute).  150 µL of each antibody bead vial (one per analyte) was added to a mixing 
bottle and made up to 3 mL with bed diluent.  Prepared magnetic beads (25 µL) were 
added to each well, the plate was sealed, wrapped in foil and incubated on a plate 
shaker for 18 hours at 4°C.  Decanting of well contents in subsequent steps was 
performed with the assay plate on a magnetic plate.  The plate was washed three times 
with wash buffer (diluted 1:10 in deionised water, 200 µL per well).  Detection 
antibodies (50 µL) were added to each well, the plate sealed and then covered in foil 
for incubation on a plate shaker (1 hour, RT).  Streptavidin-Phycoerythrin (50 µL) 
was added to each well, the plate sealed, covered in foil and incubated on a plate 
shaker (30 minutes, RT).  Well contents were removed and the plate washed (200 µL, 
three times).  Assays were reconstituted in Drive Fluid (100 µL) prior to analysis.  A 
standard curve (logistic 5 point weighted) was constructed and sample concentration 
calculated by interpolation.  Acceptable r2 for standard curves was >0.99.   
 
2.6.4 Adiponectin (total) and resistin 
 
The method described in section 2.6.3 was employed for measurement of adiponectin 
and resistin with two exceptions: samples were added at 1:4000 or 1:8000 dilution 
and no serum matrix was added to background, standard or control wells.  Supplied 
standards covered a concentration range of 0.01 – 160 µg/mL for adiponectin and 
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2.56 – 40000 ng/mL for resistin.  Limits of detection, intra-assay CV and inter-assay 
CV (as reported by the manufacturer) were: adiponectin 145.4 pg/mL, 5.6%, 15%; 
resistin 6.7 pg/mL, 6%, 13%.   
 
2.7 Gas Chromatography Mass Spectrometry (GCMS): 
Quantification of glucose, glycerol, d2-glucose and d5-
glycerol 
 
Gas chromatography Mass Spectrometry (GCMS) is employed to separate and 
quantify chemical species.  Gas chromatographic columns comprise a stationary 
phase (immobile liquid adhering to the column wall) and a mobile phase (the gas 
passing through the column).  When a mixture of chemicals is introduced on to the 
column, the differing affinity for the mobile and stationary phases determines the 
rapidity with which individual species reach a detector at the column’s end; this is 
designated as the retention time.  Gas Chromatography is allied with Mass 
Spectrometry, for detection and for specificity, because retention time alone is not 
sufficiently discriminatory to confidently identify individual chemical species.  Upon 
leaving the GC column, molecules are ionized (either by chemical ionization or 
electron impact) and these molecular ions (and fragment ions) produce a mass 
spectrum; essentially a representation of abundance by the mass:charge ratio (m/z) for 
each ion.  Prior to analysis, samples are often derivatised to encourage ionization or to 
stabilise the analyte of interest.  In this case, for the quantification of glucose and 
glycerol, acetate derivatives were formed.  Stable isotope tracer studies rely upon 
slight differences in mass between isotope species, with mass spectrometry the only 
suitable method of differentiation. 
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2.7.1 Reagents and standards 
 
" HPLC grade water - Fisher Scientific (Loughborough, UK).   
" HPLC grade acetonitrile – VWR (Lutterworth, Leicestershire, UK) 
" Heptane – Rathburn (Walkerburn, UK) 
" Pyridine, acetic anhydride, glucose, glycerol, 13C6-glucose and butanetriol – 
Sigma Aldrich (Dorset, UK) 
" d2-Glucose and d5-glycerol – Cambridge Isotope Laboratories, Inc. (Andover, 
USA) 
 
Solutions for standard curves and enrichment curves were prepared in HPLC grade 
water and stored at 4°C, for not more than 2 weeks prior to use. 
 
Standard solutions were: 
 
a. Glucose (5 mg/mL), glycerol (0.025 mg/mL), d2-glucose (0.1 mg/mL) and d5-
glycerol (0.025 gm/mL).   
b. Internal standard mix – 13C6-glucose (5 mg/mL) and butanetriol (0.25 
mg/mL). 
 
Reagents (prepared on the day of assay): 
 
a. Acetic anhydride (5%) in heptane. 
b. Pyridine:acetic anhydride (1:1, v/v). 
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Standard curves were prepared across the expected plasma concentration ranges for 
glucose (0 – 9.25 mmol/L), glycerol (0 – 90.5 µmol/L), d2-glucose (0 – 0.018 
mmol/L) and d5-glycerol (0.90.5 mol/L).  An enrichment curve was prepared 
representing 0 – 12% enrichment for both glucose and glycerol, with d2-glucose and 
d5-glycerol, respectively. 
 
Acetonitrile (1 mL) was added to extraction wells (96-well Strata Impact™ protein 
precipitation plate, Phenomenex, Macclesfield, UK), followed by standards, 
enrichment standards and samples (200 µL).  Internal standard solution (25 µL) was 
added to the standards and samples but not to enrichment samples.  Following a 20-
minute incubation period (RT), vacuum was applied (0.3 bar) and extracts collected.  
Eluates were reduced to dryness under oxygen-free nitrogen (OFN; 37°C).  
Pyridine:acetic anhydride (200 µL, 1:1 v/v) was added to the dry residue and left to 
stand (RT, 15 mins), forming acetate derivatives (Figures 2.1 and 2.2).  The 
derivatised samples were dried under OFN (37 °C), reconstituted in 5% acetic 
anhydride in heptane (100 µL) and transferred to GCMS vials (200 µL conical glass 













































Figure 2.1 Derivatisation of glycerol (left; MW 92.09) with pyridine:acetic 






Figure 2.2 Derivatisation of glucose (left; MW 180.16) with pyridine:acetic 




The GC-MS system consisted of a Finnigan GC800TOP GC, an AS800 autosampler 
and a single quadrupole Voyager mass spectrometer operating with Xcalibur software 
version 1.2 (Finnigan, now Thermo Scientific, Manchester, UK).  The analytical 
column was an HP-Innowax column (30 m x 0.32 mm x 0.025 µm; Agilent, 
Berkshire, UK).  The sample was injected using splitless injection in a 1 µL volume.  
Injection temperature was 260 °C.  The column oven temperature was 60°C at the 
point of injection and programmed to reach 150°C at a rate of 30°C per minute; 
followed by a subsequent rise of 10°C per minute to a target of 260 °C, which was 
then held for 3 minutes.  Interface and source temperatures were 240 °C and 175 °C, 
respectively.  Helium gas was used as the mobile phase at a rate of 2.5 mL per 
minute.   
 
Mass spectra were acquired using negative chemical ionisation with methane 
(research grade, BOC, Edinburgh, UK) as the reagent gas at an electron energy of 70 
eV.  Selective ion monitoring was employed with a total run time of 18 minutes.  
Glycerol, D5-glycerol and butanetriol derivatives were monitored from 0 – 10 
minutes, with glucose, d2-glucose and 13C6-glucose derivatives monitored from 10 – 
18 minutes.  Details of the monitored ions are summarised in table 2.3, glucose 




 m/z Retention time (minutes) 
Glycerol triacetate 217 7.15 
d5-Glycerol triacetate 222 7.12 
Butanetriol triacetate 231 8.16 
Glucose pentacetate 287 15.06 & 15.38 
d2-glucose pentacetate 289 15.05 & 15.37 
13C6-glucose pentacetate 293 15.05 & 15.37 
 





2.8  Liquid Chromatography Tandem Mass Spectrometry (LC-




Accurate measurement of estrogens is technically difficult, particularly in men and 
post-menopausal women in whom circulating levels are often below the limit of 
quantification of many established assays.  LC-MS/MS offers the potential for both 
sensitive and specific quantification of sex steroid hormones although, as a 
consequence of inefficient ionisation, derivatisation is often required to introduce a 
charged moiety.  Within our laboratory, a new method was developed using 2-fluoro-
1-methylpyridinium-p-toluenesulfonate (FMP-TS), creating estrogen-FMP derivatives 
which were quantified using triple quadrupole MS in positive electrospray ionisation 
mode following LC separation (Faqehi et al. submitted).   
 
2.8.2 Reagents and standards 
 
" HPLC grade water, methanol, acetone, hexane and water – Fisher Scientific 
(Loughborough, UK) 
" Estrone, Estradiol, 17α-estradiol, formic acid, triethylamine (TEA), FMP-TS – 
Sigma Aldrich (Dorset, UK) 
" 3,4-[13C]2-estrone (13C2E1) and 3,4-[13C]2-estradiol (13C2E2) – Cambridge 






1mL plasma was centrifuged for 20 minutes (8000g, 4°C) and sediment removed.  
Volume was adjusted to 2mL with water and 200 pg internal standard (13C2 labelled 
estrogen FMP derivatives).  Solid-phase extraction was performed under gravity using 
Oasis MCX cartridges (3 cc/60 mg, Waters, Milford, USA).  Cartridges were 
conditioned with methanol (2 mL) then water (2 mL) before samples were loaded (2 
mL).  Cartridges were washed with FA (2% v/v, 2 mL) and eluted in methanol (2 mL) 
before being reduced to dryness under OFN (40 °C) in preparation for derivatisation. 
 
2.8.4 Derivatisation  
 
FMP (50 µL; 5mg/mL in acetonitrile containing TEA [1%]) was prepared 
immediately prior to reaction and added to the extract.  The mixture was vortexed (10 
s) and incubated (40°C, 15 minutes) before mobile phase (water: methanol 65:35 
containing FA 0.1%, 50 µL) was added to quench the reaction.  Figure 2.3 shows the 
example of an estrone-FMP derivative.  
 
Standard curves were prepared with aliquots containing estrogens at 0, 10, 50, 250, 





Figure 2.3  Formation of the estrone-FMP derivative following reaction with 
FMP-TS in the presence of TEA (From Faqehi et al.)  
 
  
Figure 1 Faqehi et al. 
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20 µL sample was injected into an Acquity UPLC® BEH C18 column (50 x 2.1 mm, 
1.7 µm, Waters, Milford, USA) with an isocratic solvent system of water: methanol 
(65:35), containing FA (0.1%, 0.4 mL/min).  The column and autosampler 
temperatures were 25°C and 10°C, respectively.  Estrogen FMP derivatives were 
quantified using triple quadrupole MS (QTrap 5500, AB Sciex, Warrington, UK) in 
positive electrospray ionisation mode, using Analyst software version 1.5.1 (AB 
Sciex, Warrington, UK).   
 
2.8.6 Assay performance 
 
The limit of detection for FMP derivatives of estrone and estradiol was 2 pg/mL; the 
corresponding limit of quantification was 5 pg/mL At the limit of quantification, 
intra-assay CV was 12% and 11% for estrone and estradiol, respectively; inter-assay 
CV was 15% ad 13%, respectively (Faqehi et al., submitted).   
 
2.9  Liquid Chromatography Tandem Mass Spectrometry (LC-
MS/MS) measurement of androgens 
 
2.9.1 Reagents and standards 
 
" HPLC grade water, methanol and formic acid– Fisher Scientific 
(Loughborough, UK) 
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" Testosterone, androstenedione, 2,3,4-[13C3]-testosterone and 2,3,4-[13C3]-




Solid phase extraction was employed using Oasis HLB 30mg cartridges (Waters, 
Manchester, UK).  Cartridges were primed with methanol (1 mL) followed by water 
(1 mL).  500 µL of sample was enriched with internal standard (1ng) and water added 
(500 µL).  Samples were mixed, loaded onto extraction cartridges and a wash step 
performed (50% methanol in water, 1 mL); analytes were then eluted with methanol 
(1 mL).  Eluate was dried under OFN (37°C) and then reconstituted in mobile phase 
(100 µL) 
 
2.9.3 Standard curves  
 
Standard curves were generated for testosterone and androstenedione with the 
addition of 1ng internal standard across the following concentration ranges: 
" Testosterone : 1, 2, 3, 5, 7.5, 10, 12.5, 15 ng/mL 





10 µL sample was injected into an Acquity UPLC® (Waters, Manchester, UK) using 
a Kinetex C18 column (150 x 3 mm, 2.6 µm, Phenomenex®, Macclesfield, UK) at 
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35°C. Elution was achieved with a 9 minute linear gradient from 30:70 to 80:20 
(methanol: water with 0.1% FA), with a flow rate of 250 µL/min applied.  Initial hold 
was 1 minute, then the gradient applied for 9 minutes, with a further hold until 16 
minutes.  Androgens were quantified using triple quadrupole MS (QTrap 5500, AB 
Sciex, Warrington, UK) in positive APCI mode, using Analyst software version 1.5.1 
(AB Sciex, Warrington, UK).     
 
2.9.5 Assay performance 
The limits of detection for testosterone and androstenedione were 0.003 ng/mL and 
0.08 ng/mL, respectively; the corresponding limits of quantification were 0.005 
ng/mL and 0.125 ng/mL, respectively.   At 1.8 ng/mL, the intra-assay CV was 2.8% 
and inter-assay CV 10.0% for testosterone.  At 0.18 ng/mL, the intra-assay CV was 





Associations between circulating sex 
steroid hormones and cardiometabolic risk 




Several studies have sought to investigate relationships between sex steroid hormones and 
cardio-metabolic risk factors, as well as incident diabetes (Ding et al 2006).  Frequently the 
focus has been on androgens in men and estrogens in women, although increasingly the role 
of both hormone classes has been investigated across genders (Jasuja et al. 2013; Oh et al. 
2002).  In addition, lower concentration of sex hormone-binding globulin (SHBG) has been 
consistently associated with diabetes risk in both men and women (Wallace et al. 2013). 
 
SHBG is a 90-KDa glycoprotein which avidly binds testosterone and, with approximately 
half the affinity, estradiol.  Only 2 - 3% of plasma testosterone circulates freely, the 
remainder is bound with low-affinity to albumin or with high-affinity to SHBG (de Ronde et 
al. 2006).  Conventionally regarded as simply a transport protein, increasing evidence 
suggests SHBG may have an active role in cellular uptake of sex steroids and may be capable 
of signalling via a G-protein coupled receptor (Rosner et al 2010).  Whether SHBG simply 
reflects insulin resistance or has a causative role in diabetes development is unresolved, 
although recent Mendelian randomisation studies appear to support a protective effect with 
respect to diabetes development (Ding et al.  2009; Perry et al. 2010).   
 
Lower total testosterone concentration, a measure of both bound and unbound hormone, has 
frequently been associated with greater adiposity, reduced lean mass, greater insulin 
resistance and higher diabetes risk in men (Kelly & Jones 2013). Measuring free testosterone 
is technically challenging and so it is often calculated indirectly by use of a mathematical 
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manipulation, which takes account of SHBG and albumin concentrations (Vermeulen et al. 
1999).   
 
Estradiol levels are typically higher in men with T2DM (Ding et al. 2006) and, similarly, 
higher estrone was associated with an increased risk of developing diabetes in the 
Framingham cohort, even after adjustment for potential confounders (Jasuja et al. 2013).   
 
As detailed in Chapter 1, examining the metabolic effects of androgens and estrogens is 
complicated by their substrate-product relationship, with estradiol and estrone produced by 
aromatisation of testosterone and androstendione, respectively.  It is often difficult to 
determine the extent to which effects are a consequence of androgen or estrogen changes.   
This study sought to examine the relationship between estrogens, androgens and SHBG, as 




3.2 Hypothesis and aims 
3.2.1 Hypothesis 
The principal hypothesis investigated in the study was: 
Lower circulating estrogens, androgens and SHBG are associated with an adverse cardio-
metabolic phenotype in older men. 
3.2.2 Aims 
The aims of the study were to:  
1. Determine associations between circulating sex steroid hormones. 
2. Assess determinants of estrogen levels in men. 





3.3.1 Study title and ethical approvals 
Study Title: Associations between circulating sex steroid hormones and cardiometabolic risk 
in older men: cross-sectional study 
This cohort was initially established in the early 1990s and included men born between 1920 
and 1930 in East Hertfordshire (Hales et al. 1991).  In 1997, surviving members of this 
cohort were approached to take part in a further study, which involved administration of 
0.25mg dexamethasone at 2300h followed by blood sampling on the following morning 
(Reynolds et al. 2001).  This study used stored plasma samples and previously collected data, 
with ethical approval from the east Hertfordshire ethics committee as granted at the time of 
the earlier studies. 
 
3.3.2 Study design 
3.3.2.1 Subjects: recruitment, inclusion and exclusion criteria 
197 subjects were recruited from a cohort established in 1991, whose inclusion criteria were: 
- Born in East Hertfordshire between 1920 and 1930  
- Birth weight and weight at 1 year recorded 
Subjects from this cohort were recruited again in 1997, with the following exclusions: 
- Clinical evidence of pituitary or adrenal disease 
- Oral glucocorticoid therapy within the past 3 months 
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3.3.2.2 Study protocol 
The following parameters were recorded in 1991: 
- Height, weight, waist and hip circumference. 
- Seated blood pressure (average of 2 measurements, Dinamap). 
- 75g oral glucose tolerance test (men with known diabetes excluded). 
- Measurement of glucose (hexokinase method) and insulin (two site immunometric 
assay) at time points 0, 30 and 120 minutes. 
- Fasting plasma triglyceride and cholesterol profile. 
The following parameters were recorded in 1997:  
- Height, weight, waist and hip circumference. 
- Fasting blood samples taken at 0900 following 0.25mg dexamethasone administration 
the previous evening.   
Plasma samples were stored at -80°C until analysis. 
3.3.2.3 Assays 
Estrone, estradiol, androstendione and testosterone were measured using solid phase ELISAs 
(DRG, Marburg, Germany) as described in detail in Chapter 2.  SHBG was measured using a 
solid phase, two site chemiluminescent immunometric assay (Immulite 2000, Siemens 
Healthcare, Llanberis, UK); also described in detail in chapter 2.  
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3.3.3 Data analysis 
3.3.3.1 Calculations 
Insulin sensitivity was determined by use of the QUICKI calculation (Katz et al. 2000), 
which is known to correlate closely with hyperinsulinaemic euglycaemic clamp results 
(Mather et al. 2001): 
QUICKI  = 1 / [log (fasting insulin) + log (fasting glucose)] 
Free testosterone was calculated from total testosterone, SHBG and albumin concentrations 
using the Vermeulen equation (Vermeulen  et al. 1999). 
 
3.3.3.2 Statistical methods 
Normal distribution of data was assessed by the Kolmogorov-Smirnov test and log 
transformations was performed to achieve normal distributions if required.  Associations 
between continuously distributed variables were assessed by the Pearson correlation 
coefficient (and partial correlation) using IBM SPSS Statistics for Windows (Version 19.0, 





3.4.1 Subject characteristics 
Subject characteristics (n=197) and biochemistry are summarised in table 3.1. 
 
 
 Reference range Mean  ± SEM Range 
Age (years)  70.9 ± 0.22 66.0 – 77.0  
Total testosterone (nmol/L) 6.9 – 23.9  18.3 ± 0.6 1.1 – 70.6 
Free testosterone (pmol/L) 245 - 785 364 ± 1 104 - 1319 
SHBG (nmol/l) 6 – 45  40.29 ± 1.70 8 – 306 
Androstenedione (ng/ml) 0.3 – 3.9  6.8 ± 0.5 0.5 – 30.5 
Estrone (pmol/L) 156 – 573 566 ± 90 2 - 12102 
Estradiol (pmol/L) 36.7 – 132.1 10.3 ± 0.8 1.4 – 62.4 
BMI (kg/m2)  26.91 ± 0.26 17 – 42 
Waist circumference (cm)  99.35 ± 0.74 65 – 142 
Waist-hip ratio  0.931 ± 0.004 0.77 – 1.06 
Fasting plasma glucose 
(mmol/L) 
 6.1 ± 0.097 3.4 – 17.3 
Systolic blood pressure 
(mmHg) 
 161.5 ± 1.5 110 – 232 
Diastolic blood pressure 
(mmHg) 
 89.3 ± 0.8 59 – 121 
QUICKI  0.363 ± 0.003 0.25 – 0.48 
Triglycerides (mmol/l)  1.57 ± 0.06 0.5 – 5.3 
 




3.4.2 Relationship between sex steroid hormones 
Reflecting their substrate: product relationships with respect to aromatase, strong positive 
correlations existed between testosterone and estradiol and between androstenedione and 
estrone, even after adjustment for waist circumference (table 3.2).  The only positive 
correlation with SHBG was with estrone, which also persisted following correction for waist 












Table 3.2  Pearson correlations exploring relationship between sex hormone levels 
(expressed as r values).  Results above the line are uncorrected; those below the 












Androstenedione Estrone Estradiol SHBG 
.235* .293** .460* .053NS 




.473** .239* .497** 
.203* 
.013NS .151* .158NS -.141NS 
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3.4.3 Relationship between sex steroid hormones and metabolic syndrome 
71 subjects (35%, cases) fulfilled the NCEP ATPIII diagnostic criteria for metabolic 
syndrome; the remaining 65% were controls.  With reference to controls, the metabolic 
syndrome cases had significantly lower levels of SHBG (mean difference 12.5nmol/L, 
p<0.01), total testosterone (mean difference 4.5 nmol/L, P<0.01) and androstenedione (mean 
difference 2.2 nmol/L, p<0.05).  A similar trend was noted with free testosterone, although 
this did not reach statistical significance, and no differences were observed with estrogen 
levels. 
 
3.4.4 Relationship between androgens and cardiometabolic risk factors 
Results are summarised in table 3.3.  Androstenedione, free testosterone and total 
testosterone were all negatively correlated with indices of adiposity.  In addition these 
hormones were all associated with beneficial effects upon glucose metabolism (either fasting 
glucose or insulin sensitivity), although these relationships did not persist after correction for 
waist circumference.  The only association which persisted following correction for adiposity 
was between total testosterone and plasma triglycerides.   
 
3.4.5 Relationship between estrogens and cardiometabolic risk factors 
Estrone showed a weak inverse association with insulin resistance and plasma triglycerides; 
only the latter was independent of waist circumference.  Estradiol was inversely related to 




3.4.6. SHBG and cardiometabolic risk factors 
SHBG was inversely correlated with plasma insulin levels (r = -.256, p<0.001), waist 
circumference (r = -.242, p<0.001) and BMI (r = -.225, p<0.05).  Estradiol was not 
significantly correlated with SHBG although a weak association existed with estrone (r = 
.169, p<0.05).  SHBG was more closely correlated with features of metabolic syndrome than 
any of the sex steroid hormones and the inverse associations with insulin resistance, glucose 
and plasma triglycerides were independent of waist circumference (table 3.3). The inverse 
relationship between SHBG and plasma triglycerides (but not glucose or insulin resistance) 




Table 3.3  Pearson correlations exploring relationship between sex hormones and 
components of metabolic syndrome (expressed as r values. * p<0.05, § p<0.01,  
BMI, body mass index; WC, waist circumference; QUICKI, quantitative insulin sensitivity check index; 
TG, triglyceride; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; 
TC, total cholesterol SBP, systolic blood pressure 
 
BMI$ WC$ glucose$ QUICKI$ TG$ HDL$ TC$ LDL$ SBP$
Free$testosterone$ 8.182*$ 8.177*$ 8.112$ .164*$ 8.155$ .043$ .002$ .035$ 8.050$
Controlled$for$WC$ 8.087$ .106$ 8.101$ .031$ .021$ .051$ 8.049$
Controlled$for$BMI$and$
SHBG$
8.063$ .015$ 8.110$ .055$ .030$ .051$ .8.049$
Total$testosterone$ 8.229§$ 8.230§$ 8.032$ .147*$ 8.260§$ .006$ 8.042$ .003$ 8.063$
Controlled$for$WC$ 8.006$ .068$ 8.198§$ 8.014$ 8.031$ .012$ 8.094$
Controlled$for$BMI$and$
SHBG$
8.049$ .099$ 8.204*$ .089$ 8.020$ .020$ 8.095$
Bioavailable$testosterone$ 8.144$ 8.133$ 8.053$ .082$ 8.126$ .078$ .041$ .062$ 8.045$
Controlled$for$WC$ 8.046$ .024$ 8.106$ .074$ .050$ .066$ 8.032$
Controlled$for$BMI$and$
SHBG$
8.046$ .021$ 8.115$ .090$ .050$ .063$ 8.032$
Androstenedione$ 8.176*$ 8.209*$ 8.181*$ .080$ 8.197*$ .098$ .090$ .128$ .076$
Controlled$for$WC$ 8.157$ .006$ 8.132$ .063$ .085$ .103$ .093$
Controlled$for$BMI$and$
SHBG$
8.170$ .047$ 8.171$ .149$ .080$ .098$ .007$
Estrone$ 8.122$ 8.098$ 8.124$ .154*$ 8.167*$ .071$ .091$ .093$ 8.018$
Controlled$for$WC$ 8.114$ .128$ 8.143*$ .063$ .098$ .116$ .022$
Controlled$for$BMI$and$
SHBG$
8.020$ 8.008$ .020$ 8.046$ .113$ .129$ .030$
Estradiol$ 8.019$ .041$ 8.220*$ .143$ 8.065$ 8.015$ .020$ .041$ 8.046$
Controlled$for$WC$ 8.226§$ .177*$ 8.087$ 8.012$ .034$ .075$ 8.048$
Controlled$for$BMI$and$
SHBG$
8.116$ .045$ 8.029$ 8.045$ .025$ .051$ 8.021$
SHBG$ 8.225*$ 8.242*$ 8.190*$ .283*$ 8.297§$ 8.095$ 8.134$ 8.171*$ 8.116$





In this cross-sectional study of elderly men, SHBG consistently demonstrated the strongest 
relationships with features of the metabolic syndrome.  Lower circulating androgens, but not 
estrogens, were associated with indices of obesity.  Lower testosterone levels (free and total) 
were also correlated with lower insulin sensitivity, which is likely mediated by adiposity.  
The relationship between lower estradiol and lower insulin sensitivity, in contrast, appeared 
to be independent of adiposity.  Obesity has the potential to affect sex steroid hormone levels, 
through greater aromatase activity, but adiposity is also likely to be influenced by changes in 
estrogen and androgen action. Substrate availability (androgen) appeared to be of greater 
importance than adiposity in determining estrogen concentration.   
 
Although associations of sex hormone levels with cardiometabolic risk factors were mostly 
negated by controlling for waist circumference, the same did not pertain to SHBG.  SHBG is 
principally, though not exclusively, secreted by the liver under the regulation of a variety of 
hormones, including insulin and estradiol (Plymate et al. 1990). In vitro, insulin inhibits 
SHBG secretion in hepatoblastoma cell lines (Plymate et al. 1988) and in vivo SHBG is 
reduced during hyperinsulinaemic euglycaemic clamp studies (Katsuki et al. 1996).  The 
converse also holds; SHBG levels rose in men when diazoxide was administered to suppress 
insulin secretion (Pasquali et al. 1995).  Similarly, IGF-1 suppresses SHBG production in 
hepatoblastoma cell lines (Crave et al. 1995). In premenopausal but not postmenopausal 
women, estradiol appears to be a positive determinant of SHBG levels, whilst a negative 
association with testosterone is ubiquitous (Pasquali et al. 1997). In hypogonadal and 
eugonadal men, testosterone supplementation was shown to effect reductions in SHBG 
(Plymate et al. 1983).  Here, no significant correlations between SHBG and either 
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testosterone or estradiol were found, permitting the inference that these hormones do not 
occupy a central role in the regulation of SHBG in elderly men. A positive association was 
observed with estrone, perhaps indicating an association of SHBG with aromatase activity in 
elderly men. 
 
SHBG binds between 40 – 65% of circulating testosterone and 20 – 40% of circulating 
estradiol (de Ronde et al. 2005); when bound these hormones are protected from conversion 
to inactive metabolites.  The prevailing orthodoxy suggests that bound steroid hormones are 
prevented from leaving the blood stream and interacting with their cognate intra-cellular 
receptors.  The calculation or measurement of ‘free’ or ‘bioavailable’ hormone seeks to 
address this potential confounder by excluding ‘inert’ bound steroids. (Mendel 1989).  
However, this concept has been challenged by the discovery that SHBG interacts with 
megalin, an endocytic receptor, to induce the active cellular uptake of SHBG bound 
androgens and estrogens in mice (Hammes et al. 2005).  A widening role for SHBG is also 
suggested by the identification of a cell surface SHBG receptor, which generates cAMP when 
occupied by an SHBG-steroid complex (Kahn et al. 2002).  Mindful of these potential 
caveats, determining free hormone levels remains a useful clinical tool.   
 
Evidence from in vitro studies had suggested increasing levels of SHBG, by virtue of its 
greater binding affinity for testosterone, might amplify the bioavailable fraction of estradiol 
(Burke et al. 1972).  However this does not appear to apply in young eugonadal men, in 
whom the hypothalamic-pituitary-gonadal axis adjusts to maintain free testosterone levels (de 
Ronde et al. 2005; Vanbillemont et al. 2010).  Whether SHBG acts as an ‘estrogen amplifier’ 
in older men, with potentially less compensatory reserve, remains an important but 
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unresolved question.   SHBG may simply reflect, rather than contribute to, an adverse 
cardiometabolic profile.  However, recent Mendelian randomisation studies have shown that 
common polymorphisms, resulting in higher and lower SHBG concentrations, are associated 
with lower and higher risk of developing T2DM, respectively (Ding et al. 2009; Perry et al. 
2010). 
 
The results of this study are congruent with the strong body of evidence supporting an 
association between SHBG and glucose intolerance.  In two separate cross-sectional studies 
in middle-aged men (mean ages 57 and 60 years, respectively), SHBG associated with insulin 
resistance, independent of body fat (Tsai et al. 2004), and with hyperinsulinaemia (Muller et 
al. 2005).  Similarly in elderly men (age 70 – 89), lower SHBG levels were noted in subjects 
with metabolic syndrome, pre-diabetic states and T2DM, independent of BMI (Kalme et 
al.2005).  Prospective follow up of the Massachusetts aging study demonstrated an increased 
risk of developing T2DM (Stellato et al. 2000) and metabolic syndrome (Kupelian et al. 
2006) in middle aged men with lower baseline SHBG levels, again independent of body 
mass.  A similar study of middle-aged men in Finland attributed an increased risk of diabetes 
(OR 4.3) and metabolic syndrome (OR 2.8) to those in the lowest SHBG quartile; these 
relationships were attenuated but remained significant after adjusting for baseline insulin 
levels and BMI (Laaksonen et al. 2004).  Results from the Baltimore study of aging 
(Rodriguez et al. 2007) and MRFIT study (Haffner et al. 1996) also attest to the strong 
relationship between SHBG, metabolic syndrome and diabetes, respectively. Nielsen et al. 
(2007) demonstrated an inverse correlation between subcutaneous adipose mass (as 
determined by MRI) and SHBG though no independent relationship with visceral adipose 
mass was noted. 
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Low SHBG is unequivocally associated with a deleterious plasma lipid profile, namely low 
HDL cholesterol and high triglyceride levels.  In both the PRIME study (Bataille et al.2005) 
and the San Antonio Heart Study (Haffner et al. 1993) these associations were independent of 
BMI and insulin concentrations.  Whilst our findings confirm the robust association between 
SHBG and triglyceride, we did not find a significant relationship between SHBG and HDL 
cholesterol.  This discrepancy may be a consequence of the significantly older age in this 
cohort. 
 
Significant correlations involving total testosterone may substantially reflect SHBG levels 
thus complicating their interpretation.  Free testosterone was associated with reduced waist 
circumference and body mass index, as well as having a modest positive correlation with 
insulin sensitivity in this study. The relationship between free testosterone and insulin 
sensitivity was not independent of waist circumference, which is consistent with previous 
studies suggesting that free testosterone is independently associated with reduced visceral 
adiposity (Nielsen et al.  2007). In older men a similar relationship has been noted between 
free testosterone and subcutaneous adiposity (Abate  et al.  2005). Inhibition of lipoprotein 
lipase and triglyceride uptake, evident in obese male recipients of testosterone replacement, 
may provide a mechanistic underpinning of these observations (Marin et al. 1995). Previous 
cross sectional studies have produced evidence of a positive relationship between free 
testosterone and glucose tolerance.  The San Antonio Heart Study demonstrated an inverse 
correlation between directly measured free testosterone and glucose and insulin levels in 
middle-aged men (Haffner et al. 1994).  This association with free testosterone was 
independent of BMI although a similar study, employing DEXA and CT assessment, 
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suggested the positive influence of both free and total testosterone was mediated by changes 
in total body and abdominal fat (Tsai et al. 2004).  Abate et al. (2002) found no relationship 
between directly measured bioavailable testosterone and insulin resistance.  In prospective 
studies free testosterone has been independently associated with the development of T2DM in 
middle aged men (Stellato et al. 2000).  However, the Massachusetts aging study did not 
detect a relationship between free testosterone and the development of metabolic syndrome 
(Kupelian et al. 2006), whilst the relationship with free testosterone noted by Laaksonen et 
al. (2004) did not withstand correction for BMI.  The findings of a recent meta-analysis 
(Ding et al. 2006) support the link between low testosterone and the development of T2DM.   
 
Our failure to detect a relationship between testosterone and either HDL cholesterol or 
triglyceride contrasts with the findings of Haffner et al. (1993) who report increased HDL 
cholesterol and lower triglyceride being associated with free testosterone levels independent 
of WHR and insulin resistance.  Gyllenborg et al. (2001) surprisingly found the opposite with 
free androgen levels associated with a deleterious pattern of low HDL cholesterol and high 
triglyceride. 
 
Relationships between estrogens and metabolic parameters are less extensively studied but a 
meta-analysis, pooling 12 retrospective studies, suggested higher estradiol levels are 
associated with the development of T2DM (Ding et al. 2006). Nielsen et al. (2007) found an 
independent relationship between estradiol and subcutaneous adipose mass in young men 
which could be explained by an increase in total aromatase activity.  In this study an inverse 
relationship with estradiol and glucose, independent of waist circumference was observed.  
This relationship was independent of testosterone (free and total) and so does not appear to 
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simply reflect elevated androgen substrate.  Plausible biological mechanisms exist to explain 
beneficial effect of estradiol upon glucose metabolism independent of altering body fat 
distribution:  estrogens have been shown to augment the insulin response to glucose 
(Godsland, 2005), whilst upregulation of muscle GLUT4 expression has been attributed to 
ERα activation in mice (Barros et al.  2006).   
 
The positive association between plasma estradiol and HDL cholesterol reported elsewhere 
(Gyllenborg et al.  2001), was not replicated in this study, although plasma estrone was 
negatively correlated with triglyceride levels. 
 
Interestingly, the relationship between the substrates for aromatase, testosterone and 
androstenedione, which are converted to estradiol and estrone respectively, were minimally 
affected by correction for waist circumference or BMI.  In postmenopausal women, 
peripheral aromatisation (as determined by urinary metabolite analysis) has previously been 
strongly correlated with adiposity (Longcope et al.  1986).  Our results raise the possibility 
that, in elderly men, absolute androgen levels are of greater importance and that any predicted 
gain in aromatase activity accrued with increasing adiposity, may be negated by reduced 
substrate availability.  
 
The inability to determine the direction of association is a weakness inherent in cross-
sectional studies, although it is tempting to speculate, and is certainly plausible, that many of 
the relationships reported herein may be bi-directional (e.g. sex steroids influence adipose 
deposition which, in turn, influences sex steroid concentration).  Reports of the stability of 
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SHBG (Lapidus et al. 1986) and androgens after prolonged storage at -80°C (Kley et al. 
1985) assuaged concerns around the interval between sampling and analysis in this study.  
Ideally, all clinical measurements and assays would have been obtained at a single visit. 
However, as a consequence of the study design, an interval of approximately six years existed 
between some measurements (as detailed in section 3.3.2.2).   The single low dose of 
dexamethasone (0.25mg) administered to our subjects could conceivably have resulted in 
minor suppression of adrenal androgens.  In young men, 0.5mg dexamethasone administered 
twice daily for 4.5 days resulted in an approximate 50% decline in androstenedione but no 
change in testosterone (Lac et al. 1999).   A potential strength of this study is the relative 
homogeneity of the cohort, particularly with respect to age, which is likely to have limited 
confounding effects present in studies surveying wider ranges, although this does limit the 
generalizability of the findings.  Immunometric sex steroid assays are no longer regarded as 
the gold standard, having been supplanted by sensitive and specific mass spectrometric 
assays.  All results fell within the expected reference range for this population, with the 
exception of estrone, for which results were significantly higher than would be plausible in 
men.  Whilst absolute values for estrone are therefore unreliable, subsequent correlation 
findings (i.e. with estradiol and androstenedione) indicate overall trends are sound.  Problems 
with estrone results well outside the physiological range attest to the difficulty in measuring 
estrogens at low concentration with immunometric assays (Huhtaniemi et al. 2012).   Any 
analysis of circulating androgens and, particularly, estrogens is ultimately limited by the 
potential that local steroid concentrations in target tissue may be of greater physiological 





This cross-sectional survey of sex hormones and features of metabolic syndrome supports 
many of the key findings of previous investigators; in particular the clear relationship 
between SHBG and features of the metabolic syndrome.  Our results suggest higher levels of 
both androgens and estrogens may be associated with metabolic health in elderly men; the 
former potentially through its effects upon fat distribution and the latter independent of this.    
The lack of association between SHBG and sex hormone levels suggests their role in 
regulating SHBG is marginal in elderly men.  Finally, we raise the prospect that substrate 
androgen levels rather than adiposity (and attendant higher whole body activity of aromatase) 
determine estrogen levels; an unexpected finding which requires confirmation with more 





The metabolic effects of aromatase 
inhibition in post-menopausal women: 




Pre-menopausal women have a lower risk of T2DM and cardiovascular disease than 
age-matched men, a protection associated with a gynoid distribution of body fat. 
Estrogens appear to play a central role in maintenance of gynoid fat distribution, 
whilst menopause is associated with a switch to android adiposity (Kuk et al. 2005) 
and with convergence to male levels of diabetes risk (Lemieux et al. 1994).  However, 
no prospective studies have confirmed the role of menopausal status, as opposed to 
ageing, in the development of diabetes (Kim et al. 2011).  Hormone replacement 
therapy is associated with a significantly reduced risk of diabetes, with a number 
needed to treat (NNT) of 30 to prevent one case (Kanaya et al. 2003).  In contrast, 
endogenous estradiol levels are positively associated with incident T2DM in post-
menopausal women, even after adjustment for adiposity and insulin resistance 
(Kalyani et al. 2009). 
 
Manipulation of estrogen receptor signalling has been a central component in the 
management of ‘hormone-receptor positive’ breast carcinoma, in post-menopausal 
women, for over two decades.  Over 1.5 million prescriptions are issued annually for 
hormonal breast cancer therapies in England (Health and Social Care Information 
Centre, Government Statistical Service, 2012). Both tamoxifen (an ER partial agonist) 
and third-generation aromatase inhibitors (e.g. anastrozole, letrozole and exemestane) 
are associated with increased disease-free survival.  However, aromatase inhibitor 
therapy has not been proven to improve overall survival and is associated with an 
increased risk of cardiovascular disease (Amir et al. 2011), when compared to 
tamoxifen therapy.  The effects of aromatase inhibition upon lipid profile have been 
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widely investigated (Bundred 2005), with mixed results, and do not necessarily 
represent a class effect.  
 
Post-menopausal plasma estradiol levels are at least 50% lower than those observed in 
men.  It follows that aromatase inhibition, by lowering circulating estradiol, may 
result in an exaggerated post-menopausal phenotype. This may be particularly 
pronounced in adipose tissue as aromatase inhibitors have an even greater suppressive 
effect upon estradiol in breast adipose tissue, than upon circulating estradiol 
concentration, in breast cancer patients (Geisler et al. 2008).  The effects of aromatase 
inhibition upon insulin sensitivity have not been assessed in post-menopausal women.  
I sought to address this by assessing body fat distribution and cardio-metabolic 
parameters in breast cancer patients treated with aromatase inhibition, in comparison 
















The principal hypothesis investigated in this study was: 
 
Inhibition of aromatase results in reduced insulin sensitivity and deleterious 




The aims of the study were to establish whether women taking aromatase inhibitor in 
comparison with age-matched controls have: 
 
1. different body composition. 
2. reduced insulin sensitivity. 
3. changes in adipose tissue mRNA transcript levels. 
4. differences in circulating adipokine and pro-inflammatory cytokine levels. 








4.3.1 Study Title and Ethical Approvals 
 
Study title: Assessing the effects of aromatase inhibition on body fat distribution and 
insulin sensitivity in postmenopausal breast cancer patients 
 
Principal Investigator: Dr Fraser W Gibb 
 
Ethical approval was gained from the Lothian Research Ethics Committee in October 
2008 (LREC number 08/S1101/54). NHS Lothian granted Research and Development 
approval in October 2008 (R&D number 2007/W/ON/30).  The study was carried out 
at the Wellcome Trust Clinical Research Facility at the Western General Hospital, 
Edinburgh.   
 
4.3.2 Study design 
 
Study design was that of a case-control study, comparing breast cancer patients 
currently receiving aromatase inhibitor therapy with age-matched controls.  
 
4.3.2.1 Subjects: recruitment, inclusion and exclusion criteria 
 
20 post-menopausal women were recruited from the Edinburgh Breast Cancer Clinic.  
The investigator identified eligible patients by screening of case notes; such patients 
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were provided with written study information and contact details for the investigator, 
during their annual clinic appointment.  The main inclusion criteria were a diagnosis 
of ER positive breast carcinoma and current aromatase inhibitor therapy (either 
anastrozole, letrozole or exemestane) for at least one year.  20 age-matched controls 
were recruited from the South East Scotland Breast Cancer Screening service, by 
responding to posters or written study information, available in the waiting area of the 
screening centre.   
 
Exclusion criteria included: metastatic breast carcinoma, significant medical co-
morbidities, hormone replacement therapy, previous diagnosis of diabetes mellitus 
and recent (within 3 months) therapy with glucocorticoids.   
 
4.3.2.2 Study protocol 
 
Subjects attended the clinical research facility at the Western General Hospital (08:30 
am) following an overnight fast.  Patients were asked to abstain from alcohol, tobacco 
and caffeine from the evening prior to attendance. During this attendance, subjects 
received an oral glucose tolerance test, basic anthropometric measurements, 
subcutaneous adipose needle biopsy and also submitted a 24-hour urine collection. On 
a separate day, within 2 months of this visit, patients attended the Western General 





4.3.3 Clinical methods 
 
4.3.3.1 Demographic data 
 
Scottish Index of Multiple Deprivation (SIMD) was ascertained for participants based 
on their current post code. 
 
4.3.3.2 Basic clinical measurements 
 
Systolic and diastolic blood pressure and pulse rate were measured after sitting for at 
least 10 minutes using a 705IT automatic blood pressure monitor (OMRON 
Healthcare, Netherlands).   
 
Weight, height, waist circumference and hip circumference were obtained in all 
subjects. 
 
4.3.3.3 Oral glucose tolerance test 
 
An antecubital vein was cannulated with a 20G cannula and baseline blood samples 
collected in serum gel and fluoride tubes (Sarstedt Monovette®, UK).  A slow 
infusion of 0.9% saline was commenced to maintain the patency of the cannula.  
Blood samples were taken at -30, -15, 0, +30, +60, +90 and +120 minutes; in 
reference to oral administration of 75g of anhydrous glucose.  Blood samples 
collected in fluoride tubes were sent to the hospital biochemistry laboratory for 
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measurement of glucose.  Serum gel tubes were processed immediately by 
centrifugation (1912g, 10 minutes, 4°C) and serum stored at -80°C for later analysis. 
 
4.3.3.4 Subcutaneous adipose biopsy 
 
At completion of the oral glucose tolerance test, a subcutaneous adipose tissue needle 
biopsy was performed (as described in chapter 2.2.2), with the exception of two 
subjects in the control group who opted out.  To summarise, following subcutaneous 
administration of 5mL local anaesthetic (5ml 2% lidocaine, Hameln Pharmaceuticals, 
Gloucester, UK), a 19G needle was inserted approximately 10cm lateral to the 
umbilicus and subcutaneous adipose tissue aspirated by vacuum.  The samples were 
collected in sterile eppendorf tubes, stored immediately in dry ice before transfer to -
80°C refrigeration.  Adipose tissue was later processed and RNA extracted, as 
described in detail in chapter 2.4.3.  Following reverse transcription (described in 
chapter 2.4.5), PCR was performed to analyse the mRNA transcript levels of a battery 
of genes related to adipogenesis, steroid metabolism and adipocytokines (described in 
chapter 2.4.6).   
 
4.3.3.5 24-hour urine collection 
 
Participants were asked to perform a 24-hour urine collection in the day prior to 
attending the clinical research facility.  The volume of urine was measured and 20mL 
aliquots of urine stored at -20°C for later analysis of uric acid and creatinine (as 
described in section 4.3.3.7).  2 subjects in the control group were unable to provide 
24-hour urine samples. 
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4.3.3.6 Dual-energy x-ray absorptiometry  
 
On a separate occasion, within two months of the initial study, subjects attended for a 
dual-energy x-ray absorptiometry scan (Discovery A, Hologic, Bedford MA, USA) 
for assessment of body composition. The whole body scanning protocol involves a 
scan time of 165 seconds and exposure to 0.008 mGy ionising radiation. Estimated 
bone mineral content, fat mass, lean mass and percentage fat are reported for 5 
separate compartments:  head, trunk, left arm, right arm, left leg and right leg.  The 
proportion of android fat is defined as: (trunk fat+ arm fat) / total body fat.  The 
proportion of gynoid fat is defined as: leg fat / total body fat (Cao et al. 2013).    Fat 
distribution index is the ratio of trunk:leg fat (Kirchengast et al. 2004). 
 
 
4.3.3.7 Laboratory assays 
 
Fasting lipid profile (including total cholesterol, triglyceride, LDL cholesterol and 
HDL cholesterol), uric acid (serum and urine), creatinine (serum and urine) and 
glucose were all analysed on the Vitros platform (Ortho-Clinical Diagnostics, High 
Wycombe, UK), by the biochemistry lab of the Western General Hospital. 
 
Insulin was analysed using a chemiluminescent microparticle immunoassay 
(Architect 8K41, Abbott Laboratories, Wiesbaden, Germany) as detailed in chapter 
2.5.2.6.   
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Adiponectin, resistin, leptin, MCP-1 and IL-8 were measured by multiplex 
immunoassay (Merck Millipore, Watford, UK) as detailed in chapter 2.6.1. 
 
4.3.4 Data analysis 
 
4.3.4.1 Fractional excretion of uric acid (FEUA) 
 
Fractional excretion of uric acid was calculated as: 
 
FEUA (%) =  Urine [uric acid] x Plasma [creatinine]       x 100 
            Urine [creatinine] x Plasma [uric acid] 
 
 
4.3.4.2 Insulin sensitivity index – Matsuda 
 
‘Insulin sensitivity index – Matsuda’ was calculated as: 
10,000/ √([fasting glucose (mg/dL) x fasting insulin (uU/mL)] x [mean glucose during 
OGTT (mg/dL) x mean insulin during OGTT (uU/mL)]) 
 
 
4.3.4.3 Statistical methods 
 
All statistical analyses were carried out using IBM SPSS Statistics for Windows 
(Version 19.0, Armonk, NY: IBM Corp.) software.  Data are presented as mean ± 
SEM unless otherwise stated.  Comparisons between cases and controls were 
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performed using independent-samples Student’s t-tests when data were normally 
distributed.  When data were not normally distributed, as determined by the 
Kolmogorov-Smirnov test, logarithmic transformation was performed and 
subsequently compared with Student’s t-tests if a normal distribution was obtained or 
by independent-samples Mann-Whitney U tests if data remained not normally 
distributed.  Assessment of the influence of co-variates was performed using Analysis 
of Co-variance (ANCOVA).  Correlation between normally distributed variables was 
performed using the Pearson’s correlation coefficient and the influence of potential 
confounders was assessed by partial correlation. Statistical significance was accepted 
at p < 0.05.   
 
At the study design stage, power calculations were performed suggesting a sample 
size of 40 would provide 80% power in detecting a 50% difference in insulin 











4.4.1 Subject characteristics 
 
Anastrozole was the most prevalent aromatase inhibitor (n=12), with the remaining 
patients receiving letrozole (n=6) and exemestane (n=2). The mean duration of 
aromatase inhibitor therapy was 27.4 ± 2.8 months.   Cases and controls were well 
matched with respect to age (61.4 ± 1.4 [range 51 – 72] vs. 59.4 ± 1.0 [range 52 – 67] 
years, p = 0.259) and BMI (27.1 ± 0.8 vs. 26.6 ± 1.0 kg/m2, p=0.68).  No significant 
difference was observed in SIMD between cases and controls (4806 ± 355 vs. 5013 ± 
419, p=0.71). 5 of the 20 cases had previously received systemic chemotherapy, 
although this was not associated with any significant differences in any of the 
parameters measured in this study.  Regular medication use was largely limited to 
levothyroxine replacement and anti-hypertensive agents (Table 4.1). 
 
 
 Case (n = 20) Control (n = 20) 
Levothyroxine 7 1 
Anti-hypertensives 4 1 
Bisphosphonate 2 0 
Anti-depressants 1 3 
HMG-CoA reductase inhibitors 0 1 
 








4.4.2 Blood pressure 
 
No significant differences were noted in systolic blood pressure between cases and 
controls (139 ± 4 vs. 131 ± 3 mmHg, p=0.140).  Diastolic blood pressure was 
significantly higher in aromatase treated patients (82 ± 2 vs. 75 ± 2 mmHg, p <0.05).  
4 aromatase inhibitor treated patients were receiving anti-hypertensive medication 
versus a single patient in the control group. 
 
4.4.3 Fasting lipid profile 
 
No significant differences were observed in fasting lipid profile between cases and 
controls (Table 4.2). 
 
 Case (n = 20) Control (n = 20) p 
Total cholesterol (mmol/L) 6.0 (0.1) 5.7 (0.2) 0.18 
HDL Cholesterol (mmol/L) 1.6 (0.1) 1.7 (0.1) 0.37 
LDL Cholesterol (mmol/L) 3.8 (0.1) 3.5 (0.2) 0.13 
Triglycerides (mmol/L) 1.1 (0.1) 1.0 (0.1) 0.53 
Cholesterol:HDLC ratio 3.8 (0.2) 3.5 (0.2) 0.19 
 
Table 4.2 Fasting plasma lipid profile data presented as mean (SEM) and 
analysed by unpaired Student’s t-test. 
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4.4.4 Body composition 
 
No significant differences were noted in basic measures of body composition, as 
summarised in table 4.3. 
 
More detailed assessment of body composition was obtained by dual-energy x-ray 
absorptiometry (DEXA).  Lean mass was significantly lower in cases than controls 
across almost all compartments.  Peripheral percentage body fat was significantly 
greater in aromatase inhibitor treated patients than in controls, although no difference 
was noted in trunk body fat.  Whilst differences in percentage fat were observed, no 
differences in total fat mass were noted.  Fat distribution index (the ratio of trunk to 
leg fat) did not differ between groups. The full DEXA characteristics of cases and 




 Cases (n=20) Controls (n=20) p 
Height (cm) 159.8 ± 0.9 165.1 ± 1.7 0.001 
Weight (kg) 69.2 ± 2.3 72.5 ± 2.9 0.38 
BMI (kg/m2) 27.1 ± 0.9 26.6 ± 1.0 0.68 
Waist circumference (cm) 90.1 ± 2.0 88.4 ± 2.6 0.61 
Hip circumference (cm) 102.3 ± 1.6 103.4 ± 1.8 0.68 
Waist:Hip ratio 0.88 ± 0.01 0.85 ± 0.01 0.23 
 
Table 4.3  Basic anthropometric measurements presented as mean ± SEM 
and compared by Student’s t-test.  
 
 Case (n=20) Control (n=18) p 
BMC total (g) 1917.3 ± 56.5 2047.8 ± 81.3 0.189 
Total body fat (g) 26722.1 ± 1493.7 25613.9 ± 2010.5 0.657 
Total body lean (g) 40284.4 ± 929.9 44726.2 ± 1494.3 0.014 
Total body % fat 38.4 ± 1.0 34.6 ± 1.3 0.026 
Fat distribution index 1.3 ± 0.1 1.3 ± 0.1 0.584 
Proportion android fat 0.6 ± 0.01 0.6 ± 0.02 0.909 
Proportion gynoid fat 0.4 ± 0.01 0.4 ± 0.01 0.729 
 
Table 4.4  Detailed DEXA body composition analysis in cases and controls.  
Data are expressed as mean ± SEM and compared by Student’s t-test 
(normally distributed as determined by Kolmogorov-Smirnov test).   
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4.4.5 Insulin sensitivity 
 
All 40 participants had normal fasting blood glucose levels (i.e. < 6mmol/L), with 6 
patients in the aromatase inhibitor group displaying impaired glucose tolerance 
(glucose 7.8 – 11.0 mmol/L at 2 hours following 75g oral glucose) compared to 3 
patients in the control group.  In addition, 2 patients in the control group had 2-hour 
glucose levels in the diagnostic range for diabetes (i.e. >11 mmol/L).   
 
The pre-specified primary method for determining insulin sensitivity was the 
‘Matsuda Index’ (Matsuda et al. 1999).  The Matsuda calculation, as originally 
described, requires paired glucose and insulin measurements at baseline, 30, 60, 90 
and 120 minutes following a 75g oral glucose load. Severe haemolysis of plasma 
samples is recognised to cause significant underestimation of insulin concentration as 
a consequence of accelerated insulin degradation (Bellomo et al. 2012).  Baseline 
insulin concentration was determined from the mean of 3 measures at -30, -15 and 0 
minutes, although as a consequence of severe haemolysis, 4 samples in the AI treated 
group and 1 sample in the control group were not included.  During the 2 hours 
following glucose administration, 7 samples in the AI group and 2 in the control 
group were excluded due to severe haemolysis. Mean substitution (for the relevant 
time point) of unusable samples was employed to permit calculation of the Matsuda 
Index, which did not substantively affect the statistical analysis.   Aromatase inhibitor 
treated individuals were significantly more insulin resistant than controls, based on a 
24.3% increase in Matsuda index (Table 4.5), an effect which was independent of age 
but not body fat percentage.  Peak insulin concentration was also significantly greater 
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in AI treated patients than in controls, with a similar non-significant trend towards 




 Case (n=20) Control (n=20) P 
Matsuda index 5.15 ± 0.45 6.80 ± 0.64 0.041 
AUC glucose 
(mmol/L.120 mins) 
913.75 ± 43.07 898.63 ± 37.24 0.792 
AUC insulin* 
(pmol/L.120 mins) 
51680 ± 5510 42295 ± 6729 0.079 
Fasting glucose 
(mmol/L) 
4.56 ± 0.10 4.66 ± 0.08 0.588 
Fasting insulin* 
(pmol/L) 
50.10 ± 4.89 42.55 ± 5.06 0.217 
2-hour glucose* 
(mmol/L) 
7.21 ± 0.35 7.04 ± 0.50 0.556 
Peak glucose 
(mmol/L) 
9.40 ± 0.39 9.2 ± 0.38 0.744 
Peak insulin* 
(mmol/L) 
693.40 ± 78.58 527.60 ± 85.54 0.035 
 
Table 4.5  Indices of glucose tolerance in aromatase inhibitor treated patients 
and controls presented as mean ± SEM.  Compared with independent-
samples Student’s t-test (data log transformed where not normally distributed 








Figure 4.1 Mean plasma insulin (A) and mean plasma glucose (B) across 2-













































4.4.6 Uric acid  
 
No significant differences were noted in plasma or urine uric acid concentration 
between cases and control; similarly, no significant difference was observed in 
fractional excretion of uric acid (Table 4.6).  FEUA was negatively correlated with 
age (Pearson R -0.398, p <0.05) but not with BMI, percentage body fat or insulin 
sensitivity index.  Even after adjustment for age, no significant effect of aromatase 
inhibition was observed upon FEUA. 
 
 Case (n=20) Control (n=18) p 
Plasma uric acid (mmol/L) 0.27 ± 0.01 0.26 ± 0.01 0.693 
Urine uric acid (mmol/L)* 0.95 ± 0.11 1.1 ± 0.11 0.146 
Plasma creatinine (µmol/L) 60.8 ± 1.4 58.9 ± 1.4 0.344 
Urine creatinine (mmol/L) 5.2 ± 0.6 4.8 ± 0.6 0.894 
FEUA (%) 5.0 ±0.6 4.9 ± 0.5 0.908 
 
Table 4.6  Plasma and urine uric acid levels and calculated fractional 
excretion of uric acid presented as mean ± SEM.  Compared by Independent-
samples Student’s t-test except where not normally distributed, where 






4.4.7 Adipokines and pro-inflammatory cytokines 
 
Serum leptin was significantly higher in aromatase inhibitor treated patients (table 
4.8), although this relationship did not persist when adjusted for percentage body fat.  
IL-8, MCP-1, adiponectin and resistin did not differ significantly between cases and 
controls (Table 4.7).  Serum leptin, as expected, was strongly correlated with 
percentage body fat (Figure 4.2).   
 
 
 Cases Controls p 
Leptin (pg/mL) 23485 ± 2826 15527 ± 2286 0.035* 
Adiponectin (µg/mL) 43.0 ± 5.9 35.4 ± 3.7 0.516 
IL-8 (pg/mL) 7.6 ± 1.1 6.7 ± 0.6 0.871 
MCP-1 (pg/mL) 292.5 ± 33.8 268.3 ± 20.2 0.957 
Resistin (pg/mL) 22.2 ± 1.1 22.9 ± 1.9 0.828 
 
Table 4.7 Comparison of serum adipokines between aromatase inhibitor 
treated patients and controls.  Data are mean ± SEM.  Comparison by 
independent-samples Student’s t-test * or independent-samples Mann-






Figure 4.2  The association between percentage body fat and serum leptin 




4.4.8 Adipose tissue mRNA 
 
mRNA expression was assessed for genes where current evidence suggested a 
potential regulatory role for sex steroid hormones. Increased subcutaneous adipose 
tissue expression of LKB1 (32%), β-catenin (27%) and leptin (40%) was observed in 
aromatase inhibitor treated patients.  There were non-significant trends towards 
greater expression of perilipin 2 (21%), PPARγ (25%) and lipoprotein lipase (14%).  
The full results for all genes assessed are summarised in table 4.8.  A significance 
level of <0.05 was chosen as all transcripts were selected on the basis of prior 
evidence of estrogen or androgen responsiveness.  Serum leptin was strongly 
correlated with leptin mRNA expression (Pearson R 0.574, p <0.001) (Figure 4.3).  
Percentage body fat (Pearson R 0.658, p <0.001) (Figure 4.4) and BMI (Pearson R 
0.456, p <0.01) but not WHR (Pearson R 0.320, p >0.05) were significantly correlated 













 Case (n=20) Control (n=18) p 
Steroid hormone synthesis and metabolism 
HSD11B1* 
11βHSD1 
0.91 ± 0.15 0.78 ± 0.10 0.689 
AKR1C2* 
Aldo-keto reductase 1C2 
1.01 ± 0.20 0.80 ± 0.11 0.845 
CYP19A1* 
Aromatase 
0.66 ± 0.14 0.42 ± 0.09 0.192 
Steroid hormone receptors 
AR* 
Androgen receptor 
0.77 ± 0.06 0.71 ± 0.05 0.622 
ESR1* 
Estrogen Receptor α 
0.74 ± 0.10 0.59 ± 0.07 0.176 
ESR2 
Estrogen Receptor β 
0.41 ± 0.03 0.42 ± 0.03 0.919 
 
Adipogenesis, lipogenesis and lipolysis  
ACACA 
Acetyl CoA carboxylase 
0.76 ± 0.09 0.65 ± 0.11 0.443 
 
UCP2* 
Uncoupling protein 2 
0.44 ± 0.04 0.46 ± 0.03 0.468 
FASN 
Fatty acid synthase 
0.65 ± 0.07 0.62 ± 0.07 0.735 
 
LIPE 
Hormone sensitive lipase 




0.70 ± 0.07 0.55 ± 0.05 0.077 
 
LKB1* 
Liver kinase B1 
1.44 ± 0.19 0.98 ± 0.15 0.030 
CTNNB1 
β-catenin 
0.62 ± 0.04 0.45 ± 0.02 0.023 
 
PNPLA2* 
Adipose triglyceride lipase 
0.58 ± 0.07 0.62 ± 0.08 0.724 
PPARG* 
Peroxisome proliferator-
activated receptor γ 




0.67 ± 0.08 0.58 ± 0.08 0.420 
 
Lipid and sterol metabolism  
CETP* 
Cholesterol ester transfer 
protein 
0.62 ± 0.14 0.90 ± 0.24 0.343 
LPL* 
Lipoprotein lipase 





 Case (n=20) Control (n=18) p 
SREBF1 
Sterol regulatory element 
binding transcription factor 1 
0.86 ± 0.10 0.70 ± 0.12 0.314 
 
SREBF2* 
Sterol regulatory element 
binding transcription factor 2 
0.76 ± 0.64 ± 0.303 
Adipokines   
IL6* 
Interleukin-6 
0.87 ± 0.15 1.00 ± 0.20 0.953 
LEP* 
Leptin 
0.92 ± 0.10 0.55 ± 0.06 0.003 
ADIPOQ 
Adiponectin 




0.73 ± 0.06 0.62 ± 0.04 0.179 
 
IGF1 
Insulin-like growth factor-1 












0.74 ± 0.07 0.65 ± 0.05 0.380 
 
Table 4.8  Subcutaneous adipose tissue mRNA transcript levels in aromatase 
inhibitor treated women and controls.  Data are presented as means  ± SEM 
(relative to cyclophyllin) and compared with independent-samples Student’s t-
test (data log transformed where not normally distributed as determined by 
Kolmogorov-Smirnov test*) or Independent-samples Mann-Whitney U Test 






Figure 4.3 The relationship between leptin mRNA expression and serum 







Figure 4.4 The relationship between leptin mRNA expression and body fat 





















A substantial body of evidence attests to the importance of androgens and estrogens in 
modulating body composition and insulin sensitivity.  Consequently, it is plausible 
that aromatase inhibitors, by suppressing estrogens and increasing androgen levels, 
may exert a deleterious effect upon metabolic health in women.  Despite the 
widespread use of aromatase inhibitors, principally in the treatment of post-
menopausal breast cancer, no systematic assessment of their potential metabolic 
effects has been undertaken.  Although aromatase inhibitors are effective in 
preventing cancer recurrence, this has not been accompanied by improved overall 
survival, perhaps a consequence of increased cardiovascular events.  A meta-analysis 
comparing outcomes with tamoxifen and aromatase inhibitors identified a 26% 
increased risk of cardiovascular events in women receiving aromatase inhibitors 
(Amir et al. 2011). Aromatase inhibitors may exert subtle changes in plasma lipid 
profile, however the evidence for this is inconsistent and does not appear sufficient to 
account for an excess of cardiovascular disease.  This study was designed to assess 
whether postmenopausal women receiving aromatase inhibitors display significant 
differences in body composition and insulin sensitivity in comparison to age-matched 
peers.   
 
Case-control methodology, whilst subject to a number of limitations, was selected on 
pragmatic grounds.  It would have been preferable to perform prospective evaluation 
of the metabolic effects of aromatase inhibitors by assessing women prior to 
commencement of therapy and again at an interval following commencement, and to 
have studied a control group comprising hormone-negative cancer patients.  However, 
this option was considered ethically problematic, as it would have involved inviting 
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women to take part in a clinic study very shortly after receiving a diagnosis of breast 
cancer.  Furthermore, hormone-negative cancer patients are often offered cytotoxic 
chemotherapy, which has the potential to influence body composition, thus 
confounding any comparison with aromatase inhibition.  Another potential study 
design would have been a within-subject comparison performed during therapy and 
repeated at a pre-specified interval following cessation.  This would not have 
benefitted from a control group comparison and would have failed to detect any 
residual aromatase inhibitor effects, such as those mediated by changes in body 
composition, which may persist following treatment cessation.  
 
Patient recruitment achieved satisfactory age matching.  Breast cancer patients were 
recruited from clinics, whilst controls were recruited from the national breast cancer-
screening programme.  This could potentially have introduced a bias, as attendance at 
breast cancer screening is positively associated with affluence (Moser et al. 2009), 
with the opposite true of obesity and T2DM (Scottish Diabetes Survey, Monitoring 
Group, 2008).  The Scottish Index of Multiple Deprivation (SIMD) assesses the 
extent of deprivation, based on 38 measures across 7 categories, in 6505 geographical 
‘datazones’. No significant difference was noted in SIMD scores between cases and 
controls, suggesting no major disparity in affluence.   
 
Whilst no specific effort was made to match groups with respect to anthropometric 
parameters, no significant difference in weight, BMI or waist circumference were 
observed.  Fortunately, this addresses a potentially important criticism of the case-
control design, as increasing BMI is associated with a higher risk of breast cancer in 
post-menopausal women.  BMI < 21 kg/m2 is associated with the lowest risk of 
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breast-cancer in post-menopausal women, with a non-linear increased risk observed in 
higher BMI categories (van den Brandt et al. 2000).  Substantial weight gain 
following menopause (>10 kg) is also associated with an increased breast cancer risk.   
Although there is a recognised association between increased height and post-
menopausal breast cancer risk (van den Brandt et al. 2000), surprisingly the mean 
height in the control group was significantly higher than breast cancer patients in this 
study.  Whilst height has previously been associated with differences in blood 
pressure, no association between height and blood pressure was evident in this study. 
 
With the exception of breast cancer, both cases and controls were generally in good 
health, as mandated by the study exclusion criteria.  There was, however, a striking 
disparity in levothyroxine treated patients between groups (7 cases and 1 control).  If 
levothyroxine therapy is associated with alterations in body composition or insulin 
sensitivity, this could represent a significant confounder.  However, post-menopausal 
women, treated with thyroidectomy and subsequent levothyroxine, did not develop 
any significant changes in weight or body composition (as determined by DEXA), 
over a 12-month period (Kormas et al. 1998).  A potential association between 
autoimmune thyroid disease and breast cancer is well recognised, although the 
direction of the relationship remains unclear.  Higher levels of thyroid peroxidase 
antibody have been observed in patients with malignant breast disease (Giustarini et 
al. 2006) but in a large series of breast cancer patients, primary hypothyroidism was 
less common than in age-matched controls (Cristofanilli et al. 2005).   
 
The decision to include women treated with any of the third generation aromatase 
inhibitors, rather than electing to assess the effects of a single agent, was expedient in 
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order to complete the study within a reasonable time; although the majority of cases 
received anastrozole (n=12).  The degree of estradiol suppression appears equivalent 
between letrozole and anastrozole (Geisler et al. 2008), however there is evidence to 
suggest that letrozole is less specific in its inhibition of steroid production and may 
exert a suppressive effect upon glucocorticoids and mineralocorticoids (Bisagni et al. 
1996; Bajetta et al. 1996).  The sample size was too small to detect any differences 
between agents, although a more comprehensive assessment of potential differences 
would certainly be welcome. 
 
 
Blood pressure displays sexual dimorphism, increases following menopause, varies 
across the menstrual cycle and falls, in parallel with increased estradiol, in pregnancy; 
all these factors support a role for estrogens in regulating blood pressure (Dubey 
2002).  In this study, diastolic (but not systolic) blood pressure was higher in 
aromatase inhibitor treated women than controls, despite a higher proportion of anti-
hypertensive therapy in the former.    Interestingly, polymorphisms in CYP19 have 
been associated with differences in diastolic blood pressure in women (Peter et al. 
2005) and identified as potential markers for essential hypertension in both genders 
(Shimodaira et al. 2008).  Remarkably, despite concerns regarding increased 
cardiovascular events, no formal assessment of the effect of aromatase inhibition 
upon blood pressure has been reported in the literature.   
 
No significant difference in fasting lipid profile was noted between cases and 
controls, which is broadly in accord with existing evidence.  The suggestion that 
aromatase inhibitors may increase LDL cholesterol is largely based on head-to-head 
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studies with tamoxifen (ATAC Trialists’ Group  2006), however the disparity is most 
likely a consequence of the lipid-lowering properties of tamoxifen.  Prospective 
evaluation of cholesterol, following anastrozole therapy, failed to detect any 
significant difference in fasting lipid profile (Van Poznak et al. 2012).   
 
Whilst basic anthropometric parameters were no different between cases and controls, 
more detailed body composition, by DEXA, revealed greater body fat percentage and 
lower lean mass in aromatase inhibitor treated women.  DEXA was selected as the 
modality for assessment of body composition on the basis of evidence suggesting it 
accords closely with the reference standard, underwater weighing (Fogelholm et al. 
1997), as well as providing estimates of body composition across a number of 
compartments. Only two previous studies have assessed the effect of aromatase 
inhibition upon body composition and are potentially confounded by patients in the 
comparator groups receiving tamoxifen.  In one study, 11 recently menopausal breast 
cancer patients receiving aromatase inhibitors were compared with 71 women on 
alternative therapies (mostly tamoxifen).  Over a 24-month period, aromatase 
inhibitor treated women gained lean mass, whilst non-aromatase inhibitor treated 
women developed increased fat percentage (van Londen et al.  2011).  Conversion 
from tamoxifen to exemestane was associated with a significant reduction in fat mass 
(and increase in FM/FFM ratio) in 28 post-menopausal breast cancer patients, over a 
period of 1 year (Francini et al. 2006). Prospective evaluation of tamoxifen treated 
women, over 2 years, failed to show any significant changes in body composition, as 
assessed by DEXA, albeit with a limited set of parameters reported (Grey et al. 1995); 
however, tamoxifen may be associated with increased visceral adiposity (Nguyen et 
al. 2001).  The findings in this study conflict with these earlier investigations, 
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however elevated serum leptin in aromatase inhibitor treated women corroborates the 
apparent increase in body fat as determined by DEXA.  Furthermore, a trend towards 
increased LPL mRNA expression in subcutaneous adipose tissue is consistent with 
the established literature on estrogen effects on adipose tissue (Mauvais-Jarvis et al. 
2013). ER-α is thought to protect against sarcopenia through activation of Akt and 
MAPK pathways.  HRT has consistently been associated with improvements in lean 
body mass (Chen et al. 2005; Sørensen et al. 2001), therefore estrogen suppression, 
through aromatase inhibition, may result in reduced muscle mass, as suggested from 
this study.  It would be of interest to determine the differential effects of aromatase 
inhibition upon visceral and subcutaneous adipose volume, by CT or MRI analysis. 
 
 
Aromatase inhibitor treated women were more insulin resistant than controls, as 
determined by ‘Insulin Sensitivity Index – Matsuda’. This is consistent with the 
predicted effects of reduced estrogen and increased androgen activity upon skeletal 
muscle, liver, beta cells and adipose tissue, in women, as described in chapter 1.  The 
largest change appears to have been greater hyperinsulinaemia following a glucose 
load, suggesting peripheral insulin resistance mediates a large component of the 
aromatase inhibitor effect.  ‘ISI – Matsuda’ was selected as the primary outcome 
measure for this study as it integrates information from both the fasting and fed state, 
to provide an estimate of insulin sensitivity which accords well with gold-standard 
glucose clamp studies.  Clamp studies would have provided more information 
regarding the relative contribution of hepatic and peripheral insulin sensitivity, as well 
as effects on lipolysis, however time and cost constraints precluded pursuing this 
methodology.   
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Recent observations that uric acid may have a contributory role towards the 
development of insulin resistance (Johnson et al. 2009), paired with a potential role 
for estrogens in modulating the excretion of uric acid (Yahyaoui et al. 2008), raised 
the possibility that aromatase inhibition may effect suppression of uric acid excretion.  
In a rat model of hyperuricaemia (induced by high-fructose feeding), lowering of 
urate with allopurinol was shown to mitigate hypertension, weight-gain, 
hypertriglyceridaemia and hyperinsulinaemia (Nakagawa et al. 2006).  Elevated uric 
acid levels have long been considered a consequence of insulin resistance rather than 
a cause, however prospective studies have identified uric acid as an independent risk 
factor for the development of metabolic syndrome in men and women (Sui et al. 
2008).   A study in male to female transsexuals, demonstrated a dose-dependent 
suppressive effect of estrogen replacement upon serum uric acid, with an 
accompanying increase in fractional excretion of uric acid (Yahyaoui et al. 2008).  
However, in the current study, no significant difference was noted in either serum 
levels, or urinary excretion, of uric acid between cases and controls.  This suggests 
that below a threshold estradiol concentration, further suppression does not exert any 
additional influence upon uric acid.   
 
Serum leptin was significantly higher in aromatase inhibitor treated patients compared 
to controls, an observation consistent with the increased body fat percentage detected 
by DEXA.  Furthermore, leptin mRNA transcript levels in subcutaneous adipose 
tissue were also increased in aromatase inhibitor treated women, suggesting an effect 
in addition to simple expansion of adipose volume.  Consistent with this study, 
aromatase knockout mice, of both sexes, display substantially elevated serum leptin 
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levels and, in this murine model, central leptin sensitivity appears preserved, on the 
basis of reduced food intake (Jones et al. 2001). Similar findings are observed in 
aromatase knockout mice with respect to leptin adipose mRNA transcript levels, 
which are lowered by estradiol administration (Misso et al. 2003).   
 
In contrast, the hormonal manipulations undertaken in male-to-female and female-to-
male transsexuals, result in increased and decreased serum leptin, respectively (Elbers 
et al. 1997). Omental adipocytes from women, but not men, are stimulated to produce 
leptin when incubated with estradiol (Casabiell et al. 1998).  In cultured adipocytes 
from male rats, DHT exposure reduces leptin mRNA expression, whilst the opposite 
effect is observed in female adipocytes exposed to estradiol (Machinal et al. 1999).  A 
paradox exists between what may be expected from our understanding of the 
regulation of leptin expression, based on cell culture studies and exogenous 
administration of sex steroids, and what is observed in aromatase knockout mice and 
here in aromatase inhibitor treated women.  
 
Aromatase inhibitor therapy, in post-menopausal women, does not appear to exert any 
influence on adiponectin, as determined by serum concentration and adipose mRNA 
expression in this study.  Serum adiponectin levels are typically higher in women and, 
in post-menopausal women, transdermal estrogen replacement is associated with an 
increase in circulating adiponectin (Chu et al. 2006).  Conversely, in hypogonadal 
men, testosterone replacement appears to effect a reduction in circulating adiponectin 
(Lanfranco et al. 2004).  Given the anticipated changes in adipose and circulating sex 
hormones, it is perhaps surprising that no influence upon adiponectin was observed.  
No differences were observed, between groups, in serum IL-8, MCP-1 or resistin 
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concentrations.  We did not assess TNF-α in this study, however TNF-α mRNA 
expression has been positively correlated with estrogen sulfotransferase (EST) 
expression in human subcutaneous adipose tissue (Ahima et al. 2011).  Whether 
adipose inflammation promotes EST expression or, alternatively, reduced adipose 
estradiol (through increased EST expression) promotes inflammation, is not clear; it 
would be of interest to see whether aromatase inhibition influences adipose EST and 
TNF-α expression. 
 
A range of mRNA transcript levels were assessed in subcutaneous adipose tissue, 
based on previous evidence of regulation of expression by sex hormones. β-Catenin 
transcript levels, a central component of Wnt signalling, were higher in AI treated 
women.  β-Catenin has been shown to interact with both ER and AR and appears to 
exert an effect on transcription factors, which is broadly anti-adipogenic (Singh et al. 
2006; Kouzmenko et al. 2004).  LKB1is an upstream activator of AMPK, which 
promotes fatty acid oxidation and suppresses fatty acid synthesis in adipocytes.  Cell 
culture studies have shown estradiol up-regulates transcription of LKB1 whilst DHT 
exerts the opposite effect (McInnes et al. 2012).  Surprisingly, in the context of 
reduced estrogen and increased androgen levels, AI treated women had significantly 
higher LKB1 transcript levels compared to controls. To summarise, the statistically 
significant differences in transcript levels are consistent with an anti-adipogenic effect 
(increased LKB1 and β -catenin) although leptin mRNA levels were higher.  This 
study has not taken into account the potential effects of EST activity and no direct 
measurements of adipose tissue sex steroid levels were performed; both of which 
would contribute useful additional information.  Subcutaneous adipose tissue was 
studied because of the relative ease of acquiring tissue from this compartment, in 
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contrast to visceral adipose.  However, the visceral and subcutaneous adipose 
compartments have distinct characteristics and ideally assessment of the effects of 




The findings in relation to decreased lean mass and insulin sensitivity highlight the 
potential role of sex hormone manipulation upon skeletal muscle, the main source of 
peripheral glucose uptake.  Indeed, in men at least, it has been suggested that skeletal 
muscle is the largest pool of non-gonadal aromatization (Longcope et al. 1978).  
Further characterisation of the effects of aromatase inhibition upon skeletal muscle in 
women, through analysis of gene expression and quantification of intramyocellular 
lipid would be of particular interest.  As hypothesised, aromatase inhibition was 
associated with increased insulin resistance and adverse changes in body composition, 
although this manifested as reduced lean mass rather than, as predicted, a shift from 
gynoid to android adiposity.  These results should prompt a more comprehensive 






The metabolic effects of short-term 
aromatase inhibition in healthy male 
volunteers: a double-blind, placebo-




A substantial body of evidence, at both a cellular and whole organism level, has 
accumulated in support of the influence of sex steroid hormones upon energy 
metabolism (Mauvais-Jarvis et al. 2013; Kelly & Jones 2013).  However the emphasis 
of investigation is frequently focussed on estrogens in females and androgens in 
males, with much less information available regarding the role of androgens in 
women and, even less regarding estrogens in men.  In view of the interdependence of 
substrates and products, particularly of aromatase, most experimental manipulation is 
complicated, by exerting significant effects upon both androgens and estrogens. 
Greater insulin resistance, visceral adiposity, diabetes risk and cardiovascular 
morbidity are observed in men, when compared to age-matched premenopausal 
women; with lower estrogen levels implicated as a potential explanation for this 
disparity (Moran et al. 2008).  
 
In clinical and experimental medicine, relatively little attention has been paid to the 
potentially deleterious effects of estrogen deficiency in men.  Male aromatase 
knockout mice display a characteristic phenotype of increased adiposity, hepatic 
steatosis, reduced lean mass and insulin resistance, which is largely reversible 
following estradiol replacement; a similar phenotype is observed in rare human cases 
of aromatase deficiency (Simpson et al. 2005).  A handful of small studies have 
investigated the effects of pharmacological aromatase inhibition in men, resulting in 
either improved insulin sensitivity (Lapauw et al. 2009; Lapauw et al. 2010) or no 
significant change in insulin sensitivity (Dougherty et al. 2005).  An elegant study 
sought to determine the relative contribution of androgens and estrogen to changes in 
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body composition, by suppressing LH (with goserelin) and administering varying 
doses of testosterone, with or without aromatase inhibitor; increasing body fat 
(particularly intra-abdominal) was associated with estrogen suppression (Finkelstein 
et al. 2013).  It is unsurprising that changes in the balance of estrogen and androgen 
signalling should effect changes in adipose volume, as several genes involved in 
adipogenesis are known to be regulated by sex steroid hormones (section 1.1).   
 
Little is currently known about the specific effects of aromatase inhibition upon 
transcriptional regulation in adipose tissue and no detailed assessment of their 
influence upon glucose and fat metabolism has been undertaken.  In the previous 
chapter, aromatase inhibition was associated with reduced insulin sensitivity in post-
menopausal women.  The current chapter describes a study which sought to further 
characterise the metabolic effects of aromatase inhibition, employing superior study 
design (double-blind, placebo-controlled) and gold standard methodology for 
assessing insulin sensitivity (hyperinsulinaemic euglycaemic clamp with stable 















The principal hypothesis investigated was: 
 
Aromatase inhibition in healthy men results in increased insulin resistance, associated 




The aims of the study in men were to: 
 
1. Determine whether short-term aromatase inhibition adversely effects insulin 
sensitivity, resulting in altered lipid and glucose homeostasis. 
2. Assess the effects of aromatase inhibition upon circulating adipokines and 
pro-inflammatory cytokines. 
3. Characterise the effect of aromatase inhibition upon relevant mRNA transcript 
levels in the subcutaneous adipose compartment. 
 
To address these aims, I undertook a double-blind randomised balanced crossover 
study of pharmacological aromatase inhibition in healthy male volunteers utilising 
hyperinsulinaemic eugycaemic clamp studies (with stable isotope tracers), 
measurement of adipokines and pro-inflammatory cytokines in plasma, and 




5.3.1 Study Title and Ethical Approvals 
 
Study title: The metabolic effects of aromatase inhibition 
 
Principal Investigator: Dr Fraser W Gibb 
 
Ethical approval was gained from the Lothian Research Ethics Committee in 
September 2007 (LREC number 07/S1101/03). NHS Lothian granted research and 
Development approval in August 2007 (R&D number 2007/R/END/03).  The study 
was carried out at the Wellcome Trust Clinical Research Facility at the Western 




Full details of materials are provided in chapter 2. 
 
Fasting lipid profile, plasma glucose, liver function tests and urea and electrolytes 
were measured at the biochemistry laboratory of the Royal Infirmary of Edinburgh.   
 
The candidate undertook all of the clinical measurements and sample collection, and 
gained experience with all of the laboratory assay techniques, but as a result of 
samples being analysed after the end of his PhD fellowship, he is grateful for the 
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assistance in completion of qPCR by Karen French and Kerry McInnes, of GCMS by 
Sanjay Kothiya, and of plasma biochemistry analyses by Rita Upreti 
 
5.3.3 Study design 
 
The design was a double-blind randomised balanced crossover study in healthy male 
volunteers.   
 
5.3.3.1 Subjects: recruitment, inclusion and exclusion criteria 
 
Recruitment took place between March 2008 and October 2009.  Advertisements 
were placed in local newspapers and posters displayed across the University of 
Edinburgh, NHS Lothian and other public areas.  20 individuals proceeded through 
the baseline screening visit but 3 subjects dropped out prior to randomisation.  The 
initial screening visit involved a brief clinical assessment, principally to ensure 
inclusion and exclusion criteria were satisfied. 
 
Inclusion criteria:  
 
! Men aged between 18 – 65 years 
! Normal screening blood tests (urea & electrolytes, liver function tests, lipid 







! Any significant illness 
! Regular medication 
! Abnormal screening blood tests (as described above) 
! Alcohol excess (defined as greater than 28 units per week) 
! Inability to give informed consent  
 
All screened volunteers (n=20) fulfilled the inclusion and exclusion criteria, although 
three individuals elected not to participate further following the screening visit.  
 
5.3.3.2 Study protocol 
 
Subjects were randomised to initially receive either 1mg anastrozole once daily or 
identical placebo capsules once daily for 6 weeks (Tayside Pharmaceuticals, Dundee, 
UK), at the end of which they attended the clinical research facility for a 
hyperinsulinaemic euglycaemic clamp study (described in detail in section 5.3.5). 
After a 2 week ‘washout’ period, subjects ‘crossed-over’ to the opposite treatment 
allocation for six weeks, followed by a further clamp study (summarised in figure 
5.1).  Randomisation codes were generated by one of the project supervisors (RA) and 
the study was only un-blinded to the principal investigator following completion of 
analyses.   
 
Subjects who were willing to have a subcutaneous adipose tissue biopsy performed 
(n=6), attended on a morning separate to the clamp study, within a five-day period 
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prior to completion of their course of study medication.  Paired adipose biopsies (i.e. 
for both the placebo and anastrozole phases) were collected in all six of these 
individuals.   
 
5.3.3.3 Clinical measurements 
 
Systolic and diastolic blood pressure and pulse rate were measured, after sitting for at 
least 10 minutes, using a 705IT automatic blood pressure monitor (OMRON 
Healthcare, Netherlands).  Weight and height were obtained in all subjects.  Body fat 
percentage was measured by electrical bioimpedance using a handheld OMRON 
BF306 Body Fat Monitor (OMRON Healthcare, Henfield, UK). 
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5.3.4 Adipose tissue biopsy 
 
Paired subcutaneous adipose biopsies were performed (as described in section 2.2.2) 
within the final 5 days of both the anastrozole and placebo phases.  To summarise, 
following subcutaneous administration of 5mL local anaesthetic (5ml 2% lidocaine, 
Hameln Pharmaceuticals, Gloucester, UK), a 19G needle was inserted approximately 
10cm lateral to the umbilicus and subcutaneous adipose tissue aspirated by vacuum.  
The samples were collected in sterile eppendorf tubes, stored immediately in dry ice 
before transfer to -80°C refrigeration.  Adipose tissue was later processed and RNA 
extracted, as described in detail in section 2.4.3.  Following reverse transcription 
(described in section 2.4.5), real time PCR was performed to analyse the mRNA 
transcript levels of a battery of genes related to adipogenesis, steroid metabolism and 
adipocytokines (described in section 2.4.6).   
 
 
5.3.5 Hyperinsulinaemic euglycaemic clamp with deuterated 
glucose and glycerol tracers 
 
5.3.5.1 Drug preparation and dosage calculations 
 
Actrapid® insulin was prepared in 0.9% saline at a concentration of 0.3 U/mL.  
Infusion rates for insulin were based on body surface area.  The rate of infusion was 
calculated as follows:  
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Rate (mL/min)  =  (10 [low dose] or 40 [high dose]) x BSA x 60  
                    1000 x 0.3 
 
Stable isotope tracers were prepared by Dr Alistair Millar (Radiopharmacist, Royal 
Infirmary of Edinburgh), using water as diluent.  1,1,2,3,3-2H5-glycerol (d5-glycerol) 
was provided in 8.5 mL vials (40 mg/mL) and 6,6,-2H2-glucose (d2-glucose) in 5 mL 
vials (350 mg/mL).   
 
Final preparation was performed on the morning of administration, when both glucose 
and glycerol tracers were diluted in 0.9% saline. Priming boluses of tracer were 
prepared by addition of 0.5 mL (20 mg) d5-glycerol to 19.5 mL 0.9% sodium chloride  
and 1 mL (350 mg) d2-glucose to 19 mL 0.9% sodium chloride, giving concentrations 
of 1 mg/mL and 17.5 mg/mL, respectively.  For continuous infusion, d5-glycerol (7.5 
mL, 300mg) and d2-glucose (3.2 mL, 1.12g) were added to make up a total volume of 
500 mL. Administration of tracers is described in detail in section 5.3.5.2.  
 
 
5.3.5.2 Clamp protocol 
 
Clamp studies were performed, at completion of both the placebo and anastrozole 
phases of the study, for assessment of insulin sensitivity (protocol summarised in 
figure 5.1).  Subjects attended the clinical research facility at 07:30 in a fasted state 
(from 22:00 the preceding evening).  Subjects were also asked to abstain from alcohol 
and tobacco on the day prior to the clamp study.  Upon arrival, two venous cannulae 
were inserted for infusions and a third cannulae was retrogradely inserted in a 
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contralateral hand vein for sampling of arterialised blood for glucose measurements.  
Hand veins were ‘arterialised’ by external heating with an electric blanket throughout 
the clamp study.  The study can be separated into three 90-minute periods: 
 
1. 0 – 90 minutes:  Administration of priming boluses of stable isotope tracers 
and subsequent infusion (as described in section 5.3.5.1).  Priming boluses of 
d2-glucose (17 µmol/kg) and d5-glycerol (1.6 µmol/kg) were administered 
over 1 minute to attain earlier steady state conditions.  Thereafter, continuous 
infusion of d2-glucose (0.22 µmol/kg/min) and d5-glycerol (0.11 
µmol/kg/min) was commenced and maintained at this rate through the full 
clamp protocol. 
2. 90 – 180 minutes: Low dose insulin. An infusion of Actrapid® insulin (Novo 
Nordisk, Denmark) was commenced at a rate of 10 mU/m2/min with a parallel 
infusion of 20% dextrose, adjusted every 5 minutes, to maintain euglycaemia.  
The low dose period was designed to assess inhibition of lipolysis and 
suppression of hepatic glucose output. 
3. 180 – 270 minutes: High dose insulin. For the final period, the insulin infusion 
rate was increased to 40 mU/m2/min, with continuing adjustment of the 20% 
dextrose infusion rate.  The high dose period was designed to assess peripheral 
glucose uptake.   
 
During the final 15 minutes of each period, 4 blood samples were collected (at 5 
minute intervals) in serum gel tubes.  These steady state samples were used to 
measure plasma tracer and tracee concentrations (as described in chapter 2.7).  
Throughout the insulin infusion (periods 2 and 3), blood glucose levels were clamped 
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between 4.5 to 5.5 mmol/L, with glucose measurement taking place at 5 minute 
intervals, from arterialised whole blood, using a glucometer (Accu-Check® 




Figure 5.2   Schematic of hyperinsulinaemic euglycaemic clamp, showing 
period 1 (0 to 90 minutes; no insulin), period 2 (90 to 180 minutes; low dose 
insulin) and period 3 (180 to 270 minutes; high dose insulin).  Blood sampling 
was performed in the final 15 minutes of each period, as represented by 
arrows.  20% dextrose infusion was adjusted to maintain euglycaemia in 




5.3.5.3 Sample collection 
 
Following insertion of an intravenous cannula, baseline blood samples were taken at 
approximately 07:30.  All blood tubes were S-Monovette® (Sarstedt, Germany) with 
serum gel 7.5 mL tubes to collect serum, 5.5 mL lithium heparin tubes to collect 
plasma and 2.5 mL fluoride gel tubes for glucose samples.  Glucose samples (fluoride 
tubes) were sent directly to the Western General Hospital biochemistry laboratory; all 
other samples were processed in the Clinical Research Facility and stored for future 
analysis.   
 
All blood samples were centrifuged on a Sigma 4K14 instrument (Munich, Germany) 
under the following conditions: 1912 g, 10 minutes, 4°C.  The resultant plasma / 
serum was stored at -80°C.   
 
5.3.5.4 Gas-Chromatography Mass Spectrometry 
 
Plasma glucose, glycerol and their respective tracers were quantified by GCMS as 








Body mass index was calculated as:  
 
BMI (kg/m2) = weight    (kg) 
   (height (m))2 
 






   
 
Glucose disposal (M) under steady state conditions was calculated as the mean 
volume of glucose infused in the final 15 minutes for phases 2 and 3 of the tracer 
study (low dose insulin and high dose insulin, respectively) and reported in 
mg/kg/min.   
 
Rate of appearance (Ra) [glucose and glycerol] and rate of disappearance (Rd) 
[glucose] were calculated as follows,using the tracer:tracee ratio (TTR), where tracer 
refers to the isotopically labelled glucose and glycerol, whilst tracee refers to 
! 170 
unlabelled (endogenous) glucose and glycerol. The ratio is derived from the peak 
areas on the mass spectrum for the respective isotopomers.   
 
For Ra glucose: 
 
 
Tracer  =  T/Tr = Ra d2glucose 
Tracee    Ra glucose 
 
Therefore: 
Ra Glucose = Ra d2Glucose 
   T/Tr 
 
Ra = Rd at steady state  
The rate of tracer infusion corresponds to the rate of appearance of labelled glucose 
and glycerol:   
 
Ra d2-Glucose  =  4mg/kg/hour   =  0.067mg/kg/min 
Ra d5-Glycerol = 0.64mg/kg/hour = 0.01mg/kg/min 
 
The same calculation is used to determine the Ra for glycerol, which equates to the 




As a consequence of naturally occurring glucose isotopomers in both the variable rate 
glucose and d2-glucose infusions, adjustments are required to account for this in the 
Ra d2-glucose and glucose infusion rate (GIR).  The true abundance of pure d2-
glucose in the tracer infusion was 92.5%, with the remaining 7.5% containing other 
naturally occurring isotopic species, such as 13C.  Similarly 1.1% of the variable rate 
glucose infusion was composed of naturally occurring d2-glucose.  The following 
calculation takes this variation into account: 
 
True Ra d2-glucose  = 92.5% rate of d2-glucose infusion + 1.1% variable GIR 
   = (0.0925 X 0.067) + (0.011 x GIR) 
   = 0.062 + (0.011 x GIR) 
 
Rate of endogenous glucose production (EGP) was calculated using steady state 
values for Ra glucose.  Ra glucose comprises both EGP and the infusion of variable 
rate unlabelled glucose.  An identical 92.5% correction for unlabelled glucose is also 
required, taking into account the fact that 7.5% of this infusion is composed of other 
mass isomers, including d2-glucose and 13C species.  EGP is calculated thus: 
 
EGP  = Ra glucose - (0.925 x GIR)  
 
No correction was required for glycerol, as no exogenous infusion was administered 





5.3.6.2 Statistical analysis 
 
All statistical analyses were undertaken using IBM SPSS for Windows  (Version 
19.0, Armonk, NY: IBM Corp).  Data are presented as mean ± SEM unless otherwise 
stated.  Comparisons between the anastrozole and placebo phases were made using 
paired Student’s t-tests.  When data were not normally distributed, logarithmic 
transformation was undertaken.  Where transformation did not result in normally 
distributed data, non-parametric analyses were undertaken, as detailed in the results 
section. 
 
Statistical significance was accepted at p <0.05.  
 
The intention was to recruit 20 participants, which was calculated to have 80% power 
to detect a 15% difference in rates of glucose disposal and appearance, based upon 
similar studies undertaken in the supervisors’ laboratory (Sandeep et al. 2005).  
Unfortunately, due to difficulties in recruitment, only 17 subjects completed the 







5.4.1 Subject characteristics 
 
17 individuals completed the study protocol, including 6 who consented to paired 
subcutaneous adipose biopsies. The first treatment phase was anastrozole in nine 
subjects and placebo in the remaining eight.  The mean age of volunteers was 27.7 ± 
2.5 years (range 18 – 50 years).  No participants were on any regular medication or 
suffered from any significant co-morbidity. 
 
5.4.2 Blood pressure 
 
Anastrozole was associated with a 4.7 mmHg increase in systolic blood pressure (138 
± 3 vs. 134. ± 3 mmHg, p <0.05) although no significant difference was observed in 
diastolic blood pressure (79 ± 2 vs. 78 ± 2 mmHg, p=0.847).  Heart rate was 
significantly lower during anastrozole treatment (66 ± 3 vs. 71 ± 3 bpm, p <0.05). 
 
5.4.3 Weight and body composition 
 
No significant differences were noted in weight between the aromatase inhibitor and 
placebo phases of the study (82.2 ± 3.4 vs. 81.8 ± 3.4 kg, p=0.404).  Similarly, no 
differences were observed with respect to percentage body fat (16.4 ± 1.9  vs. 16.4 ± 




5.4.4 Effect of aromatase inhibition upon circulating sex steroid 
concentrations 
 
Sex steroids were measured in 14 of the 17 subjects, subject to the availability of 
sufficient serum sample (Table 5.1).  Serum estradiol fell in all 14 subjects during 
aromatase inhibitor therapy, although in one case this difference was negligible.  
Serum estrone did not fall in 2 of 14 subjects during aromatase inhibitor therapy.   It 
would be reasonable to infer that the single subject with no appreciable change in 
either estrone or estradiol was not compliant with the study medication.  No 
significant differences were observed in either testosterone or androstenedione 
concentration between study phases. 
 
 
 Anastrozole  Placebo p 
Estradiol (pmol/L) 53.7 ± 2.2 64.5 ± 1.7 < 0.001 
Estrone (pmol/L) 28.3 ± 1.5 35.3 ± 1.9 < 0.001 
Testosterone (nmol/L) 19.4 ± 0.5 19.7 ± 0.6 0.777 
Androstenedione (nmol/L) 4.5 ± 0.3 4.5 ± 0.2 0.845 
 
Table 5.1   Serum sex steroid hormone concentrations during anastrozole 
and placebo phases of the study.  Data are presented as mean ± SEM and 




5.4.5 Clamped glucose levels, insulin concentration and glucose tracer: 
tracee ratios (TTR) 
 
Plasma glucose was clamped with a target of 4.5 – 5.5 mmol/L being achieved (mean 
glucose 5.2 ± 0.03 mmol/L) (Figure 5.3).  Achieved plasma insulin concentrations 
were 3.3 ± 0.7 mU/L, 11.6 ± 1.1 mU/L and 43.6 ± 2.2 mU/L in steady state samples at 
baseline, low dose and high dose clamps, respectively.  No significant differences 
were observed in insulin concentration between the placebo and anastrozole phase at 
baseline and during high dose insulin infusion; there was a non-significant trend 
towards lower insulin concentration during the low dose insulin infusion in the 
anastrozole phase (Table 5.2). TTRs at each stage of the clamp are shown in figure 
5.4.   d2-Glucose: glucose ratios achieved steady state during each sampling period.  
TTR decreased, as expected, during the high dose insulin phase, in concert with 













































































































































Time (minutes) Anastrozole Placebo p 
80 3.0 ± 0.9 3.5 ± 1.0 0.551 
170 9.8 ± 1.4 13.4 ± 1.6 0.066 
260 43.6 ± 3.0 43.8 ± 3.3 0.916 
 
 
Table 5.2  Achieved plasma insulin concentration (mU/L) across the course of 




















































































































































5.4.6 Whole body glucose disposal 
 
Whole body glucose disposal is inferred from the glucose infusion rate (M) during the 
high dose insulin phase of the clamp. Glucose infusion rates throughout the clamp 
studies are represented in figure 5.5.  No difference in M value was noted between 
anastrozole and placebo phases during the high dose clamp. However a significantly 
higher M value was observed in the placebo phase during the low dose clamp (Table 
5.3).  M values were also corrected for fat free mass (FFM), which largely represents 














































































 Anastrozole Placebo p 
Glucose infusion rate – 
Low dose clamp 
(mg/kg/min) 
2.19 ± 0.24 2.55 ± 0.28 0.024 
Glucose infusion rate – 
Low dose clamp 
(mg/kgFFM/min) 
2.57 ± 0.25 2.99 ± 0.27 0.025 
Glucose infusion rate – 
High dose clamp 
(mg/kg/min) 
7.53 ± 0.66 7.77 ± 0.75 0.599 
Glucose infusion rate – 
High dose clamp 
(mg/kgFFM/min) 
8.87 ± 0.71 9.14 ± 0.80 0.626 
 
Table 5.3  Glucose infusion rates (M) during low and high dose insulin phases 
of clamp studies.  Presented as mean ± SEM and compared by paired 
Student’s t-tests.  
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5.4.7 Rate of glucose disposal (Rd glucose)  
 
Rd glucose is derived from the M value and TTR; it permits adjustment for residual 
hepatic glucose production, as well as glucose infusion.  The results of Rd glucose 
during low dose insulin were congruent with previously reported M values, namely a 
trend towards decreased glucose disposal associated with anastrozole.  Of greater 
significance was the recognition of a 23.7% decrease in glucose disposal rate during 





















 Anastrozole Placebo p 
Tracer only 
(µmol/kg/min) 
7.77 ± 0.56 7.50 ± 0.46 0.271 
Tracer only 
(µmol/kgFFM/min 
9.35 ± 0.58 9.04 ± 0.60 0.313 
Low-dose insulin 
(µmol/kg/min) 
15.04 ± 1.13 16.46 ± 1.50 0.053 
Low-dose insulin 
(µmol/kgFFM/min) 
16.79 ± 1.26 18.28 ± 1.47 0.068 
High-dose insulin 
(µmol/kg/min) 
38.52 ± 7.73 47.61 ± 5.25 0.039§ 
High-dose insulin 
(µmol/kgFFM/min) 
38.56 ± 7.73 50.50 ± 5.40 0.039§ 
 
Table 5.4  Total Rd glucose across hyperinsulinaemic euglycaemic clamp 
presented as mean ± SEM with and without adjustment for fat free mass 
(FFM) and compared by paired Student’s t-tests.  * Log transformed to 
normalise distribution. § Compared by Related-Samples Wilcoxon Signed 
Rank Test, as non-parametric tests deemed more appropriate due to lower 







5.4.8 Endogenous glucose production 
 
Endogenous glucose production (EGP) in the fasting state prior to insulin infusion is 
equivalent to Rd glucose.  EGP was calculated during low dose insulin, and was not 
affected by anastrozole.  No significant difference in EGP was noted between the 
placebo and anastrozole phases of this study (Table 5.5).  EGP is not reported for the 


















 Anastrozole Placebo p 
EGP: Tracer only 
(µmol/kg/min) 
7.77 ± 0.46 7.50 ± 0.46 0.271 
EGP: Tracer only 
(µmol/kgFFM/min) 
9.35 ± 0.58 9.04 ± 0.60 0.313 
EGP: Low-dose 
insulin (µmol/kg/min) 




5.55 ± 1.12 5.19 ± 1.25 0.652 
Suppression glucose 
production: Low-dose 
insulin (%)  
61.21 ± 13.02 64.96 ± 12.47 0.723§ 
Suppression glucose 
production: Low-dose 
insulin (%) [corrected 
for FFM] 
49.75 ± 11.50 51.97 ± 11.32 0.981§ 
 
Table 5.5 Endogenous glucose production (EGP) during first two phases of 
hyperinsulinaemic euglycaemic clamp. Presented as mean ± SEM compared 
by paired Student’s t-tests.  § Data not normally distributed despite 
transformation and therefore compared by Related-Samples Wilcoxon Signed 











5.4.9  Glycerol concentrations during clamp 
 
As expected, glycerol concentration fell progressively across the low and high dose 
phases of the clamp studies, as a consequence of reduced lipolysis.  No significant 
differences were detected between the anastrozole and placebo phases of the study 






 Anastrozole Placebo p 
Tracer only 62.3 ± 5.1 66.4 ± 4.7 0.223 
Low-dose insulin 35.5 ± 5.2 38.1 ± 4.0 0.388 
High-dose insulin 27.9 ± 5.0 32.1 ± 3.9 0.086 
% suppression from 
baseline to low dose 
clamp 
52.8 ± 4.3 57.3 ± 3.4 0.426 
% suppression from 
baseline to high 
dose clamp 
40.8 ± 4.2 46.8 ± 3.7 0.071 
 
Table 5.6 Plasma glycerol concentrations (µmol/L) across the hyperglycaemic 
euglycaemic clamp (mean of four steady state values).  Presented as mean ± 





5.4.10 Tracer: Tracee Ratios for d5-glycerol: glycerol 
 
Steady state values were obtained for d5-glycerol: glycerol Tracer: tracee ratios 
(TTR) across the clamp studies, as demonstrated in figure 5.6.  TTRs increased across 







































































































































5.4.11 Glycerol kinetics 
 
Rate of appearance for glycerol (Ra glycerol) was not altered by anastrozole, as 




 Anastrozole Placebo p 
Ra glycerol: Tracer 
only (µmol/kg/min) 
2.85 ± 0.36 2.79 ± 0.34 0.777 
Ra glycerol: Tracer 
only 
(µmol/kgFFM/min) 
3.39 ± 0.43 3.31 ± 0.38 0.704 
Ra glycerol: Low-dose 
insulin (µmol/kg/min) 
1.87 ± 0.19 1.73 ± 0.17 0.287 
Ra glycerol: Low-dose 
insulin 
(µmol/kgFFM/min) 








2.03 ± 0.22 2.11 ± 0.24 0.594 
% suppression of 
glycerol Ra from base 
to low dose 
28.0 ± 4.6 32.0 ± 4.5 0.302 
% suppression of 
glycerol Ra from base 
to high dose 
34.3 ± 5.2 31.9 ± 5.6 0.609 
 
Table 5.7  Ra glycerol and % suppression of glycerol Ra across 
hyperinsulinaemic euglycaemic clamp. Data presented as mean ± SEM and 










5.4.12  Lipid profile 
 
Anastrozole treatment resulted in a 6.4% reduction in total serum cholesterol (p 
<0.05). This was a consequence of non-significant trends towards lower HDL 
cholesterol (7.4%) and LDL cholesterol (6.6%).  No significant differences in either 




 Anastrozole Placebo p 
Total cholesterol 
(mmol/L) 
3.86 ± 0.13 4.12 ± 0.14 0.041 
HDL cholesterol 
(mmol/L) 
1.01 ± 0.05 1.09 ± 0.05 0.080 
LDL cholesterol 
(mmol/L) 
2.39 ± 0.14 2.56 ± 0.14 0.118 
Triglyceride (mmol/L) 1.02 ± 0.09 1.05 ± 0.16 0.770 
Total cholesterol:HDL 
ratio 
3.99 ± 0.23 3.96 ± 0.25 0.816 
 
Table 5.8  Effect of anastrozole therapy on circulating lipid profile presented 











5.4.13 Adipokines and pro-inflammatory cytokines 
 
Serum leptin was reduced by 28% following 6 weeks of anastrozole administration.  
No significant differences were noted in any of the other adipokines and cytokines 




 Anastrozole Placebo p 
Leptin  
(pg/mL) 
4249 ± 999 5890 ± 1349 0.039§ 
Adiponectin 
(µg/mL) 
11.7 ± 4.7 14.6 ±2.6 0.188* 
Resistin (pg/mL) 32.6 ± 2.9 32.2 ± 2.8 0.830 
IL-8  
(pg/mL) 
5.6 ± 0.8 6.2 ± 1.4 0.868§ 
MCP-1  
(pg/mL) 
226.2 ± 13.4 216.1 ± 10.0 0.362 
 
Table 5.9  Effect of anastrozole therapy on circulating adipokines and pro-
inflammatory cytokines presented as mean ± SEM.  Compared by paired 
Student’s t-tests (log transformed data*) except where data not normally 
distributed following log transformation, where Related-Samples Wilcoxon 







5.4.14 Adipose tissue mRNA 
mRNA expression was assessed for genes where current evidence suggested a 
potential regulatory role for sex steroid hormones.  Of 27 genes assessed, only 2 
demonstrated changes in expression related to anastrozole (Table 5.10): Estrogen 
receptor β and perilipin 2, both of which were down-regulated by anastrozole (45.1% 





















 Anastrozole Placebo p 
Steroid hormone synthesis and metabolism 
HSD11B1 
11βHSD1 
1.215 ± 0.388 1.202 ± 0.356 0.959 
CYP19A1 
Aromatase 
1.042 ± 0.269 0.961 ± 0.320 0.848 
Steroid hormone receptors 
AR 
Androgen receptor 
1.264 ± 0.113 1.332 ± 0.108 0.650 
ESR1 
Estrogen receptor α 
1.064 ± 0.172 0.885 ± 0.061 0.398 
ESR2 
Estrogen receptor β 
0.538 ± 0.276 0.979 ± 0.344 0.040 
Adipogenesis, lipogenesis and lipolysis 
ACACA 
Acetyl CoA carboxylase 
1.097 ± 0.207 1.169 ± 0.297 0.775 
UCP2 
Uncoupling protein 2 
1.108 ± 0.029 1.198 ± 0.140 0.474 
FASN 
Fatty acid synthase 
0.911 ± 0.281 0.938 ± 0.339 0.807 
LIPE 
Hormone sensitive lipase 
1.080 ± 0.296 0.906 ± 0.262 0.223 
LPL 
Lipoprotein lipase 
1.093 ± 0.109 1.053 ± 0.114 0.750 
PLIN2 
Perilipin 2 
1.069 ± 0.094 1.172 ± 0.101 0.045 
CTNNB1 
β-catenin 




0.763 ± 0.106 0.763 ± 0.115 0.999 
PPARG 
Peroxisome proliferator-
activated receptor γ 
1.098 ± 0.171 1.077 ± 0.119 0.855 
PPARGC1A 
PGC-1α 
1.267 ± 0.172 1.043 ± 0.289 0.270 
Lipid and sterol metabolism 
CETP 
Cholesterol ester transfer 
protein 
0.909 ± 0.347 0.890 ± 0.420 0.953 
SREBF1 
Sterol regulatory element 
binding transcription 
factor 1 





 Anastrozole Placebo p 
SREBF2 
Sterol regulatory element 
binding transcription 
factor  
1.108 ± 0.029 1.198 ± 0.140 0.150 
HMGCR 
HMG CoA Reductase 
0.788 ± 0.089 0.915 ± 0.130 0.529 
HMGCS1 
HMG CoA Synthase 
(soluble) 
1.012 ± 0.044 0.881 ± 0.058 0.083 
LDLR 
LDL receptor 








0.959 ± 0.150 1.041 ± 0.175 0.613 
ADIPOQ 
Adiponectin 




0.829 ± 0.191 0.954 ± 0.263 0.617 
ADRA2A 
α-2-adrenergic receptor 
0.871 ± 0.088 1.028 ± 0.211 0.513 
ADRB1 
β-1-adrenergic receptor 
0.861 ± 0.101 1.057 ± 0.241 0.298 
 
Table 5.10  Subcutaneous adipose tissue mRNA transcript levels (relative to 
cyclophylin) during anastrozole and placebo treatment phases in 6 subjects.  








Predicting the metabolic effects of aromatase inhibition in men is potentially more 
difficult than in women; where both estrogen deficiency and relative androgen excess 
would be expected to exert deleterious effects.  In men, the effects of suppressing 
estrogen are much less clear and, in most prior investigations, have been accompanied 
by subnormal testosterone concentrations.  As noted previously, congenital absence of 
aromatase activity results in adverse metabolic phenotypes in both mice and men 
(Simpson et al. 1995), however it does not necessarily follow that acquired 
suppression of aromatase would have similar consequences.  In this chapter I have 
presented a double-blind randomised controlled study designed specifically to address 
this issue.  Consistent with the original hypothesis, I have shown that short-term 
aromatase inhibition is associated with decreased insulin-stimulated glucose disposal, 
with no significant effect on hepatic glucose production or lipolysis. No effect on 
body fat was observed, although serum leptin concentration was lower during 
aromatase inhibitor therapy. No substantial effect upon mRNA transcript levels was 
noted in the subcutaneous adipose compartment.  Aromatase inhibition was also 
associated with a significant increase in systolic blood pressure and decreased plasma 
total cholesterol.   
 
A number of potential populations could have been selected for assessment in this 
study, including men with late onset hypogonadism (LOH), obesity related 
hypogonadism or T2DM.  Ultimately a decision was made to determine the metabolic 
effect of aromatase inhibition on healthy volunteers.  Whilst there is potentially 
significant merit in determining whether aromatase inhibition is capable of 
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ameliorating testosterone deficiency (and its consequences), it is also important to 
determine whether a shift in the balance of androgen and estrogen action can itself 
generate a pathological metabolic state in previously healthy men.  Recruitment of 
healthy volunteers for a study which mandated daily adherence to medication for a 
total of 12 weeks (6 weeks placebo and 6 weeks anastrozole) proved challenging and 
fell 3 short of the target of 20 subjects.  Had recruitment been more straightforward, it 
would have been preferable to limit the degree of heterogeneity within the study 
population, with respect to age (which ranged from 18 to 50 years) and also body 
composition (percentage body fat ranged from 4 to 28%).  Age has been identified as 
a factor which influences the metabolic effects of aromatase inhibitors, albeit in much 
older men (mean age 76) than the current study (Lapauw et al. 2009).  
 
Anastrozole was selected in preference to the other 3rd generation aromatase inhibitors 
on the basis of its pharmacokinetic profile and superior specificity.  Anastrozole has a 
shorter half-life than letrozole (41 hours vs. 2 – 4 days) and consequently a shorter 
time to steady state plasma levels (7 days vs. 60 days) (Buzdar et al. 2002).  These 
properties were attractive given the relatively short treatment period (6 weeks) and 
also ensured that sufficient ‘wash out’ was achieved during the two weeks between 
placebo and anastrozole phases.  Letrozole has been associated with significant 
reductions in both morning plasma cortisol (Bisagni et al. 1996) and ACTH-
stimulated cortisol (Bajetta et al. 1999), across similar time-scales to that employed in 
this study (and other studies assessing the metabolic effect of aromatase inhibitors).  
Cortisol suppression is potentially an important confounder in any study of insulin 
sensitivity.  The relationship between glucocorticoid excess and insulin resistance is 
well established, however even pharmacological antagonism of the glucocorticoid 
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receptor in eucortisolaemic individuals is associated with significant changes in   
glucose metabolism (Garrel et al. 1995).  Anastrozole is not associated with any 
changes in plasma cortisol (Buzdar et al. 2001) and is therefore ideally suited to 
purely assess effects related to changes in sex steroid concentration.   
 
The duration of aromatase inhibitor administration in this study (6 weeks) compares 
favourably to other similar studies, which have been limited to between 1 and 4 weeks 
(Lapauw et al. 2009; Lapauw et al. 2010).  6 weeks was selected as a reasonable 
period to achieve stable plasma levels of anastrozole and observe changes mediated 
by sex hormone mediated transcriptional regulation; it was likely to have been too 
short to detect significant changes in body composition and consequent effects on 
insulin sensitivity.   
 
Aromatase inhibition in post-menopausal women is associated with durable, profound 
(> 90%) suppression of circulating estradiol (Bajetta et al. 2002) but this is not the 
case in men, where a compensatory increase in luteinizing hormone (LH) mitigates 
the degree of estradiol suppression. This occurs because feedback at the 
hypothalamic-pituitary level is principally mediated via estrogen receptor rather than 
androgen receptor (Raven et al. 2006), with consequent increase in LH and 
testosterone overcoming the aromatase inhibitor ‘block’. It is likely that duration of 
therapy is also relevant, as estradiol suppression was 20% in men treated with 
anastrozole for 12 months (Burnett-Bowie et al. 2009) compared to 62% following 4 
weeks of letrozole in a similar study population (Lapauw et al. 2009).  In this study, 
estradiol fell by a modest 16.7%, which is significantly less than most other reports in 
the literature.  Only a single subject appeared to achieve no estrogen suppression, 
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presumably a consequence of non-compliance but this did not significantly skew the 
mean suppression.  Planned measurement of plasma anastrozole concentrations will 
provide further information with respect to compliance. More surprising than the 
modest reduction in circulating estrogens, was the absence of any effect upon 
androgen concentration (testosterone and androstenedione) following six weeks of 
anastrozole administration.  This is difficult to reconcile, as the obvious explanation 
for limited suppression of estradiol would be a compensatory elevation of LH, and 
consequently testosterone, following a prolonged period of treatment.  Planned 
measurement of LH will offer clarification, although it would be surprising to observe 
any significant change, in the context of unaltered testosterone concentration.   In 
mice, anastrozole is significantly less abundant in brain tissue than letrozole 
(Miyajima  et al. 2013), which may account for less pronounced excursions in LH 
observed with anastrozole in human studies; assuming local hypothalamo-pituitary 
generation of estradiol is more important than availability of circulating estrogen 
(Burnett-Bowie  et al. 2009; Raven et al. 2006; T’Sjoen et al. 2005).  However, one 
week of anastrozole in healthy men did result in substantial elevations in LH (100%) 
and testosterone (53%) with concomitant suppression of estradiol (50%), albeit using 
a daily dose ten times greater than the standard dose (1 mg) employed in this study 
(Hayes et al. 2000).    
 
Reported androgen and estrogen results were based on LC MS/MS analysis, regarded 
as the gold standard for measurement of sex steroid hormones.  The superiority of 
mass spectrometric analysis has been demonstrated in the context of aromatase 
inhibition, where immunometric methods are prone to significantly underestimate 
estradiol suppression in post-menopausal women (Stanten et al. 2007).  The vast 
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majority of previously reported aromatase inhibitor studies, including all those in 
men, have relied upon immunoassays, which are known to perform poorly at low 
estradiol concentrations, where a positive bias is often observed (Huhtaniemi et al. 
2012).  A significant limit in interpreting plasma sex steroid levels is the fact that they 
do not necessarily reflect tissue concentrations.  This has been observed in breast 
tissue from pre- and post-menopausal women where, despite markedly divergent 
plasma concentrations, tissue estradiol concentration is equivalent (Pasqualini  et al. 
1996)   In men and post-menopausal women, local generation and action of estradiol, 
in adipose tissue and skeletal muscle, is likely to be more physiologically relevant 
than distant action.  In view of the lower than anticipated suppression of serum 
estradiol in this study, it would be interesting to determine the extent to which 
anastrozole altered the tissue concentration of sex steroids. 
 
This study is the first in men to achieve suppression of circulating estradiol, whilst 
maintaining a stable testosterone level, with aromatase inhibitor alone.  Another 
approach designed to deal with LH compensation, is to suppress gonadotrophins with 
a GnRH agonist and maintain plasma testosterone concentration with transdermal 
testosterone replacement (Finkelstein et al. 2013), permitting a clearer assessment of 
the relative contributions of estrogens and androgens, although this approach does not 
mimic physiological daily variation in sex steroid levels.  This elegant model suggests 
that estrogen deficiency, but not androgen deficiency, is associated with insulin 
resistance, although it is not clear whether this is independent of changes in intra-
abdominal fat, which is increased with estrogen deficiency (Joel Finkelstein, personal 
communication, May 2014). In failing to ‘clamp’ testosterone levels during aromatase 
inhibition, as observed in most aromatase inhibitor studies, it can be argued that 
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metabolic changes may be related to concurrent elevation of testosterone, as much as 
suppression of estradiol. No evidence exists to suggest supra-physiological 
testosterone levels are associated with insulin resistance and, indeed, recent work by 
Finkelstein et al. appears to refute a role for testosterone in mediating insulin 
sensitivity. However, supra-physiological estradiol is associated with reduced muscle 
GLUT4 expression (Barros et al. 2008) and an increased risk of T2DM in women 
(Ding et al. 2006), thereby establishing a possible precedent of deleterious effects 
associated with excessive sex steroid action. 
 
In this study, body fat percentage was estimated using a hand-held bioelectric 
impedance meter, an inexpensive but relatively imprecise modality, which provides 
no additional information regarding compartment specific changes (Fogelholm et al. 
1997).  No difference was detected in weight, BMI, WHR or body fat percentage 
between anastrozole and placebo phases, which was not unexpected as it may take 
longer than six weeks to observe sex hormone mediated changes in body composition, 
particularly with such low sensitivity methodologies.  In support of this, 10 weeks of 
anastrozole therapy (1mg daily) did not result in any change in body composition, as 
determined by DEXA and calliper measurement, in healthy young men  (age 15 – 22 
years) (Mauras et al. 2000). Despite no obvious change in body composition, in this 
study, serum leptin concentration was reduced by 28% during the anastrozole phase; 
consistent with the effect reported previously, following 4 weeks of letrozole 
administration (Lapauw et al. 2009). In the current study, no effect on leptin mRNA 
expression was observed in subcutaneous adipose tissue, suggesting reduced leptin 
concentration is not mediated by a direct effect on transcription in the subcutaneous 
depot. Longer duration of aromatase inhibitor therapy in men (16 weeks) has been 
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shown to increase body fat percentage, with a disproportionate increase in intra-
abdominal fat (Finkelstein et al. 2013).  Leptin is preferentially secreted by 
subcutaneous, rather than omental adipocytes (Gottschling-Zeller et al. 1999), raising 
the possibility that the change in leptin concentration, observed in this study, is a 
consequence of shift from subcutaneous to visceral adipose deposition.  This is 
certainly consistent with the observed increase in insulin resistance but would require 
verification by more detailed assessment of body fat compartments (e.g. single-slice 
CT).   Alternatively, the aromatase inhibitor related reduction in insulin sensitivity 
observed in this study may be mediated by factors independent of adiposity. 
 
A significant strength of this study was the use of the gold-standard 
hyperinsulinaemic euglycaemic clamp technique to determine insulin sensitivity (De 
Fronzo et al. 1979).  The use of deuterated glucose tracer provides supplemental 
information regarding the contribution of peripheral and hepatic insulin sensitivity 
and deuterated glycerol permits assessment of lipolysis.  Deuterated glucose was 
selected, as unlike 13C labelled tracers, the label cannot be recycled via gluconeogenic 
pathways and therefore provides the most accurate measure of endogenous glucose 
production (Choukem & Gautier 2008).  Deuterated glycerol provides a measure of 
adipose tissue insulin sensitivity; as there is no re-uptake of glycerol into adipocytes, 
the rate of appearance of glycerol corresponds to rate of lipolysis.  Adjustments for fat 
free mass were reported, as this is the primary site of glucose uptake, however these 
adjustments did not materially affect the results. In particularly insulin sensitive 
individuals, maximal effects of insulin may occur at a lower concentration than is 
conventionally employed during standard clamp protocols, thus introducing the 
possibility of missing real differences between groups; this may have been an issue 
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given the young age and lean body composition of several subjects.  Glucose TTR 
data during the high dose insulin phase were less consistent than during earlier 
phases, due to the requirement for higher glucose infusion rates, with high dose 
insulin, and subsequent fall in TTR.  This is a relatively common issue and has led to 
a change in practice, namely the addition of glucose tracer to the variable 20% 
dextrose infusion fluid.  Notwithstanding these technical challenges, this study has 
provided clear evidence of increased peripheral insulin resistance, manifesting as a 
23.7% decrease in glucose disposal, during aromatase inhibitor therapy.  No effect on 
hepatic or adipose insulin sensitivity was detected.  
 
Previous investigators have either failed to demonstrate any aromatase inhibitor effect 
on insulin sensitivity or have reported improved insulin sensitivity following short-
term aromatase inhibition.  The first study to suggest improved insulin sensitivity 
assessed letrozole in 18 healthy men (divided into older and younger age groups) over 
a 4-week period (Lapauw et al. 2009).  Due to insufficient washout in the 2-week 
interval between treatment phases, placebo results were discarded in all subjects who 
initially received letrozole (n = 10).  Improved insulin sensitivity was inferred from 
changes in fasting glucose and insulin, in the younger subjects only, although no 
specific indices of insulin sensitivity were reported (e.g. HOMA-IR or QUICKI).  As 
alluded to previously, letrozole is known to significantly suppress plasma cortisol 
levels, however morning cortisol concentrations were not reported in this study, 
leaving open the possibility that improvements in insulin sensitivity may have been a 
consequence of cortisol suppression.  A subsequent study by the same investigators 
assessed letrozole effects over a 1-week period either alone (n = 10) or in combination 
with transdermal estradiol (n = 10) to maintain physiological levels (Lapauw et al. 
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2010). Hyperinsulinaemic euglycaemic clamp studies suggested improved insulin 
sensitivity in the AI group, but not the AI plus estradiol group, although only after 
correction for FFM.  The same potential criticisms apply regarding the choice of 
aromatase inhibitor and absence of cortisol measurement.  Furthermore, the estradiol 
replacement group developed subnormal testosterone levels, suggesting 
supraphysiological estradiol replacement and consequent LH suppression.  It is 
difficult to conclude from these data that estrogen suppression is metabolically 
beneficial in men; even if this were the case, the net effect of deleterious longer term 
changes in body composition may be of greater import with respect to insulin 
sensitivity.  10 weeks of anastrozole in young men and 12 weeks of anastrozole in 
elderly hypogonadal men did not alter fasting insulin or glucose concentrations 
(Mauras et al. 2000; Dougherty et al. 2005).  Despite discordance in relation to these 
earlier studies, insulin sensitivity findings in this thesis are consistent with the 
outcome of the largest and longest study of anastrozole in men where estrogen 
deficiency, but not androgen deficiency, was associated with increased insulin 
resistance (Joel Finkelstein, personal communication, May 2014).  
 
The absence of a demonstrable effect upon subcutaneous adipose tissue mRNA 
transcription or rudimentary measures of body composition does not, as noted 
previously, preclude the possibility that changes in insulin sensitivity are mediated, at 
least in part, by a shift in fat distribution.  Nonetheless, given the principal metabolic 
consequence of aromatase inhibition is peripheral insulin resistance, direct effects 
upon skeletal muscle are likely to be involved.  Aromatase is expressed in skeletal 
muscle and may generate equivalent quantities of estrogen to adipose tissue, in men 
and post-menopausal women (Larionov et al. 2003; Longcope et al. 1978). Pre-
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menopausal women are protected from nonesterified fatty acid (NEFA) induced 
peripheral insulin resistance, compared to age and BMI-matched men (Frias et al. 
2001); insights from animal models raise the possibility that this difference is 
estrogen related.  Estrogen receptor α-knockout mice (ERαKO) are peripherally 
insulin resistant, with impaired insulin signalling in skeletal muscle (despite normal 
GLUT4 levels), impaired fatty acid oxidation and accumulation of inflammatory lipid 
intermediates (Ribas et al. 2009).  Estrogen replacement in ovariectomized mice shifts 
transcription patterns in skeletal muscle towards favouring fatty acid oxidation and 
rapidly activates AMPK (D’Eon et al. 2005).  Whilst some reports suggests a negative 
effect on insulin sensitivity in the face of supraphysiological estradiol levels (Barros 
et al. 2008), the balance of evidence supports a salutary role for estrogens with 
respect to peripheral insulin sensitivity and offers a plausible explanation for the 
effects observed following aromatase inhibition.  With hindsight, it would have been 
desirable to obtain skeletal muscle biopsies to determine anastrozole-induced changes 
in transcription and also to have considered assessment of intramyocellular lipid 
content. 
 
Contrary to what was hypothesised, subcutaneous adipose tissue does not appear to 
significantly mediate the metabolic effects of aromatase inhibition in men.  No effect 
upon lipolysis was detected through assessment of rate of appearance of glycerol.  
Furthermore, of 27 subcutaneous adipose mRNA transcript levels investigated, only 2 
were found to be significantly different between treatment phases.  The biological 
significance of slight reductions in perilipin 2 (more associated with lipid droplet 
formation in non-adipose cells) and estrogen receptor β is questionable.  The 
proportion of subjects suitable (or willing) to have paired adipose biopsies was low (n 
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= 6) which reduced the power to detect differences, although there were no 
discernable trends in the remaining 25 genes. With the exception of leptin, no 
significant differences were observed in adipokines or pro-inflammatory cytokines, 
lending further support to a lack of meaningful effect upon the adipose compartment.   
 
Ideally it would have been interesting to obtain visceral as well as subcutaneous 
adipose tissue, although this is not possible outwith the context of surgery.  Needle 
biopsy of adipose tissue is associated with relative under sampling of the stroma-
vascular fraction (Mutch et al. 2009), which is potentially relevant, as the pre-
adipocyte fraction is particularly active with respect to sex steroid hormone 
metabolism.  Assessment of estrogen sulfotransferase mRNA expression would be of 
value as another factor capable of significantly influencing tissue estrogen levels.   
 
Anastrozole resulted in a significant reduction in total cholesterol, which comprised 
non-significant downward trends in both LDL and HDL cholesterol. This contrasts 
with a significant increase in LDL cholesterol, observed following 4 weeks of 
letrozole in younger men, although within this study no LDL cholesterol effect was 
observed in older men  (Lapauw et al.  2009).  A study of older men with ‘mild 
hypogonadism’ failed to demonstrate any significant difference in lipid profile 
following 12 weeks of anastrozole therapy (Dougherty et al.  2005). The most 
systematic assessment of changes in cholesterol associated with aromatase inhibition, 
involved 6-week administration of GnRH agonist, testosterone and testolactone (to 
determine the effects of estrogen deficiency); in young men this revealed aromatase 
inhibition was association with significant reductions in HDL cholesterol (primarily 
the HDL2 fraction) (Bagatell et al. 1994).  The less marked decline in HDL 
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cholesterol in the current study is likely to reflect less pronounced suppression of 
estradiol (in the absence of GnRH agonist).   
 
Systolic blood pressure was significantly higher and heart rate significantly lower 
during the anastrozole phase of this study.  The opposite phenotype is observed in 
aromatase knockout mice, namely increased heart rate and lower diastolic blood 
pressure (Head et al. 2004).  Polymorphisms in CYP19A1 have been associated with 
essential hypertension in a sex-specific manner (Shimodaira et al. 2008).  The role of 
estrogen in influencing blood pressure is complex and evidence often conflicting. 
Most studies of HRT suggest a modest effect in reducing BP.  Estrogens exert an 
influence upon endothelial function through a number of mechanisms (Yanes & 
Reckelhoff  2011), however a detailed exploration of the vascular effects of aromatase 




As hypothesised, in healthy men, aromatase inhibition resulted in decreased insulin 
sensitivity, primarily manifesting as reduced peripheral glucose disposal.  No 
significant effects upon hepatic glucose output or lipolysis were observed.  
Anastrozole resulted in lower serum leptin levels, in the absence of any effect on 
leptin adipose mRNA expression, which potentially reflects either redistributed or 
reduced adiposity.  Relatively modest changes in circulating sex steroid hormones 












It is clear that sex steroid hormones exert an influence upon body composition and 
energy metabolism; multiple sources of evidence attest to this in animal models and in 
humans.  Aromatase occupies a central role in determining estrogen levels in men and 
post-menopausal women both in the circulation and, perhaps more importantly, 
within target tissues.  Models of aromatase deficiency are associated with adverse 
metabolic phenotypes yet, despite their widespread clinical use, little attention has 
focused on the potential metabolic consequences of aromatase inhibitors.   
 
The study described in chapter 3 confirmed associations between sex steroids and 
measures of cardiometabolic risk in men.  It also raised the possibility that, in men, 
availability of substrate androgen, rather than abundance of aromatase (using 
adiposity as a proxy), is of greater significance in determining plasma estrogen 
concentrations.  However this study was subject to a number of important limitations, 
not least the inherent difficulty in establishing direction of association in a cross-
sectional design.  In addition, plasma steroid measurements were performed using 
immunometric assays, which are increasingly recognised to be unreliable at the lower 
end of expected concentration ranges (Huhtaniemi  et al. 2012).  This simple study 
raised questions regarding the extent to which adipose tissue and total body aromatase 
activity mediates circulating estradiol concentration in men.  To address these 
questions, a study was designed where labelled androstenedione would be infused 
into subcutaneous adipose tissue, using microdialysis, with measurement of the 
resultant conversion to labelled estrone.  Preliminary assessment of the feasibility of 
this approach (not reported in the thesis) identified a significant, ultimately 
insurmountable, problem with adsorption of sex steroid hormones to the plastic 
microdialysis tubing (Bruning et al. 1981).  An alternative approach would be to 
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infuse stable isotope estrogen tracers systemically in order to measure whole body 
aromatisation; preparatory work was performed, not reported in the thesis, to establish 
the pharmacokinetics of stable estrogen tracers.  However, challenges in the accurate 
LC-MS/MS measurement of estradiol at low picomolar concentrations thwarted 
progress in this regard to date.  The flux of sex steroids through the aromatase 
pathway in men therefore remains unquantified.  Another approach to deduce its 
significance, however, is to use enzyme inhibitors and this avenue proved fruitful, 
generating the results reported in chapters 4 and 5. 
 
The study described in chapter 4 sought to assess the metabolic effects of aromatase 
inhibition in post-menopausal breast cancer patients, the main group exposed to this 
medication class in clinical practice.  Aromatase inhibitors were associated with 
reduced lean mass, greater body fat percentage, significantly higher serum leptin and 
correspondingly greater leptin mRNA levels in subcutaneous adipose tissue.  
Aromatase inhibitor therapy was also associated with significantly greater insulin 
resistance, as determined by ‘Matsuda-ISI’.  Whilst cases and controls were matched 
as closely as possible, with no significant difference in age or BMI, case-control 
design is susceptible to confounding by unrecognised factors.  Furthermore, although 
reported to correlate closely with the results of insulin infusion clamps (Matsuda et al. 
1999), ‘Matsuda-ISI’ is not the gold standard method for assessing insulin sensitivity 
and does not inform the relative contributions of hepatic, adipose and peripheral 
insulin sensitivity.  
 
The study described in chapter 5 represented an advance upon the earlier studies with 
respect to study design (randomised, double-blind, placebo-controlled crossover 
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study), assessment of insulin sensitivity (hyperinsulinaemic euglycaemic clamp with 
stable glucose and glycerol tracers) and measurement of sex steroid hormones (LC-
MS/MS).  Aromatase inhibition, in men, was associated with decreased insulin 
sensitivity; specifically, with reduced insulin-stimulated peripheral glucose disposal. 
Although sensitive modalities for detecting change in body composition were not 
employed, a fall in serum leptin is consistent with previously observed shifts from 
subcutaneous to visceral adiposity with aromatase inhibition in men (Finkelstein et al. 
2013).   
 
A significant deleterious effect upon insulin sensitivity was observed both in women 
(24.3% lower by ‘Matsuda-ISI’) and in men (23.7% decrease in peripheral glucose 
disposal during high dose clamp) following aromatase inhibitor therapy.  This raises 
the possibility of an important pathogenic effect of aromatase inhibition in skeletal 
muscle, particularly as lean mass was lower in women treated with aromatase 
inhibitors.  In support of this, estrogen deficiency impairs skeletal muscle glucose 
uptake (Campbell et al. 2002), reduces transcription of genes involved in muscle fatty 
acid oxidation (D’Eon et al. 2005) and reduces muscle AMPK signalling in rodent 
models (Rogers et al. 2009).  The focus in this thesis had been on potential adipose 
tissue effects of aromatase inhibition but, in view of these findings, it would be 
interesting to assess effects upon intramyocellular lipid content in skeletal muscle and 
to determine whether significant changes in mRNA transcription are effected in 
muscle.   
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The effects of aromatase inhibition upon body composition may be sexually 
dimorphic.  In women, higher serum leptin levels were observed in those receiving 
aromatase inhibitors whereas, in men, serum leptin fell following anastrozole 
administration.  Detailed assessment of body composition was only performed in 
women, as the duration of the male study was not considered long enough to detect 
any significant differences.  A low estrogen-high androgen state, as expected in 
aromatase inhibitor treated adipose tissue, would be predicted to favour android fat 
deposition (Elbers et al. 2003). However, body fat percentage was increased across 
both lower limbs and trunk.  Future detailed assessment of changes in the visceral and 
subcutaneous adipose compartment would be of value.  Previous investigations in 
men have shown aromatase inhibitors to preferentially increase visceral adiposity 
(Finkelstein  et al.  2013), which is potentially consistent with the observed fall in 
serum leptin (Gottschling-Zeller et al. 1999). 
 
The effect of aromatase inhibition upon mRNA transcript levels in subcutaneous 
adipose was minimal in men.  In women, upregulation of genes associated with anti-
adipogenic effects was observed (LKB1 and β-catenin) although leptin mRNA levels 
were greater, in keeping with higher serum levels.  Overall, effects on transcription in 
adipose tissue were less than anticipated, based on previously described 
transcriptional effects of estrogens and androgens in adipose tissue.   
 
Plasma sex steroid measurements were performed using gold standard LC-MS/MS 
methodology for the male aromatase inhibitor study reported in chapter 5, where all 
previous similar investigators have employed less reliable immunometric assays.  The 
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degree of estradiol suppression by anastrozole was less than observed in previous 
similar studies and the absence of any effect upon circulating androgens was 
unanticipated (T’Sjoen et al. 2005); measurement of LH should help elucidate the 
reason for these findings. Measurement of SHBG is also planned, as a fall in SHBG 
may occur with estrogen suppression (Pasquali et al, 1997), leaving open the 
possibility of differences in calculated free testosterone.  Ultimately, the most relevant 
sex steroid measurements in men and post-menopausal women are likely to be direct 
assessment of target tissue levels (e.g. adipose tissue or skeletal muscle), as 
circulating values are substantially lower and only passively reflect local tissue 
generation  (Simpson et al. 2005).  However, measurement of tissue sex steroid 
hormones is technically challenging, not to mention the difficulties in accessing the 
necessary tissue compartments.  The possibility that changes in aromatase activity 
may be compensated for by changes in estrogen sulfotransferase (or other enzymes 
involved in estrogen metabolism) requires further assessment. 
 
A potential confounder encountered in previous aromatase inhibitor studies is the 
suppressive effect of letrozole, although apparently not anastrozole (Buzdar  et al. 
2001), upon basal (Bisagni  et al. 1996) and ACTH-stimulated cortisol (Bajetta et al. 
1999).  The fact that this effect appears to be durable over several months, by which 
point ACTH compensation would be expected, raises the possibility that the effect is 
mediated by changes in corticosteroid-binding globulin (CBG).  Further elucidation of 
effects of aromatase inhibition upon the CBG concentration is planned.  Previously 
reported effects of aromatase inhibition on the growth hormone axis, specifically a 
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fall in IGF-1 in younger men, also require further attention (Mauras et al. 2000; 
Lapauw et al. 2009).   
 
Having established that aromatase inhibitors are likely to exert deleterious effects 
upon insulin sensitivity in post-menopausal women, it is important that larger studies 
are undertaken to confirm these findings.  With over a million prescriptions issued 
annually for aromatase inhibitors in England alone (Prescribing and Primary Care 
Services, Health and Social Care Information Centre, 2013), there are potentially 
significant implications related to an increased risk of T2DM in this population.   
 
Another interesting avenue for further investigation would be establishing whether 
increased aromatase activity is responsible for obesity related male hypogonadism, 
secondary to the expanded adipose pool of aromatase.  Tracer studies assessing total 
body aromatase activity, as well as changes in estrogen generation across the adipose 
tissue arterio-venous gradient, would help resolves this contentious question. 
Aromatase inhibition employed in the treatment of hypogonadism in obese men, 
targeting normalisation of testosterone and estradiol, may not result in adverse 






Addressing the original hypotheses advanced in this thesis: 
 
1. Lower levels of circulating estrogens are associated with poorer metabolic 
health in both men and women:  The results presented in chapter 3 support an 
association between plasma estrogens and metabolic health in men, albeit 
unavoidably confounded by androgen levels. 
 
2. Aromatase inhibition is associated with deleterious effects upon body 
composition: The results presented in chapter 4 are consistent with an adverse 
effect upon body composition in aromatase inhibitor treated women. 
 
3. Aromatase inhibition is associated with increased insulin resistance:  Increased 
insulin resistance was observed in aromatase inhibitor treated women (chapter 
4) and men (chapter 5). 
 
4. Aromatase inhibition results in alterations in circulating adipokines and 
cytokines, through an effect on transcription in adipose tissue:  A sexually 
dimorphic effect was observed with respect to leptin, which was higher in 
aromatase inhibitor treated women but fell during aromatase inhibitor therapy 
in men.  Effects upon adipose transcription were limited, suggesting changes 
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Supplemental information (Chapter 5) 
 
Although baseline (screening) cholesterol profiles were measured, these were 
obtained at varying times and in a non-fasted state.  Consequently, a comparison 
between baseline and the anastrozole treatment phase was not regarded as valid.  This 
is confirmed by comparison of baseline samples and placebo phase samples.  The 
significant differences in total cholesterol, triglyceride and HDL cholesterol (table) 
are highly likely to be accounted for by differences in sampling conditions.   
 Baseline Placebo p 
Total cholesterol 
(mmol/L) 
4.5 4.1 0.04 
Triglyceride (mmol/L) 1.7 1.1 0.003 
HDL cholesterol 
(mmol/L) 
1.21 1.08 0.007 
LDL cholesterol 
(mmol/L) 
2.5 2.5 0.6 
